

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The Impact of Immunosuppressive Therapy on SARS-CoV-2 mRNA Vaccine Effectiveness in Patients with Immune-mediated Inflammatory Diseases: A Danish Nationwide Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-077408
Article Type:	Original research
Date Submitted by the Author:	04-Jul-2023
Complete List of Authors:	Elmahdi, Rahma; Statens Serum Institut, Epidemiology; Imperial College London, Equality, Diversity and Inclusion Ward, Daniel; Center for Molecular Prediction of Inflammatory Bowel Disease, Ernst, Martin; University of Southern Denmark, Clinical Pharmacology and Pharmacy, Department of Public Health Poulsen, Gry; Aalborg University, Department of Clinical Medicine, Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT) Hallas, Jesper; University of Southern Denmark, Clinical pharmacology and pharmacy Pottgard, Anton; University of Southern Denmark, Clinical Pharmacology and Pharmacy, Department of Public Health Jess, Tine; Aalborg Universitet, Center for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Epidemiology; Statens Serum Institut, Department of Epidemiology Research
Keywords:	COVID-19, EPIDEMIOLOGY, Inflammatory bowel disease < GASTROENTEROLOGY, RHEUMATOLOGY, Psoriasis < DERMATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 **The Impact of Immunosuppressive Therapy on SARS-CoV-2 mRNA Vaccine Effectiveness in Patients**
5
6 2 **with Immune-mediated Inflammatory Diseases: A Danish Nationwide Cohort Study**

7
8 3 **Short Title: COVID-19 Vaccination in Immunosuppressed IMID Patients**
9
10 4

11
12 5 Rahma Elmahdi^{*1,2} (0000-0002-7013-9548), Daniel Ward^{*1} (0000-0003-0405-7250), Martin Thomsen Ernst³
13 6 (0000-0001-9003-3823), Gry Juul Poulsen¹ (0000-0003-2744-2469), Jesper Hallas³ (0000-0002-8097-8708),
14
15 7 Anton Pottegård³ (0000-0001-9314-5679), Tine Jess^{1,4} (0000-0002-4391-7332)
16
17 8

18
19 8 * Co-first author
20
21 9

22
23 10 Rahma Elmahdi, Clinical Research Associate, Center for the Molecular Prediction of Inflammatory Bowel
24 11 Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Denmark (1)

25
26 12 Doctor, Department of Lung and Infectious Disease Medicine, Nordsjællands Hospital, Hillerød, Denmark (2)

27
28 13 Daniel Ward, Doctoral Fellow, Center for the Molecular Prediction of Inflammatory Bowel Disease
29 14 (PREDICT), Department of Clinical Medicine, Aalborg University, Denmark (1)

30
31 15 Martin Ernst Thomsen, Data Manager, Department of Public Health, Clinical Pharmacology, Pharmacy and
32 16 Environmental Medicine, University of Southern Denmark, J.B. Winsløvs Vej 19, 5000 Odense, Denmark (3)

33
34 17 Gry Juul Poulsen, Statistician, Center for the Molecular Prediction of Inflammatory Bowel Disease
35 18 (PREDICT), Department of Clinical Medicine, Aalborg University, Denmark (1)

36
37 19 Jesper Hallas, Professor, Research Unit of Clinical Pharmacology, University of Southern Denmark, J.B.
38 20 Winsløvs Vej 9, 5000 Odense, Denmark (3)

39
40 21 Anton Pottegård, Professor, Department of Clinical Pharmacology and Pharmacy, University of Southern
41 22 Denmark, J.B. Winsløvs Vej 9, 5000 Odense, Denmark (3)

42
43 23 Tine Jess, Professor, Center for the Molecular Prediction of Inflammatory Bowel Disease (PREDICT),
44 24 Department of Clinical Medicine, Aalborg University, Denmark (1)

45
46 25 Professor, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark
47 26 (4)
48
49 27
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

28 **Correspondence:** Dr Daniel Ward, National Center of Excellence for the Molecular Prediction of
29 Inflammatory Bowel Disease, PREDICT, Aalborg University, A. C. Meyers Vænge 15, DK-2450
30 Copenhagen, Denmark. E-mail: djwa@dcm.aau.dk

31
32 **Key words:** Immune-mediated inflammatory disease; Cohort study; SARS-CoV-2; Vaccination;
33 Immunosuppressives

34
35 **Word count:** Abstract 250; manuscript 3020

For peer review only

1
2
3
4 37 **ABSTRACT**
5
6

7 38 **Background:** Investigation of SARS-CoV-2 vaccine efficacy in immune-mediated inflammatory disease
8
9 39 (IMID) patients receiving immunosuppressives have been restricted to small sized serological studies. We
10
11 40 therefore undertook an investigation of immunosuppressants' impact on real-world effectiveness of vaccines
12
13 41 in these patient groups.
14
15 42

17 43 **Methods:** We performed a nationwide cohort study to assess the risk of COVID-19 infection in vaccinated
18
19 44 IMID patients exposed to immunosuppressives compared to propensity score matched unexposed patients in
20
21 45 the period from 1 January 2021 to 30 November 2021. Patients were followed from date of second vaccination,
22
23 46 and weighted Cox models were used to estimate the risk of infection associated with immunosuppressives.
24
25 47 Secondary outcomes included hospitalization and death associated with a positive SARS-CoV-2 test. Risk of
26
27 48 infection by immunosuppressant drug class was also analysed.
28
29 49

30
31
32 50 **Results:** Immunosuppressants were associated with a significantly increased risk of infection overall (HR: 1.4,
33
34 51 95% CI: 1.2, 1.5), in inflammatory bowel disease (IBD) (HR: 1.6, 95% CI: 1.4, 1.9) and arthropathy (HR: 1.3,
35
36 52 95% CI: 1.1, 1.4) but not psoriasis (HR: 1.1, 95% CI: 0.88, 1.4). Immunosuppressants were also associated
37
38 53 with an increased risk of hospitalization overall (HR: 1.4, 95% CI: 1.0, 2.0), particularly in IBD (HR: 2.1, 95%
39
40 54 CI: 1.0, 4.1). No significantly increased risk of death in immunosuppressants exposed patients was identified.
41
42 55 Analyses by immunosuppressant drug class showed increased COVID-19 infection and hospitalization with
43
44 56 anti-TNF, systemic corticosteroid, and rituximab exposure.
45
46 57

47
48
49 58 **Conclusions:** Immunosuppressive therapies reduced effectiveness of mRNA SARS-CoV-2 vaccination
50
51 59 against infection and hospitalization in IMID patients. Anti-TNF, systemic corticosteroids, and rituximab were
52
53 60 particularly associated with these risks.
54
55 61

56 61

57 62

58 62

59

60

63 INTRODUCTION

64 SARS-CoV-2 mRNA vaccines Comirnaty® (Pfizer-BioNTech) and Spikevax® (Moderna) were found to be
65 efficacious in clinical trials prior to authorisation, and as of December 2022 over 758 million doses of Pfizer-
66 BioNTech and 164 million doses of Moderna were administered in the EU/EAA (1). Pre-marketing trials
67 excluded individuals considered at risk of immunocompromise, including those receiving immunosuppressive
68 therapies (2,3), therefore there remains a paucity of data on the real-world effectiveness of SARS-CoV-2
69 vaccines in patients treated with immunosuppressive drugs.

70
71 Research published early in the SARS-CoV-2 epidemic suggested that, in the absence of vaccination, some
72 types of immunosuppressives including rituximab, sulfasalazine, and corticosteroids are associated with an
73 increased risk of severe outcomes in COVID-19 infection (4–8). Immune-mediated inflammatory diseases
74 (IMID), including inflammatory bowel disease, inflammatory arthropathy, and psoriasis have themselves
75 independently been associated with lower serological responses to SARS-CoV-2 vaccination than in healthy
76 controls (9). Immunosuppressants are key therapies in IMID, so patients with IMID may be at increased risk
77 of infection and severe outcomes of COVID-19 infection both due to the natural history of the diseases and
78 the therapies used to treat them. Even in the context of second vaccination against SARS-CoV-2, exposure to
79 immunosuppressives has been associated with a significantly poorer humoral response; lower than that which
80 is required to confer immunity against infection and severe outcomes of COVID-19 infection in patients treated
81 with immunosuppressive therapies (10–12).

82
83 It is therefore important to investigate the impact of immunosuppressants on SARS-CoV-2 vaccine
84 effectiveness, while controlling for the underlying disease-indicating treatment, and other confounders that
85 may impact vaccine effectiveness.

86
87 The real-world effectiveness of SARS-CoV-2 mRNA vaccinations against COVID-19 infection and associated
88 outcomes such as hospitalization or death, in the context of immunosuppressive therapy exposure among IMID
89 patients has not yet been investigated. The aim of this study was to use Danish nationwide population-based
90

1
2
3
4 90 data to assess the impact of immunosuppressive exposure on the risk of COVID-19 infection in three cohorts
5
6 91 of vaccinated IMID patients.
7

8 92

10 93 **METHODS**

12 94 **Data sources**

14
15 95 We conducted a nationwide cohort study using the Danish COVID-19 cohort (13), based on data from the
16
17 96 Danish Microbiology Registry (14), which includes individual-level information on vaccine type, dose, and
18
19 97 date of administration; SARS-CoV-2 test type and date administered. This data was linked at the individual
20
21 98 level to both the Danish National Patient Registry (15) and the Danish National Prescription Registry (16)
22
23 99 using a unique Danish Civil Registration number (assigned to all individuals residing in Denmark). The Danish
24
25 100 National Patient Registry, a register of hospital activities, includes medical diagnoses coded using International
26
27 101 Classification of Disease (ICD-10), and medical procedures and prescriptions including treatment with
28
29 102 intravenous medications. The Danish National Prescription Registry contains information on prescriptions
30
31 103 dispensed at all community retail pharmacies, including date of dispensing, tablet strength, and pack sizes.
32
33
34 104

36 105 **Population, follow-up, and outcomes**

37
38 106 The IMID cohort comprised of three disease specific cohorts of all patients diagnosed with inflammatory bowel
39
40 107 disease (IBD; ICD-10: K50, K51), inflammatory arthropathy (ICD-10: M45, M46, M05, M06, M07) or
41
42 108 psoriasis (ICD-10: L40) in Denmark, who had received two doses of SARS-CoV-2 mRNA (Pfizer-BioNTech
43
44 109 or Moderna) vaccine. Patients with more than one of these IMID diagnoses were included in only one cohort,
45
46 110 with IBD taking precedence, then inflammatory arthropathy, finally psoriasis. Therefore, only patients with
47
48 111 psoriasis and neither an IBD nor an inflammatory arthropathy diagnosis were included in the psoriasis cohort.
49
50 112 This order was preferred as extent of organ-specific disease likely determines the dose for immunosuppressive
51
52 113 therapy.
53
54
55 114

56
57 115 Patients were followed from the date of administration of second mRNA vaccine (the index date) after 1
58
59 116 January 2021. The primary outcome was a positive SARS-CoV-2 PCR test in the observation period.
60

1
2
3
4 117 Secondary outcomes were hospitalization between 7 days prior to and up to 28 days after a positive test or
5
6 118 death within 60 days of a positive test (in Danish National Patient Register and Danish Civil Register). Follow-
7
8 119 up was censored at administration of a third vaccination, emigration, death (in the absence of a positive SARS-
9
10
11 120 CoV-2 test) or the end of the study period, 30 November 2021, as prevalence of the omicron variant became
12
13 121 substantial after 28 November 2021(17).
14

15 122

17 123 **Exposures**

18
19 124 The exposures for this study include dispensed prescriptions or hospital administration of an
20
21 125 immunosuppressive in the 120 days preceding the index date (date of administration of second vaccination).
22
23 126 Immunosuppressants included selective immunosuppressants, anti-TNFs, interleukin inhibitors, calcineurin
24
25 127 inhibitors, corticosteroids, rituximab and other immunosuppressants (see Supplementary Table 1 for complete
26
27 128 list and ACT codes for immunosuppressants). The 120-day exposure window is chosen to cover the largest
29
30 129 pack sizes of prescriptions which can contain medications for up to 120 days. A minimum daily dose of
31
32 130 corticosteroids equivalent to 7.5 mg prednisolone per day was estimated as the entire dispensed quantity of
33
34 131 corticosteroids during a sequence of prescriptions (within the 120-day exposure period) divided by the number
35
36 132 of days from the first prescription to the index date. Unexposed IMID patients were defined as those with a
37
38 133 diagnosis of one of the three IMID, who had not received an immunosuppressive in the 120 days preceding
39
40 134 the index date, and those receiving <7.5 mg prednisolone-equivalent average per day.
41

42 135

44 136 **Statistical models**

46 137 Covariates included age (handled as a continuous covariate), sex, comorbidities (cardiovascular disease,
48 138 pulmonary disease, liver disease, kidney disease, other gastrointestinal diseases, skin disease, and
50 139 musculoskeletal disease), medications (cardiovascular drugs, antibiotics, oral anticoagulants, diabetes, and
52
53 140 chronic airway disease medications). Testing frequency varied during the period studied due to changes in
54
55 141 national and international guidelines and travel restrictions, along with the background prevalence of SARS-
56
57 142 CoV-2, which could introduce bias in case detection. We therefore adjusted for individual testing frequency
58
59 143 by including number of tests in the month preceding index date as a continuous covariate. Further, covariates
60

1
2
3
4 144 specific to each IMID were included separately for each cohort. For the IBD cohort this included any IBD-
5
6 145 related hospital admissions in the previous year, Crohn's disease, ulcerative colitis, 5-ASA/sulfasalazine,
7
8 146 budesonide, IBD-related procedures, and endoscopy of the gastrointestinal tract (see Supplementary Table 2
9
10
11 147 for complete list of IMID cohort specific covariates).
12

13 148
14
15 149 To balance the covariates in the exposed and unexposed groups, we fitted propensity score (PS) models for
16
17 150 each IMID cohort separately. Propensity scores were calculated using logistic regression for the probability of
18
19 151 exposure (treatment with immunosuppressives) conditional on the covariates defined above (18). We
20
21 152 subsequently implemented the PS using standardized mortality ratio (SMR) weights (with trimming of subjects
22
23 153 with extreme weights beyond 1st and 99th centiles). We assessed the distribution of covariates with
24
25 154 standardized differences before and after PS weighting.
26

27 155
28
29 156 We used weighted Cox proportional-hazards regression models (19) to estimate risk of the COVID-19
30
31 157 infection in IMID patients exposed to immunosuppressive therapy compared to unexposed patients for each
32
33 158 disease cohort separately. We used calendar time as the underlying time scale to account for period effects on
34
35 159 the risk of the outcomes which may relate to varying infection prevalence and patient characteristics as patients
36
37 160 vulnerable to severe outcomes were vaccinated earlier in the year. We then undertook Fixed Effects Model
38
39 161 (FEM) meta-analysis to calculate the pooled HR of infection, hospitalization, and death for IBD, arthropathy
40
41 162 and psoriasis cohorts as overall risk in immunosuppressive exposed IMID by COVID-19 outcome.
42
43 163
44

45 164
46
47 164 Finally, we undertook drug specific analysis for risk of COVID-19 infection by immunosuppressive drug class.
48
49 165 In this analysis, patients receiving multiple immunosuppressive treatments were treated as independently
50
51 166 exposed to each drug class. To account for the potential impact of immunosuppressants commonly prescribed
52
53 167 in a weaning dose, which would not be captured using the definition of ≥ 7.5 mg dose equivalent per day, we
54
55 168 undertook a sensitivity analysis to assess whether having any prescription for systemic corticosteroids over the
56
57 169 120-day period before the index date had an impact on the risk of infection, hospitalization, or death for those
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

170 exposed to this class of immunosuppressants. We used the statistical software Stata version 16.1 (StataCorp,
171 College Station, TX, USA).

173 RESULTS

174 A total of 184,391 patients diagnosed with IBD, arthropathy or psoriasis were identified. Following exclusion
175 of those not receiving two doses of SARS-CoV-2 mRNA vaccine, migration prior to receipt of second
176 vaccination, and trimming of the population with extreme propensity scores, a total 152,440 patients were
177 included, contributing a total 19,341 person-years of follow-up. During the 120-day exposure assessment
178 period, 39,765 IMID patients received immunosuppressive treatment (10,480 IBD, 24,261 arthropathy, and
179 5,024 psoriasis), and 112,675 IMID patients (47,001 IBD, 44,669 arthropathy, and 21,005 psoriasis) patients
180 did not. A total of 9 exposed and 51 unexposed IMID patients are censored from overall analysis due to
181 migration or inclusion on the date of study end (therefore contributing no follow-up time). See Figure 1 of
182 inclusion and exclusion flow chart. Following application of SMR weighting, the cohorts were balanced on
183 the included covariates (see Table 1 for covariate prevalence and standardised differences [SD]).

184
185 A total of 866 (2.2%) COVID-19 infections were recorded among immunosuppressive exposed IMID patients
186 during the follow-up period compared with 2,077 (1.8%) for unexposed IMID patients. A significantly
187 increased weighted hazard for infection among exposed patients was seen for both IBD (HR: 1.6, 95% CI: 1.4,
188 1.9) and arthropathy (HR: 1.3, 95% CI: 1.1, 1.4) cohorts but not for the psoriasis cohort (HR: 1.1, 95 % CI:
189 0.88, 1.4). Meta-analysis of the three IMID cohorts showed a pooled HR for COVID-19 infection in exposed
190 patients of 1.4 (95% CI: 1.2, 1.5; Figure 2). Fewer than 52 exposed and 122 unexposed IMID patients were
191 hospitalized with COVID-19 infection during the follow-up period, which corresponded to a significantly
192 increased risk of hospitalization overall for immunosuppressive exposed IMID patients (pooled HR: 1.4, 95%
193 CI: 1.0, 2.0). Less than five immunosuppressive exposed IBD patients died in the 60 days following a COVID-
194 19 diagnosis compared to six unexposed IBD patients. Six patients in the arthropathy cohort exposed to
195 immunosuppressives compared with 13 unexposed arthropathy patients died in the 60 days following a
196 COVID-19 diagnosis and fewer than five patients with a psoriasis diagnosis, either immunosuppressive

1
2
3
4 197 exposed or unexposed died with a COVID-19 diagnosis. These did not correspond to a significantly increased
5
6 198 risk of death among exposed patients in any of the three cohorts or overall (pooled HR: 0.92, 95% CI: 0.38,
7
8 199 2.2; Figure 2).

10
11 200
12
13 201 Analysis for risk of infection among IMID cohorts by immunosuppressive drug class exposure showed a
14
15 202 significantly increased risk of infection among users of anti-TNF (HR: 1.8, 95% CI: 1.6, 2.0), systemic
16
17 203 corticosteroid (HR: 1.2, 95% CI: 1.0,1.5), and rituximab and other immunosuppressant (HR: 1.3, 95% CI: 1.1,
18
19 204 1.4). No other immunosuppressant was significantly associated with COVID-19 infection following second
20
21 205 vaccination (Figure 3). Anti-TNF and systemic corticosteroid exposure were also associated with an increased
22
23 206 risk of COVID-19 associated hospitalization (HR 1.8, 95% CI 1.0, 3.3 and HR 1.8, 95% CI 1.0,3.0,
24
25 207 respectively; Figure 4). No immunosuppressive drug class was associated with death among IMID patients
26
27 208 following receipt of second vaccination.

29
30 209
31
32 210 Sensitivity analysis assessing outcomes following any systemic corticosteroid exposure in the 120-day period
33
34 211 prior to the index date showed no significant difference in risk of infection (crude HR: 1.2, 95% CI: 1.0, 1.4;
35
36 212 adjusted HR: 1.1, 95% CI: 0.95, 1.3) or death (crude HR: 3.1, 95% CI: 1.4, 7.0; adjusted HR: 1.9, 95% CI:
37
38 213 0.77, 4.7) (Supplementary Table 6). However, risk of hospitalization following infection was significantly
39
40 214 increased in those ever exposed to systemic corticosteroids in the 120-day period prior to receipt of second
41
42 215 vaccination (crude HR: 2.8, 95% CI: 1.9, 4.1; adjusted HR: 2.1, 95% CI: 1.4, 3.2), showing similar results
43
44 216 compared with analysis restricting to a ≥ 7.5 mg daily equivalent dose.

46 217 47 48 218 **DISCUSSION**

49
50 219 In this large nation-wide cohort study of three IMID patient cohorts, we identified a total of 39,755
51
52 220 immunosuppressive exposed patients matched to 112,619 immunosuppressive unexposed IMID patients to
53
54 221 investigate the risk of COVID-19 infection, hospitalization, and death among IBD, arthropathy and psoriasis
55
56 222 patients following second SARS-CoV-2 vaccination. Meta-analysis of the three cohorts showed an overall
57
58
59
60

1
2
3
4 223 35% increased risk of infection and, 42% increased risk of COVID-19 associated hospitalization in
5
6 224 immunosuppressive exposed compared to immunosuppressive unexposed IMID patients.
7

8 225
9
10 226 Mortality was not significantly increased in immunosuppressive exposed patients as these events were rare.
11
12 227 Drug class analysis showed anti-TNF, systemic corticosteroid, and rituximab and other immunosuppressant
13
14 228 exposure was significantly associated with both increased risk of COVID-19 infection and hospitalization
15
16 229 following second vaccination in immunosuppressive exposed compared to unexposed IMID patients.
17
18

19 230
20
21 231 We attempted to ascertain the effectiveness of SARS-CoV-2 mRNA vaccination among IMID patients
22
23 232 exposed to immunosuppressive therapies, while controlling for the severity of the underlying disease indicating
24
25 233 immunosuppressive treatment with a propensity score model. We found that immunosuppressants were
26
27 234 associated with an increased risk of infection, likely due to the impact of immunosuppressive medication on
28
29 235 vaccination against COVID-19 infection. This is particularly seen in IBD but is also present in arthropathy
30
31 236 patients and, to a lesser, but not significant extent, in psoriasis. Similarly, when assessing risk of hospitalization
32
33 237 following vaccination by immunosuppressive exposure, we find a significantly increased risk in IBD patients,
34
35 238 which is not observed in arthropathy or psoriasis. The poorer outcomes observed in immunosuppressive
36
37 239 exposed IBD patients have not been identified elsewhere. In a meta-analysis of serological response to SARS-
38
39 240 CoV-2 vaccination among IMID treated patients, IBD patients were found to have a higher response to second
40
41 241 mRNA vaccination dose than psoriasis or rheumatoid patients (event rate: 0.94, 95% CI: 0.86, 0.68; 0.9, 95%
42
43 242 CI: 0.33, 0.99; 0.8, 95% CI: 0.68, 0.88 respectively) (20). This finding may be an indication that serological
44
45 243 response is not a sufficient correlate of immunity for COVID-19 infection following vaccination, particularly
46
47 244 in immunosuppressive treated patients. IBD patients typically present with more extensive disease, often
48
49 245 necessitating higher doses of immunosuppressive therapy, over longer periods to achieve disease remission
50
51 246 than that required for psoriasis or arthropathies (21–23). However, overall pooled IMID cohort meta-analysis
52
53 247 showed a significantly increased risk for both these outcomes, indicating a general trend towards poorer
54
55 248 outcomes in immunosuppressive exposed patients regardless of IMID cohort.
56
57 249
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

250 Reassuringly, immunosuppressant exposure was not associated with increased risk of death due to COVID-19
251 in any of the IMID patient cohorts, suggesting immunosuppressants do not reduce the effectiveness of
252 vaccination in preventing this important outcome. However, caution should be exercised in the interpretation
253 of this finding as deaths were recorded in either immunosuppressive exposed or unexposed patients and this
254 may be due to the relatively short follow-up period of 11-months in this study.

255
256 Treatment with TNF-alpha inhibitors, systemic corticosteroid, and rituximab and other immunosuppressants
257 was associated with a significantly increased risk of infection and hospitalization following receipt of second
258 vaccination. This is consistent with previous studies, which suggests that treatment with cytokine inhibitors or
259 B-cell depleting immunosuppressives is related to particularly poor COVID-19 outcomes (24–26), however
260 the association with TNF-alpha inhibitors is novel. Our findings of increased risk of infection and
261 hospitalization, but not death, in sensitivity analysis among IMID patients exposed to systemic corticosteroids
262 is also in keeping with those other studies of unvaccinated IMID cohorts in Denmark (4) and internationally
263 (6,27). These findings indicate that corticosteroid exposure weakens the protection conferred by vaccination.
264 As glucocorticoids are known to inhibit the breadth of the immune response, including aspects of both the
265 cellular and humoral immunity induced by mRNA vaccination, these findings appear to be intuitive (28). The
266 interaction of IMID, the impact of treatments to control disease and response to vaccination, particularly
267 considering the effects of dose and duration of administration is however complex (29,30) and the small
268 number of hospitalization events, particularly in those receiving TNF-alpha inhibitors and systemic
269 corticosteroid treatment means that these findings should be interpreted with caution. Further studies directly
270 exploring the effects of vaccination whilst controlling for disease severity and exposure of immunosuppressive
271 drugs by dose and duration would be required to disentangle the association of the different
272 immunosuppressive drug classes with COVID-19 outcomes following vaccination. Such studies would also
273 better inform guidance relating to timelines for SARS-CoV-2 vaccination in relation to the administration of
274 immunosuppressive therapies in IMID patients.

1
2
3
4 276 One of the key strengths of this study is that it is large and population-representative, exploring the
5
6 277 effectiveness of COVID-19 infection using real-world data from comprehensive, nationwide health registries.
7
8 278 Vaccination does not directly correlate with protection from infection and the findings from this work provides
9
10 279 important evidence on effectiveness of post-marketing mRNA vaccination in a vulnerable patient group. To
11
12 280 our knowledge, this is the first study to assess the effectiveness of SARS-CoV-2 vaccination against COVID-
13
14 281 19 infection, hospitalization, and mortality among IMID patients, based on immunosuppressive exposure.
15
16 282 Additionally, our use of PS weighted regression models allows us to accurately control for the underlying
17
18 283 treatment indicating disease, so we are better able to extrapolate the effects of the drug exposure from the
19
20 284 disease itself. We restricted to a period of the pandemic where the delta variant was the dominant circulating
21
22 285 strain of COVID-19 to ensure consistency in the assessment of our outcomes, although this limits extrapolation
23
24 286 in the context of the omicron variant, or subsequent subvariants. Another potential limitation is the short
25
26 287 calendar time that patients are followed up for infection, hospitalization, and mortality outcomes. We do
27
28 288 however see a significantly increased risk of infection and hospitalization over the follow up time, which
29
30 289 indicates that there was a sufficient follow-up period to detect a difference in poor COVID-19 outcomes.
31
32 290 Although it is difficult to define a reliable threshold for which we consider a patient unexposed to
33
34 291 immunosuppressive medication, it is reassuring that only approximately 12% of our unexposed group had
35
36 292 filled a prescription in the 365 days prior to the 120-day exposure window assessed, and that removing the
37
38 293 minimum threshold of 7.5 mg of systemic corticosteroids as an exposure requirement did not change our
39
40 294 findings. A lack of individual-level data relating to confounders such as smoking behaviour, socio-economic
41
42 295 status and dose of drug therapies could potentially limit our findings. There may also be a residual effect of
43
44 296 confounding due to unmeasured disease severity not completely accounted for in our PS model. However,
45
46 297 these are unlikely to systemically impact the direction of association or strength of significance identified in
47
48 298 the risk of infection due to immunosuppressive exposure observed here.
49
50
51
52

53 299
54
55 300 In conclusion, our findings suggest a reduced effectiveness of mRNA SARS-CoV-2 vaccination against
56
57 301 COVID-19 infection and hospitalization in IMID patients receiving immunosuppressive therapies. This risk is
58
59
60

1
2
3
4 302 particularly seen in IBD and arthropathy patients and is associated with anti-TNF, systemic corticosteroids,
5
6 303 and rituximab and other immunosuppressant exposure.
7
8
9 304

10
11 305 **Author Contributions:** DW, RE, AP and TJ developed the study protocol. ME undertook primary data
12
13 306 analysis with support from GP. DW and RE were responsible for first draft of the manuscript. All authors were
14
15 307 responsible for interpretation of results and critical revisions to the final manuscript.
16

17 308
18
19 309 **Acknowledgements:** Funding Sources - This work was funded by grants from the Novo Nordisk Foundation
20
21 310 (NNF21OC0068631) and the Danish National Research Foundation (DNRF-148).
22

23 311
24
25 312 **Conflict of Interest Statement:** All authors have none to declare.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. European Medicines Agency. *COVID-19 vaccines safety update: 8 December 2022 Rev. 1*. [Accessed 8th February 2023]. www.ema.europa.eu.
2. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *New England Journal of Medicine*. 2021;385(19): 1774–1785. <https://doi.org/10.1056/nejmoa2113017>.
3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine*. 2020;383(27): 2603–2615. https://doi.org/10.1056/NEJMOA2034577/SUPPL_FILE/NEJMOA2034577_PROTOCOL.PDF.
4. Ward D, Gørtz S, Ernst MT, Andersen NN, Kjær SK, Hallas J, et al. The effect of immunosuppressants on the prognosis of COVID-19 infection. *The European respiratory journal*. 2022;59(4). <https://doi.org/10.1183/13993003.00769-2021>.
5. Gianfrancesco M, Hyrich KL, Al-Adely S, Al-Adely S, Carmona L, Danila MI, et al. Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Annals of the rheumatic diseases*. 2020;79(7): 859–866. <https://doi.org/10.1136/ANNRHEUMDIS-2020-217871>.
6. Brenner EJ, Ungaro RC, Geary RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. *Gastroenterology*. 2020;159(2): 481-491.e3. <https://doi.org/10.1053/J.GASTRO.2020.05.032>.
7. Salter A, Fox RJ, Newsome SD, Halper J, Li DKB, Kanellis P, et al. Outcomes and Risk Factors Associated With COVID-19 infection in a North American Registry of Patients With Multiple Sclerosis. *JAMA neurology*. 2021;78(6): 699–708. <https://doi.org/10.1001/JAMANEUROL.2021.0688>.
8. Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Annals of the Rheumatic Diseases*. 2021;80(7): 930–942. <https://doi.org/10.1136/ANNRHEUMDIS-2020-219498>.
9. Lee ARY bin, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. *BMJ (Clinical research ed.)*. 2022;376: e068632. <https://doi.org/10.1136/BMJ-2021-068632>.
10. Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZLE, Kummer LY, et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. *The Lancet. Rheumatology*. 2021;3(11): e778–e788. [https://doi.org/10.1016/S2665-9913\(21\)00222-8](https://doi.org/10.1016/S2665-9913(21)00222-8).
11. Alexander JL, Kennedy NA, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. *The lancet. Gastroenterology & hepatology*. 2022;7(4): 342–352. [https://doi.org/10.1016/S2468-1253\(22\)00005-X](https://doi.org/10.1016/S2468-1253(22)00005-X).

12. de Boer SE, Berger SP, van Leer–Buter CC, Kroesen BJ, van Baarle D, Sanders JSF. Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil-containing Immunosuppressive Regimens. *Transplantation*. 2022;106(8). <https://doi.org/10.1097/TP.0000000000004177>.
13. Pottegård A, Kristensen KB, Reilev M, Lund LC, Ernst MT, Hallas J, et al. Existing Data Sources in Clinical Epidemiology: The Danish COVID-19 Cohort. *Clinical epidemiology*. 2020;12: 875–881. <https://doi.org/10.2147/CLEP.S257519>.
14. Voldstedlund M, Haarh M, Mølbak K. The Danish Microbiology Database (MiBa) 2010 to 2013. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin*. 2014;19(1). <https://doi.org/10.2807/1560-7917.ES2014.19.1.20667>.
15. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. *Clinical epidemiology*. 2015;7: 449–490. <https://doi.org/10.2147/CLEP.S91125>.
16. Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data Resource Profile: The Danish National Prescription Registry. *International journal of epidemiology*. 2017;46(3): 798. <https://doi.org/10.1093/IJE/DYW213>.
17. Espenhain L, Funk T, Overvad M, Edslev SM, Fonager J, Ingham AC, et al. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin*. 2021;26(50). <https://doi.org/10.2807/1560-7917.ES.2021.26.50.2101146>.
18. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. *Biometrika*. 1983;70(1): 41–55. <https://doi.org/10.1093/BIOMET/70.1.41>.
19. Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. *BMJ*. 2019;367. <https://doi.org/10.1136/BMJ.L5657>.
20. Sakuraba A, Luna A, Micic D. Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis. *Gastroenterology*. 2022;162(1): 88-108.e9. <https://doi.org/10.1053/J.GASTRO.2021.09.055>.
21. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis: <https://doi.org/10.1177/2475530318812244>. 2018;4(1): 31–58. <https://doi.org/10.1177/2475530318812244>.
22. Larsen L, Jensen MD, Larsen MD, Nielsen RG, Thorsgaard N, Vind I, et al. The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease. *Clinical epidemiology*. 2016;8: 607–612. <https://doi.org/10.2147/CLEP.S99478>.
23. Cottone M, Sapienza C, Macaluso FS, Cannizzaro M. Psoriasis and Inflammatory Bowel Disease. *Digestive diseases (Basel, Switzerland)*. 2019;37(6). <https://doi.org/10.1159/000500116>.
24. Hernán MA. The hazards of hazard ratios. *Epidemiology*. 2010;21(1): 13–15. <https://doi.org/10.1097/EDE.0B013E3181C1EA43>.

- 1
2
3
4 25. Izadi Z, Brenner EJ, Mahil SK, Dand N, Yiu ZZN, Yates M, et al. Association Between Tumor Necrosis Factor
5 Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory
6 Disease and COVID-19. *JAMA network open*. 2021;4(10).
7 <https://doi.org/10.1001/JAMANETWORKOPEN.2021.29639>.
8
9
10 26. Simon D, Tascilar K, Kleyer A, Fagni F, Krönke G, Meder C, et al. Impact of Cytokine Inhibitor Therapy on the
11 Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an
12 Unvaccinated Cohort. *Arthritis & rheumatology (Hoboken, N.J.)*. 2022;74(5): 783–790.
13 <https://doi.org/10.1002/ART.42035>.
14
15 27. Simon D, Tascilar K, Fagni F, Krönke G, Kleyer A, Meder C, et al. SARS-CoV-2 vaccination responses in
16 untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory
17 diseases. *Annals of the rheumatic diseases*. 2021;80(10): 1312–1316.
18 <https://doi.org/10.1136/ANNRHEUMDIS-2021-220461>.
19
20
21 28. Favalli EG, Bugatti S, Klersy C, Biggioggero M, Rossi S, de Lucia O, et al. Impact of corticosteroids and
22 immunosuppressive therapies on symptomatic COVID-19 infection in a large cohort of patients with chronic
23 inflammatory arthritis. *Arthritis research & therapy*. 2020;22(1). [https://doi.org/10.1186/S13075-020-02395-](https://doi.org/10.1186/S13075-020-02395-6)
24 6.
25
26 29. McKay LI, Cidlowski JA. Physiologic and Pharmacologic Effects of Corticosteroids. 2003;
27 <https://www.ncbi.nlm.nih.gov/books/NBK13780/>
28
29 30. Rahier JF, Moutschen M, van Gompel A, van Ranst M, Louis E, Segaeert S, et al. Vaccinations in patients with
30 immune-mediated inflammatory diseases. *Rheumatology (Oxford, England)*. 2010;49(10): 1815–1827.
31 <https://doi.org/10.1093/RHEUMATOLOGY/KEQ183>.
32
33 31. Croce E, Hatz C, Jonker EF, Visser LG, Jaeger VK, Bühler S. Safety of live vaccinations on immunosuppressive
34 therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-
35 marrow transplantation - A systematic review of randomized trials, observational studies and case reports.
36 *Vaccine*. 2017;35(9): 1216–1226. <https://doi.org/10.1016/J.VACCINE.2017.01.048>.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Characteristics of immune-mediated inflammatory disease patients at baseline and after propensity score weighting, by exposure to immunosuppressive therapy.

	Baseline IMID Cohort*			Weighted IMID Cohort		
	Unexposed	Exposed	SD	Unexposed	Exposed	SD
Total, n (%)	112 675 (100)	39 765 (100)	NA	39 524 (100)	39 765 (100)	NA
Inflammatory bowel disease, n (%)	47 001 (41.7)	10 480 (26.4)	NA	10 284 (26.0)	10 480 (26.4)	NA
Arthropathy, n (%)	44 669 (39.6)	24 261 (61.0)	NA	24 227 (61.3)	24 261 (61.0)	NA
Psoriasis, n (%)	21 005 (18.6)	5 024 (12.6)	NA	5 014 (12.7)	5 024 (12.6)	NA
Age, median (IQR)	59 (46-71)	58 (45-71)	0.06	58 (44-71)	58 (45-71)	0.01
Male, n (%)	48 941 (43.4)	17 080 (43.0)	0.01	16 934 (42.8)	17 080 (43.0)	0.00
SARS-CoV-2 test in the previous month, median (IQR)	0 (0-1)	0 (0-1)	0.04	0 (0-1)	0 (0-1)	0.00
Comorbidities, n (%)						
Cardiovascular disease	41 056 (36.4)	14 010 (35.2)	0.03	14 050 (35.5)	14 010 (35.2)	0.01
Pulmonary disease	14 994 (13.3)	5 793 (14.6)	0.04	5796 (14.7)	5 793 (14.6)	0.00
Liver disease	3 630 (3.2)	1 528 (3.8)	0.03	1 525 (3.9)	1 528 (3.8)	0.00
Kidney disease	6 859 (6.1)	2 260 (5.7)	0.02	2 279 (5.8)	2 260 (5.7)	0.00
Other gastrointestinal diseases	21 505 (19.1)	7 086 (17.8)	0.03	6 984 (17.7)	7 086 (17.8)	0.00
Skin disease	9 889 (8.8)	3 748 (9.4)	0.02	3 703 (9.4)	3 748 (9.4)	0.00
Musculoskeletal disease	45 393 (40.3)	16 620 (41.8)	0.03	16 649 (42.1)	16 620 (41.8)	0.01
Medications, n (%)						
Cardiovascular drugs	80 529 (71.5)	28 179 (70.9)	0.01	28 054 (71.0)	28 179 (70.9)	0.00
Antibiotics	108 502 (96.3)	38 405 (96.6)	0.02	38 181 (96.6)	38 405 (96.6)	0.00
Oral anticoagulants	11 111 (9.9)	4 022 (10.1)	0.01	4 034 (10.2)	4 022 (10.1)	0.00
Drugs used in diabetes	12 935 (11.5)	4 034 (10.1)	0.04	4 030 (10.2)	4 034 (10.1)	0.00
Drugs for obstructive airway diseases	36 970 (32.8)	13 118 (33.0)	0.00	13 116 (33.2)	13 118 (33.0)	0.00
IBD-specific treatments, n (%)						
Any IBD-related hospital admissions in the previous year	564 (1.2)	714 (6.8)	0.12	584 (5.7)	714 (6.8)	0.05
5-ASA/sulfasalazine	12 596 (26.8)	2 845 (27.1)	0.00	2 857 (27.8)	2 845 (27.1)	0.01
Budesonide	646 (1.4)	272 (2.6)	0.02	277 (2.7)	272 (2.6)	0.01
IBD related procedures	18 553 (39.5)	4 551 (43.4)	0.05	4 473 (43.5)	4 551 (43.4)	0.00

Endoscopy of the gastrointestinal tract	7 454 (15.9)	3 702 (35.3)	0.12	3 543 (34.5)	3 702 (35.3)	0.02
Arthropathy-specific treatments, n (%)						
Arthropathy-related procedures	13 932 (31.2)	8 415 (34.7)	0.09	8 399 (34.7)	8 415 (34.7)	0.00
Anti-inflammatory and anti-rheumatic drugs	5 678 (12.7)	3 462 (14.3)	0.07	3 480 (14.4)	3 462 (14.3)	0.00
Hydroxychloroquine	540 (1.2)	845 (3.5)	0.15	801 (3.3)	845 (3.5)	0.01
Psoriasis-specific treatments, n (%)						
5-ASA/sulfasalazine	2 149 (10.2)	807 (16.1)	0.03	805 (16.1)	807 (16.1)	0.00
Topical corticosteroids	73 (0.3)	42 (0.8)	0.00	39 (0.8)	42 (0.8)	0.01
Anti-psoriatic medication	7 441 (35.4)	1 894 (37.7)	0.01	1 900 (37.9)	1 894 (37.7)	0.00
Topical calcineurin inhibitors	3 731 (17.8)	1 106 (22.0)	0.00	1 110 (22.1)	1 106 (22.0)	0.00
Psoriasis related procedures	542 (2.6)	144 (2.9)	0.00	144 (2.9)	144 (2.9)	0.00

Abbreviations: IMID = immune-mediated inflammatory disease; SD = standardized differences; IQR = inter-quartile range; NA = not applicable. *Total cohort numbers prior to trimming.

FIGURE LEGENDS

Figure 1. Flow chart for inclusion into the IMID cohort.

Figure 2. Risk of infection, hospitalization and death associated with immunosuppressive exposure from Jan 2021-Nov 2021 in Inflammatory Bowel Disease, Arthropathy, Psoriasis and meta-analysis across all IMID cohorts.

Abbreviations: IMID=immune-mediated and inflammatory disease; IBD=inflammatory bowel disease; w=weighted; HR=hazard ratio; 95%-CI=95% confidence interval


Figure 3. Risk of infection associated with immunosuppressive drug class exposure (Selective Immunosuppressants, Tumour Necrosis Factor Inhibitors, Interleukin Inhibitors, Calcineurin Inhibitors, Systemic Corticosteroids, and Other Immunosuppressants including Rituximab).

Abbreviations: HR=hazard ratio; 95%-CI=95% confidence interval


Figure 4. Risk of hospitalization associated with immunosuppressive drug class exposure (Selective Immunosuppressants, Tumour Necrosis Factor Inhibitors, Interleukin Inhibitors, Calcineurin Inhibitors, Systemic Corticosteroids, and Other Immunosuppressants including Rituximab).

Abbreviations: HR=hazard ratio; 95%-CI=95% confidence interval

Figure 1.



190x275mm (96 x 96 DPI)

Figure 2.

296x209mm (200 x 200 DPI)

Figure 3.




Figure 3. Risk of infection associated with immunosuppressive drug class exposure (Selective Immunosuppressants, Tumour Necrosis Factor Inhibitors, Interleukin Inhibitors, Calcineurin Inhibitors, Systemic Corticosteroids, and Other Immunosuppressants including Rituximab) in IMID patients.

296x209mm (200 x 200 DPI)

Figure 4.




Figure 4. Risk of hospitalization associated with immunosuppressive drug class exposure (Selective Immunosuppressants, Tumour Necrosis Factor Inhibitors, Interleukin Inhibitors, Calcineurin Inhibitors, Systemic Corticosteroids, and Other Immunosuppressants including Rituximab) in IMID patients.

296x209mm (200 x 200 DPI)

The Impact of Immunosuppressive Therapy on SARS-CoV-2 mRNA Vaccine Effectiveness in Patients with Immune-mediated Inflammatory Diseases: A Danish Nationwide Cohort Study

Rahma Elmahdi^{*1,2} (0000-0002-7013-9548), Daniel Ward^{*1} (0000-0003-0405-7250), Martin Thomsen Ernst³ (0000-0001-9003-3823), Gry Juul Poulsen¹ (0000-0003-2744-2469), Jesper Hallas³ (0000-0002-8097-8708), Anton Pottegård³ (0000-0001-9314-5679), Tine Jess^{1,4} (0000-0002-4391-7332)

Supplementary Tables

Supplementary Table 1. Exposures and corresponding ATC and procedure codes for immunosuppressives

Medication	ATC code	Procedure code
Selective immunosuppressants		
Muromonab-CD3	L04AA02	
Antilymphocyte immunoglobulin (horse)	L04AA03	
Antithymocyte immunoglobulin (rabbit)	L04AA04	BOHJ12
Mycophenolic acid	L04AA06	BOHJ22
Sirolimus	L04AA10	BOHJ23
Leflunomide	L04AA13	
Everolimus	L04AA18	BOHJ24
Natalizumab	L04AA23	BOHJ26
Abatacept	L04AA24	BOHJ18C1
Eculizumab	L04AA25	BWHB84
Belimumab	L04AA26	BOHJ19H6
Fingolimod	L04AA27	BOHJ27
Belatacept	L04AA28	
Tofacitinib	L04AA29	BOHJ28D
Teriflunomide	L04AA31	BOHJ28A
Aprelimast	L04AA32	
Vedolizumab	L04AA33	BOHJ19H4
Alemtuzumab	L04AA34	BOHJ16A
Ocrelizumab	L04AA36	
Baricitinib	L04AA37	
Ozanimod	L04AA38	
Emapalumab	L04AA39	
Cladribine	L04AA40	BWHA178
Imlifidase	L04AA41	
Siponimod	L04AA42	BWHB87
	L04AA43	

Ravulizumab Upadacitinib	L04AA44	
Tumour necrosis factor inhibitors		
Etanercept	L04AB01	BOHJ18A2
Infliximab	L04AB02	BOHJ18A1
Adalimumab	L04AB04	BOHJ18A3
Certolizumab pegol	L04AB05	BOHJ18A5
Golimumab	L04AB06	BOHJ18A4
Interleukin inhibitors		
Basiliximab	L04AC02	
Anakinra	L04AC03	BOHJ18B1
Ustekinumab	L04AC05	BOHJ18B3
Tocilizumab	L04AC07	BOHJ18B2
Canakinumab	L04AC08	BOHJ18B4
Secukinumab	L04AC10	BOHJ18B5
Siltuximab	L04AC11	
Brodalumab	L04AC12	BOHJ18B6
Ixekizumab	L04AC13	
Sarilumab	L04AC14	BOHJ18B9
Guselkumab	L04AC16	
Tildrakizumab	L04AC17	BOHJ18B7
Risankizumab	L04AC18	BOHJ19N1
Calcineurin inhibitors		
Ciclosporin	L04AD01	BOHJ20
Tacrolimus	L04AD02	BOHJ21
Other immunosuppressants		
Azathioprine	L04AX01	BWHB83
Thalidomide	L04AX02	BWHB81
Methotrexate	L04AX03	BWHA115
Lenalidomide	L04AX04	BWHB82
Pirfenidone	L04AX05	BWHB85
Pomalidomide	L04AX06	BWHB86
Dimethyl fumarate	L04AX07	BOHJ28B
Darvadstrocel	L04AX08	
Systemic corticosteroids	H02AB	
Rituximab	L01XC02	

Supplementary Table 2. Covariates by disease cohort

IBD COHORT		
Covariate	Categories/ ATC/ICD codes	Assessment window
Age	-	At cohort entry
Sex	-	At cohort entry
SARS-CoV-2 tests in the previous month	-	At cohort entry
Ever previous SARS-CoV-2 positive test	-	From February 2020
IBD specific covariates		
Any IBD-related hospital admissions in the previous year	K50/K51	1 year before cohort entry
Crohn's disease	K50	At cohort entry
Ulcerative colitis	K51	At cohort entry
5-ASA/sulfasalazine	MA07EC0	1 year before matching date
Budesonide	MA07EA06	3 months before matching date
IBD related procedures		Any time before cohort entry
Operations of the small bowel and colon	KJF	
Operations of the rectum	KJG	
Operations of the anus and perianal tissue	KJH	
Operational of the abdominal wall, peritoneum, mesentery and omentum	KJA	
Lysis of adhesion in the abdominal cavity	KJAP	
Closure of intestinovaginal fistula	KLEE30	
Closure of vesiculointestinal fistula	KKCH30	
Endoscopy of the gastrointestinal tract	KUJ	1 year before the cohort entry
Comorbidities		
Cardiovascular disease	DI1-I7	Any time before cohort entry
Pulmonary disease		Any time before cohort entry
Chronic disease of the lower airways	DJ4	
Other interstitial lung disease	DJ84	
Diseases with pus and necrosis in the lower airway	DJ85	
Interstitial lung emphysema	DJ982	
compensatory emphysema	DJ983	
Liver disease	DK70-K77	Any time before cohort entry
Kidney disease		Any time before cohort entry
Glomerular disease	DN0	
Tubulointerstitial kidney disease and kidney insufficiency	DN1	
Other gastrointestinal diseases		Any time before cohort entry
Gingivitis and periodontal disease	DK05	
Inflammation of the oral mucosa and related	DK12	
Stomach and duodenal ulcers	DK25-27	
Fissure and rifts in and around the anus	DK60	
Abscess in and around the anus	DK61	
Other diseases of the rectum and anus	DK62	
Other bowel disease	DK63	

1 2 3 4 5 6 7 8 9 10 11 12 13	Skin disease Bullous skin disease Dermatitis and eczema Alopecia areata Vitiligo Granulomatous disease in the skin and subcutaneous tissue Lupus Other localised connective tissue disease Vasculitis limited to the skin	DL10-14 DL20-30 DL63 DL80 DL92 DL93 DL94 DL95	Any time before cohort entry
14 15 16 17 18	Musculoskeletal disease Generalised connective tissue diseases Diseases of the muscles Soft-tissue rheumatism	DM30- DM36 DM60-63 DM70-79	Any time before cohort entry
19	Medications		
20 21 22	Cardiovascular drugs	MC01-MC10	Any time before cohort entry
23 24	Antibiotics	MJ01	Any time before cohort entry
25 26	Oral anticoagulants	MB01AA MB01AF	Any time before cohort entry
27 28	Drugs used in diabetes	MA10	Any time before cohort entry
29 30	Drugs for obstructive airway diseases	MR03	Any time before cohort entry
31	INFLAMMATORY ARTHROPATHIES COHORT		
32	Age	-	At cohort entry
33	Sex	-	At cohort entry
34	SARS-CoV-2 tests in the previous month	-	At cohort entry
35	Arthropathy-specific covariates		
36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	Arthropathy-related procedures Shoulder and upper arm Primary insertion of joint prosthesis Secondary insertion of joint prosthesis Operations on the joint capsule and ligaments Operations of the synovia and joint surface Joint resections, arthroplasties, and arthrodesis Excision of bursa Elbow and lower arm Primary insertion of joint prosthesis Secondary insertion of joint prosthesis Operations on the joint capsule and ligaments Operations of the synovia and joint surface Joint resections, arthroplasties, and arthrodesis Excision of bursa Wrist and hand Primary insertion of joint prosthesis Secondary insertion of joint prosthesis Operations on the joint capsule and ligaments Operations of the synovia and joint surface Joint resections, arthroplasties, and arthrodesis Operations on the fascia, tendon sheaths, ganglia and bursae	KNBB KNBC KNBE KNBF KNBG KBM79 KNCB KNCC KNCE KNCF KNCG KNCM79 KNDB KNDC KNDE KNDF KNDG KNDM	Any time before cohort entry

<p>Hip and thigh</p> <p>Primary insertion of joint prosthesis</p> <p>Secondary insertion of joint prosthesis</p> <p>Operations on the joint capsule and ligaments</p> <p>Operations of the synovia and joint surface</p> <p>Joint resections, arthroplasties, and arthrodesis</p> <p>Excision of bursa in the</p> <p>Knee and lower leg</p> <p>Primary insertion of joint prosthesis</p> <p>Secondary insertion of joint prosthesis</p> <p>Operations on the joint capsule and ligaments</p> <p>Operations of the synovia and joint surface</p> <p>Joint resections, arthroplasties, and arthrodesis</p> <p>Excision of bursae</p> <p>Ankle and foot</p> <p>Primary insertion of joint prosthesis</p> <p>Secondary insertion of joint prosthesis</p> <p>Operations on the joint capsule and ligaments</p> <p>Operations of the synovia and joint surface</p> <p>Joint resections, arthroplasties, and arthrodesis</p> <p>Operations on the fascia, tendon sheaths, ganglia and bursae</p>	<p>KNFB</p> <p>KNFC</p> <p>KNFE</p> <p>KNFF</p> <p>KNFG</p> <p>KNFM79</p> <p>KNGB</p> <p>KNGC</p> <p>KNGE</p> <p>KNGF</p> <p>KNGG</p> <p>KNGM79</p> <p>KNHB</p> <p>KNHC</p> <p>KNHE</p> <p>KNHF</p> <p>KNHG</p> <p>KNHM</p>	
<p>Anti-inflammatory and anti-rheumatic drugs inc. specific anti-rheumatic therapies, non-steroidals, and combination medications</p> <p>Hydroxychloroquine</p>	<p>M01</p> <p>P01BA02</p>	<p>3 months before cohort entry</p>
Comorbidities		
Cardiovascular disease	DI1-I7	Any time before cohort entry
<p>Pulmonary disease</p> <p>Chronic disease of the lower airways</p> <p>Other interstitial lung disease</p> <p>Diseases with pus and necrosis in the lower airway</p> <p>Interstitial lung emphysema</p> <p>compensatory emphysema</p>	<p>DJ4</p> <p>DJ84</p> <p>DJ85</p> <p>DJ982</p> <p>DJ983</p>	Any time before cohort entry
Liver disease	DK70-K77	Any time before cohort entry
<p>Kidney disease</p> <p>Glomerular disease</p> <p>Tubulointerstitial kidney disease and kidney insufficiency</p>	<p>DN0</p> <p>DN1</p>	Any time before cohort entry
<p>Other gastrointestinal diseases</p> <p>Gingivitis and periodontal disease</p> <p>Inflammation of the oral mucosa and related</p> <p>Stomach and duodenal ulcers</p> <p>Fissure and rifts in and around the anus</p> <p>Abscess in and around the anus</p> <p>Other diseases of the rectum and anus</p> <p>Other bowel disease</p>	<p>DK05</p> <p>DK12</p> <p>DK25-27</p> <p>DK60</p> <p>DK61</p> <p>DK62</p> <p>DK63</p>	Any time before cohort entry
<p>Skin disease</p> <p>Bullous skin disease</p> <p>Dermatitis and eczema</p> <p>Alopecia areata</p>	<p>DL10-14</p> <p>DL20-30</p> <p>DL63</p>	Any time before cohort entry

Vitiligo Granulomatous disease in the skin and subcutaneous tissue Lupus Other localised connective tissue disease Vasculitis limited to the skin	DL80 DL92 DL93 DL94 DL95	
Musculoskeletal disease Generalised connective tissue diseases Diseases of the muscles Soft-tissue rheumatism	DM30- DM36 DM60-63 DM70-79	Any time before cohort entry
Medications		
Cardiovascular drugs	MC01-MC10	Any time before cohort entry
Antibiotics	MJ01	Any time before cohort entry
Oral anticoagulants	MB01AA MB01AF	Any time before cohort entry
Drugs used in diabetes	MA10	Any time before cohort entry
Drugs for obstructive airway diseases	MR03	Any time before cohort entry
PSORIASIS COHORT		
Age	-	At cohort entry
Sex	-	At cohort entry
SARS-CoV-2 tests in the previous month	-	At cohort entry
Psoriasis-specific covariates		
Procedures Ultraviolet therapy: UV-A with psoralen/broad-spectrum UVB / narrow-spectrum UVB	BNGA1/ BNGA2/ BNGA3	Any time before cohort entry
Therapeutic steroid injection in the joints and soft tissues	BLHN0	Any time before cohort entry
5-ASA/sulfasalazine	A07EC0	1 year before cohort entry
Topical corticosteroids	D07	1 year before cohort entry
Antipsoriatic medication	D05	1 year before cohort entry
Topical calcineurin inhibitors	D11AH01-02,	1 year before cohort entry
Comorbidities		
Cardiovascular disease	DI1-I7	Any time before cohort entry
Pulmonary disease Chronic disease of the lower airways Other interstitial lung disease Diseases with pus and necrosis in the lower airway Interstitial lung emphysema compensatory emphysema	DJ4 DJ84 DJ85 DJ982 DJ983	Any time before cohort entry

Liver disease	DK70-K77	Any time before cohort entry
Kidney disease Glomerular disease Tubulointerstitial kidney disease and kidney insufficiency	DN0 DN1	Any time before cohort entry
Other gastrointestinal diseases Gingivitis and periodontal disease Inflammation of the oral mucosa and related Stomach and duodenal ulcers Fissure and rifts in and around the anus Abscess in and around the anus Other diseases of the rectum and anus Other bowel disease	DK05 DK12 DK25-27 DK60 DK61 DK62 DK63	Any time before cohort entry
Skin disease Bullous skin disease Dermatitis and eczema Alopecia areata Vitiligo Granulomatous disease in the skin and subcutaneous tissue Lupus Other localised connective tissue disease Vasculitis limited to the skin	DL10-14 DL20-30 DL63 DL80 DL92 DL93 DL94 DL95	Any time before cohort entry
Musculoskeletal disease Generalised connective tissue diseases Diseases of the muscles Soft-tissue rheumatism	DM30- DM36 DM60-63 DM70-79	Any time before cohort entry
Medications		
Cardiovascular drugs	MC01-MC10	Any time before cohort entry
Antibiotics	MJ01	Any time before cohort entry
Oral anticoagulants	MB01AA MB01AF	Any time before cohort entry
Drugs used in diabetes	MA10	Any time before cohort entry
Drugs for obstructive airway diseases	MR03	Any time before cohort entry

Supplementary Table 3. Minimum daily dose of corticosteroid in exposed persons

Compound	Equivalent dose
Cortisone	38mg
Hydrocortisone	30mg
Prednisone	7.5mg
Prednisolone	7.5mg
Triamcinolone	6mg
Methylprednisolone	6mg
Betamethasone	0.9mg
Dexamethasone	1.2mg

Supplementary Table 4. Risk of infection, hospitalisation and death associated with immunosuppressive therapy in vaccinated patients with immune-mediated inflammatory diseases

	Exposed				Unexposed				Crude HR (95% CI) ***	Weighted HR (95% CI) ***
	Total	Events	Incidence rate (95% CI) **	PY	Total	Events	Incidence rate (95% CI) **	PY		
COVID-19 Infection*										
IBD	10 477	287	54.7 (48.7-61.4)	5 246	46 974	885	42.5 (39.8-45.4)	20 809	1.7 (1.5-1.9)	1.6 (1.4-1.9)
Arthropathy	24 255	476	40.3 (36.8-44.1)	11 822	44 650	800	37.8 (35.3-40.6)	21 140	1.3 (1.1-1.4)	1.3 (1.1-1.4)
Psoriasis	5 023	103	45.3 (37.4-55.00)	2 273	20 995	392	41.5 (37.6-45.8)	9 441	1.1 (0.9-1.4)	1.1 (0.9-1.4)
Combined cohorts	39 755	866	-	19 341	112 619	2 077	-	51 390	1.4 (1.3-1.5)	1.4 (1.2-1.5)
COVID-19 Hospitalization*										
IBD	10 477	15	2.8 (1.7-4.7)	5 280	46 977	43	2.1 (1.5-2.8)	20 892	2.8 (1.5-5.1)	2.1 (1.0-4.1)
Arthropathy	24 255	37	3.1 (2.3-4.3)	11 873	44 650	59	2.8 (2.2-3.6)	21 215	1.3 (0.9-2.0)	1.3 (0.9-2.0)
Psoriasis	5 023	n<5	-	2 284	20 997	20	2.1 (1.4-3.3)	9 479	0.5 (0.1-2.3)	0.6 (0.1-2.5)
Combined cohorts	39 756	52	-	19 437	112 624	122	-	51 594	1.6	1.4

	39 755				112 619				(1.1-2.2)	(1.0-2.0)
Death*										
IBD	10 477	n<5	-	5 281	46 977	6	0.3 (0.1-0.6)	20 897	1.1 (0.1-9.7)	0.4 (0-5.6)
Arthropathy	24 255	6	0.51 (0.2-1.1)	11 875	44 650	13	0.6 (0.4-1.1)	21 222	1.0 (0.4-2.7)	1.0 (0.4-2.6)
Psoriasis	5 023	0	-	2 284	20 997	n<5	-	9 480	-	-
Combined cohorts	39 756	6	-	19 440	112 624	19	-	51 599	1.0 (0.4-2.5)	0.9 (0.4-2.2)
Abbreviations: CI = confidence interval; HR = hazard ratio; IBD= inflammatory bowel disease; PY = person-years.										
*COVID19- Infection = confirmed positive antigen or PCR test result for SARS-CoV2; COVID-19 Hospital Admission = Hospitalisation with SARS-CoV2 infection as primary diagnosis code; Death within 60 days of positive SARS-CoV2 test.										
**Events/1000 PY (95% CI)										
*** Sex and age adjusted crude and weighted hazard ratios										

Supplementary Table 5. Risk of COVID-19 infection associated with immunosuppressive therapy in vaccinated patients with immune-mediated inflammatory diseases at 0-3 months, 3-6 months, and 6-11 months post-vaccination

	Exposed				Unexposed				Crude HR (95% CI) **	Weighted HR (95% CI) **
	Total	Events	Incidence rate (95% CI) *	PY	Total	Events	Incidence rate (95% CI) *	PY		
COVID-19 infection 0-3 months post-vaccination										
IBD	10 477	57	22.2 (17.1-28.8)	2 570	46 974	196	17.0 (14.8-19.5)	11 546	1.6 (1.2-2.2)	1.5 (1.1-2.2)
Arthropathy	24 255	96	16.1 (13.2-19.6)	5 978	44 650	166	15.1 (13.0-17.6)	10 990	1.3 (1.0-1.7)	1.3 (1.0-1.7)
Psoriasis	5 023	24	19.4 (13.0-29.0)	1 236	20 995	83	16.1 (13.0-19.9)	5 163	1.3 (0.3-2.1)	1.3 (0.8-2.1)
Combined cohorts	39 755	177	-	4 403	112 619	445	-	27 699	1.4 (1.2-1.7)	1.4 (1.1-1.6)
COVID-19 infection 3-6 months post-vaccination										
IBD	10 010	123	45.8 (38.4-54.7)	2 683	45 202	526	56.8 (52.1-61.8)	9 266	0.9 (0.8-1.2)	1.0 (0.8-1.2)
Arthropathy	23 503	284	48.6 (43.2-54.5)	5 849	43 186	482	47.5 (43.4-51.9)	10 149	1.2 (1.1-1.4)	1.2 (1.1-1.4)
Psoriasis	4 860	63	60.7 (47.4-77.7)	1 038	20 203	233	54.5 (47.9-61.9)	4 279	1.1 (0.8-1.4)	1.0 (0.8-1.4)
Combined cohorts	38 373	470	-	19 437	108 591	1 241	-	23 694	1.1 (1.0-1.2)	1.1 (1.0-1.3)

COVID-19 infection 6-11 months post-vaccination										
IBD	6 058	107	160.6 (132.9-194.1)	666	15 742	163	107.1 (91.9-124.9)	1 522	1.3 (0.9-1.7)	1.4 (1.1-1.9)
Arthropathy	12 223	96	82.7 (67.7-101.0)	1 160	19 839	152	80.8 (68.9-94.7)	1 881	1.1 (0.8-1.4)	1.1 (0.8-1.4)
Psoriasis	1 719	16	93.8 (57.5-153.1)	170	7 444	76	109.8 (87.7-137.5)	691	0.9 (0.5-1.5)	0.9 (0.5-1.5)
Combined cohorts	20 000	219	-	1 996	43 025	391	-	4 094	1.1 (0.9-1.3)	1.11 (0.9-1.3)
Abbreviations: CI = confidence interval; HR = hazard ratio; IBD= inflammatory bowel disease; PY = person-years.										
*Events/1000 PY										
**Sex and age adjusted crude and weighted hazard ratios										

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Supplementary Table 6. Risk of infection, hospitalisation and death associated with immunosuppressive therapy in vaccinated patients with immune-mediated inflammatory diseases by immunosuppressive drug class

	Exposed				Unexposed				Crude HR (95% CI) ***	Weighted HR (95% CI) ***
	Total	Events	PY	Incidence rate (95% CI) **	Total	Events	PY	Incidence rate (95% CI) **		
COVID-19 Infection*										
Selective Immunosuppressants	3 384	68	1 846	39.4 (31.0-49.9)	151 936	2 079	51 334	40.5 (38.8-42.3)	1.3 (1.0-1.7)	1.3 (1.0-1.6)
Tumour Necrosis Factor Inhibitors	14 277	418	6 908	62.5 (56.7-68.7)	140 797	2 070	51 355	40.3 (38.6-42.1)	1.8 (1.6-2.0)	1.8 (1.6-2.0)
Interleukin Inhibitors	2 781	52	1 385	40.1 (30.6-52.7)	152 584	2 082	51 352	40.5 (38.8-42.3)	1.1 (0.8-1.4)	1.0 (0.8-1.4)
Calcineurin Inhibitors	154	n<5	129	-	155 309	2 073	51 298	40.4 (38.7-42.2)	1.3 (0.3-5.2)	0.5 (0.2-1.5)
Systemic Corticosteroids	5 504	97	2 991	34.6 (28.4-42.3)	149 667	2 079	51 503	40.4 (38.7-42.1)	1.3 (1.0-1.6)	1.2 (1.0-1.5)
Rituximab and Other Immunosuppressants	21 038	426	10 703	41.2 (37.5-45.3)	112 593	2 075	51 409	40.4 (38.7-42.1)	1.3 (1.2-1.4)	1.3 (1.1-1.4)
COVID-19 Hospitalization*										
Selective Immunosuppressants	3 384	7	1 735	4.0 (1.9-8.5)	112 479	122	51 531	2.4 (2.0-2.8)	3.0 (1.4-6.5)	2.2 (1.0-5.2)
Tumour Necrosis Factor Inhibitors	14 277	16	6 740	2.4 (1.5-3.9)	112 506	116	51 551	2.3 (1.9-2.1)	2.0 (1.2-3.3)	1.8 (1.0-3.3)

Interleukin Inhibitors	2 781	0	1 302	-	112 445	125	51 549	2.4 (2.0-2.9)	-	-
Calcineurin Inhibitors	154	0	83	-	112 404	122	51 493	2.4 (2.0-2.8)	-	-
Systemic Corticosteroids	5 504	18	2 811	6.4 (4.0-10.2)	112 587	122	51 699	2.4 (2.0-2.8)	2.4 (1.4-3.9)	1.8 (1.0-3.0)
Rituximab and Other Immunosuppressants	21 038	25	10 387	2.4 (1.6-3.6)	112 593	121	51 604	2.3 (2.0-2.8)	1.2 (0.5-1.0)	1.1 (0.7-1.8)
Death*										
Selective Immunosuppressants	3 384	0	1 736	-	112 479	23	51 545	0.5 (0.3-0.7)	-	-
Tumour Necrosis Factor Inhibitors	14 277	0	6 741	-	112 506	19	5 1564	0.4 (0.2-0.6)	-	-
Interleukin Inhibitors	2 781	0	1 302	-	112 445	24	51 564	0.5 (0.3-0.7)	-	-
Calcineurin Inhibitors	154	0	83	-	112 404	24	51 507	0.5 (0.3-0.7)	-	-
Systemic Corticosteroids	5 504	6	2 812	2.1 (2.0-4.8)	112 587	23	51 713	0.4 (0.3-0.7)	4.0 (1.6-9.9)	2.3 (0.9-6.2)
Rituximab and Other Immunosuppressants	21 038	n<5	10 388	-	112 593	22	51 619	0.4 (0.3-0.7)	0.5 (0.1-2.3)	0.5 (0.1-2.4)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Abbreviations: CI = confidence interval; HR = hazard ratio; IBD= inflammatory bowel disease; PY = person-years.

Immunosuppressive Drug Class: Selective Immunosuppressants, Tumour Necrosis Factor Inhibitors, Interleukin Inhibitors, Calcineurin Inhibitors, Systemic Corticosteroids, and Other Immunosuppressants including Rituximab (See Supplementary for complete ATC codes)

*COVID19- Infection = confirmed positive antigen or PCR test result for SARS-CoV2; COVID-19 Hospital Admission = Hospitalisation with SARS-CoV2 infection as primary diagnosis code; Death within 60 days of positive SARS-CoV2 test.

**Events/1000 PY

*** Sex and age adjusted crude and weighted hazard ratios

For peer review only

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

The Impact of Immunosuppressive Therapy on SARS-CoV-2 mRNA Vaccine Effectiveness in Patients with Immune-mediated Inflammatory Diseases: A Nationwide Danish Cohort Study

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5, 6
Methods			
Study design	4	Present key elements of study design early in the paper	6-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6, 7 & Fig.1
6-10Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	6-8 & Fig.1
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7,8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7,8
Bias	9	Describe any efforts to address potential sources of bias	6-9
Study size	10	Explain how the study size was arrived at	Fig. 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	7-9
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	9,10 & Table 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9,10

		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Report numbers of outcome events or summary measures over time	9 Fig.2-4
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful period	9,10 & Fig. 2-4
Other analyses	17	Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses	10 Fig.4
Discussion			
Key results	18	Summarise key results with reference to study objectives	10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13
Generalisability	21	Discuss the generalisability (external validity) of the study results	11,12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Abstract & 14

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

The Impact of Immunosuppressive Therapy on SARS-CoV-2 mRNA Vaccine Effectiveness in Patients with Immune-mediated Inflammatory Diseases: A Danish Nationwide Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-077408.R1
Article Type:	Original research
Date Submitted by the Author:	21-Dec-2023
Complete List of Authors:	Elmahdi, Rahma; Aalborg Universitet, Department of Clinical Medicine ; Aalborg University Hospital, Department of Gastroenterology and Hepatology Ward, Daniel; Aalborg Universitet, Department of Clinical Medicine Ernst, Martin; University of Southern Denmark, Clinical Pharmacology and Pharmacy, Department of Public Health Poulsen, Gry; Aalborg University, Department of Clinical Medicine Hallas, Jesper; University of Southern Denmark, Clinical pharmacology and pharmacy Pottgard, Anton; University of Southern Denmark, Clinical Pharmacology and Pharmacy, Department of Public Health Jess, Tine; Aalborg Universitet, Department of Clinical Medicine; Aalborg University Hospital, Department of Gastroenterology and Hepatology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Gastroenterology and hepatology, Infectious diseases
Keywords:	COVID-19, EPIDEMIOLOGY, Inflammatory bowel disease < GASTROENTEROLOGY, RHEUMATOLOGY, Psoriasis < DERMATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 **The Impact of Immunosuppressive Therapy on SARS-CoV-2 mRNA Vaccine Effectiveness in**
5
6 2 **Patients with Immune-mediated Inflammatory Diseases: A Danish Nationwide Cohort Study**

7
8
9 3 **Short Title: COVID-19 Vaccination in Immunosuppressed IMID Patients**

10
11 4
12
13 5 Rahma Elmahdi^{*1,2} (0000-0002-7013-9548), Daniel Ward^{*1} (0000-0003-0405-7250), Martin
14
15 6 Thomsen Ernst³ (0000-0001-9003-3823), Gry Juul Poulsen¹ (0000-0003-2744-2469), Jesper Hallas³
16
17 7 (0000-0002-8097-8708), Anton Pottegård³ (0000-0001-9314-5679), Tine Jess^{1,2} (0000-0002-4391-
18
19 8 7332)

20
21
22 9 * Co-first author

23
24
25 10
26
27 11 Rahma Elmahdi, Clinical Research Associate, Center for the Molecular Prediction of Inflammatory
28
29 12 Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Denmark (1)

30
31 13 Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark
32
33 14 (2)

34
35
36 15 Daniel Ward, Doctoral Fellow, Center for the Molecular Prediction of Inflammatory Bowel Disease
37
38 16 (PREDICT), Department of Clinical Medicine, Aalborg University, Denmark (1)

39
40
41 17 Martin Ernst Thomsen, Data Manager, Department of Public Health, Clinical Pharmacology,
42
43 18 Pharmacy and Environmental Medicine, University of Southern Denmark, J.B. Winsløvs Vej 19,
44
45 19 5000 Odense, Denmark (3)

46
47
48 20 Gry Juul Poulsen, Statistician, Center for the Molecular Prediction of Inflammatory Bowel Disease
49
50 21 (PREDICT), Department of Clinical Medicine, Aalborg University, Denmark (1)

51
52 22 Jesper Hallas, Professor, Research Unit of Clinical Pharmacology, University of Southern Denmark,
53
54 23 J.B. Winsløvs Vej 9, 5000 Odense, Denmark (3)

55
56
57 24 Anton Pottegård, Professor, Department of Clinical Pharmacology and Pharmacy, University of
58
59 25 Southern Denmark, J.B. Winsløvs Vej 9, 5000 Odense, Denmark (3)

1
2
3
4 26 Tine Jess, Professor, Center for the Molecular Prediction of Inflammatory Bowel Disease
5
6 27 (PREDICT), Department of Clinical Medicine, Aalborg University, Denmark (1)
7
8
9 28 Professor, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg,
10
11 29 Denmark (2)
12

13
14 30

15
16 31 **Correspondence:** Dr Rahma Elmahdi, National Center of Excellence for the Molecular Prediction
17
18 32 of Inflammatory Bowel Disease, PREDICT, Aalborg University, A. C. Meyers Vænge 15, DK-2450
19
20 33 Copenhagen, Denmark. E-mail: rahmae@dcm.aau.dk
21
22

23 34

24
25 35 **Key words:** Immune-mediated inflammatory disease; Cohort study; SARS-CoV-2; Vaccination;
26
27 36 Immunosuppressives
28

29
30 37

31
32 38 **Word count:** Abstract (excluding Strengths and limitations of this study), 283; manuscript body
33
34 39 (excluding tables, figure legends and references), 3840
35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

1
2
3
4 41 **ABSTRACT**
5
6

7 42 **Objective:** Patients receiving immunosuppressives have been excluded from trials for SARS-CoV-2
8
9 43 vaccine efficacy. Investigation of immunosuppressants' impact on effectiveness of vaccines,
10
11 44 particularly in patients with immune-mediated inflammatory diseases (IMID), are therefore required.
12
13
14 45

16 46 **Design:** We performed a nationwide cohort study to assess the risk of COVID-19 infection in
17
18 47 vaccinated IMID patients exposed to immunosuppressives compared to IMID unexposed to
19
20 48 immunosuppressives. Exposure to immunosuppressives in the 120 days before receiving the second
21
22 49 SARS-CoV-2 mRNA vaccination was assessed. Patients were followed from date of second
23
24 50 vaccination, and weighted Cox models were used to estimate the risk of infection associated with
25
26 51 immunosuppressives. Secondary outcomes included hospitalization and death associated with a
27
28 52 positive SARS-CoV-2 test. Risk of infection by immunosuppressant drug class was also analysed.
29
30
31
32 53

34 54 **Setting:** This study used population-representative data from Danish national health registries in the
35
36 55 period from 1st January to 30th November 2021.
37
38
39 56

41 57 **Results:** Overall, 152,440 patients were followed over 19,341 person-years. Immunosuppressants
42
43 58 were associated with a significantly increased risk of infection overall (HR: 1.4, 95% CI: 1.2, 1.5), in
44
45 59 inflammatory bowel disease (IBD) (HR: 1.6, 95% CI: 1.4, 1.9) and arthropathy (HR:1.3, 95% CI:
46
47 60 1.1, 1.4) but not psoriasis (HR: 1.1, 95% CI: 0.88, 1.4). Immunosuppressants were also associated
48
49 61 with an increased risk of hospitalization overall (HR: 1.4, 95% CI: 1.0, 2.0), particularly in IBD (HR:
50
51 62 2.1, 95% CI: 1.0, 4.1). No significantly increased risk of death in immunosuppressants exposed
52
53 63 patients was identified. Analyses by immunosuppressant drug class showed increased COVID-19
54
55
56
57
58
59
60

1
2
3
4 64 infection and hospitalization with anti-TNF, systemic corticosteroid, and rituximab and other
5
6 65 immunosuppressants.
7
8

9 66

10
11 67 **Conclusion:** Immunosuppressive therapies reduced effectiveness of mRNA SARS-CoV-2
12
13 68 vaccination against infection and hospitalization in IMID patients. Anti-TNF, systemic
14
15 69 corticosteroids, and rituximab and other immunosuppressants were particularly associated with these
16
17 70 risks.
18
19

20 71

21 72 **Strengths and limitations of this study**

- 22
23 73 • Use of a non-selected, population representative cohort to source inflammatory and immune
24
25 74 mediated disease (IMID) patients.
- 26
27 75 • Inclusion of a total of 184,346 immunosuppressive exposed IMID patients and 152,440
28
29 76 propensity score unexposed matched controls.
- 30
31 77 • Complete vaccination, and immunosuppressive treatment exposure data along with complete
32
33 78 infection, hospitalization, and death outcome data with no loss to follow-up.
- 34
35 79 • Lack of individual level data on level of exposure to infection, including shielding behaviour.
36
37
38
39
40
41

42 80

43 81

44 82

45 83

46 84

47 85

48 86

49 87

50 60

88 INTRODUCTION

89 SARS-CoV-2 mRNA vaccines Comirnaty® (Pfizer-BioNTech) and Spikevax® (Moderna) were
90 found to be efficacious in clinical trials prior to authorisation, and by December 2022 over 758 million
91 doses of Pfizer-BioNTech and 164 million doses of Moderna were administered in the European
92 Union [1]. Pre-marketing trials excluded individuals considered at risk of immunocompromise,
93 including those receiving immunosuppressive therapies [2,3], therefore there remains a paucity of
94 data on the real-world effectiveness of SARS-CoV-2 vaccines in patients treated with
95 immunosuppressive drugs.

96
97 Research published early in the SARS-CoV-2 epidemic suggested that, in the absence of vaccination,
98 some types of immunosuppressives including rituximab, sulfasalazine, and corticosteroids are
99 associated with an increased risk of severe outcomes in COVID-19 infection [4–8]. Immune-mediated
100 inflammatory diseases (IMID), including inflammatory bowel disease, inflammatory arthropathy, and
101 psoriasis have themselves independently been associated with lower serological responses to SARS-
102 CoV-2 vaccination than in healthy controls [9]. Immunosuppressants are key therapies in IMID, so
103 patients with IMID may be at increased risk of infection and severe outcomes of COVID-19 infection
104 both due to the natural history of the diseases and the therapies used to treat them. Even in the context
105 of second vaccination against SARS-CoV-2, exposure to immunosuppressives has been associated
106 with a significantly poorer humoral response; lower than that which is required to confer immunity
107 against infection and severe outcomes of COVID-19 infection in patients treated with
108 immunosuppressive therapies [10–12].

109

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

110 It is therefore important to investigate the impact of immunosuppressants on SARS-CoV-2 vaccine effectiveness, while controlling for the underlying disease-indicating treatment, and other confounders that may impact vaccine effectiveness.

113
114 The real-world effectiveness of SARS-CoV-2 mRNA vaccinations against COVID-19 infection and associated outcomes such as hospitalization or death, in the context of immunosuppressive therapy exposure among IMID patients has not yet been investigated. The aim of this study was to use Danish nationwide population-based data to assess the impact of immunosuppressive exposure on the risk of COVID-19 infection in three cohorts of vaccinated IMID patients.

120 MATERIALS AND METHODS

121 Data sources

122 We conducted a nationwide cohort study using the Danish COVID-19 cohort [13], based on data from the Danish Microbiology Registry [14], which includes individual-level information on vaccine type, dose, and date of administration; SARS-CoV-2 test type and date administered. This data was linked at the individual level to both the Danish National Patient Registry [15] and the Danish National Prescription Registry [16] using a unique Danish Civil Registration number (assigned to all individuals residing in Denmark). The Danish National Patient Registry, a register of hospital activities, includes medical diagnoses coded using International Classification of Disease (ICD-10), and medical procedures and prescriptions including treatment with intravenous medications. The Danish National Prescription Registry contains information on prescriptions dispensed at all community retail pharmacies, including date of dispensing, tablet strength, and pack sizes. Ethics board review is not required for epidemiological research using nationwide registers in Denmark as data is pseudonymised and does not involve patients.

134 **Population, follow-up, and outcomes**

135 The IMID cohort comprised of three disease specific cohorts of all patients diagnosed with
136 inflammatory bowel disease, including Crohn's disease and ulcerative colitis (IBD; ICD-10: K50,
137 K51), inflammatory arthropathy, including ankylosing spondylitis, other inflammatory
138 spondylopathies, seropositive rheumatoid arthritis, other rheumatoid arthritis, and psoriatic and
139 enteropathic arthropathies (ICD-10: M45, M46, M05, M06, M07) or psoriasis (ICD-10: L40) in
140 Denmark, who had received two doses of SARS-CoV-2 mRNA (Pfizer-BioNTech or Moderna)
141 vaccine. Exclusion criteria were not receiving two doses of SARS-CoV-2 mRNA vaccine and
142 migration prior to receipt of second vaccination. Patients with more than one of these IMID
143 diagnoses were included in only one cohort, with IBD taking precedence, then inflammatory
144 arthropathy, finally psoriasis. Therefore, only patients with psoriasis and neither an IBD nor an
145 inflammatory arthropathy diagnosis were included in the psoriasis cohort. This order was preferred
146 as extent of organ-specific disease likely determines the dose for immunosuppressive therapy.
147 Registration of IMIDs is based on clinical diagnoses, in line with national and international
148 guidelines, such as ECCO-ESGAR guidelines for IBD diagnosis [17,18].

149

150 Patients were followed from the date of administration of second mRNA vaccine (the index date)
151 after 1 January 2021. The primary outcome was a positive SARS-CoV-2 PCR test in the observation
152 period. Secondary outcomes were hospitalization between 7 days prior to and up to 28 days after a
153 positive test or death within 60 days of a positive test (both recorded in Danish National Patient
154 Register). Follow-up was censored at administration of a third vaccination, emigration, death (in the
155 absence of a positive SARS-CoV-2 test) or the end of the study period, 30 November 2021 (Figure
156 1), as prevalence of the omicron variant became substantial after 28 November 2021 [19]. As the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

157 registers are complete for the presence of patients up to emigration or death, therefore all patients are
158 retained until the event and there is no missing data.

159

160 **Patient and Public Involvement**

161 None.

162

163 **Exposures**

164 The exposures for this study include dispensed prescriptions or hospital administration of an
165 immunosuppressive in the 120 days preceding the index date (date of administration of second
166 vaccination). Immunosuppressants included selective immunosuppressants, anti-TNFs, interleukin
167 inhibitors, calcineurin inhibitors, corticosteroids, rituximab and other immunosuppressants (see
168 Supplementary Table 1 for complete list and ACT codes for immunosuppressants). The 120-day
169 exposure window is chosen to cover the largest pack sizes of prescriptions which can contain
170 medications for up to 120 days. A minimum daily dose of corticosteroids equivalent to 7.5 mg
171 prednisolone per day was estimated as the entire dispensed quantity of corticosteroids during a
172 sequence of prescriptions (within the 120-day exposure period) divided by the number of days from
173 the first prescription to the index date (Supplementary Table 2). Unexposed IMID patients were
174 defined as those with a diagnosis of one of the three IMID, who had not received an
175 immunosuppressive in the 120 days preceding the index date, and those receiving <7.5 mg
176 prednisolone-equivalent average per day.

177

178 **Statistical models**

179 Covariates included age (handled as a continuous covariate), sex, comorbidities (cardiovascular
180 disease, pulmonary disease, liver disease, kidney disease, other gastrointestinal diseases, skin disease,

1
2
3
4 181 and musculoskeletal disease), medications (cardiovascular drugs, antibiotics, oral anticoagulants,
5
6 182 diabetes, and chronic airway disease medications). Testing frequency varied during the period studied
7
8
9 183 due to changes in national and international guidelines and travel restrictions, along with the
10
11 184 background prevalence of SARS-CoV-2, which could introduce bias in case detection. We therefore
12
13 185 adjusted for individual testing frequency by including number of tests in the month preceding index
14
15 186 date as a continuous covariate. Further, covariates specific to each IMID were included separately for
16
17
18 187 each cohort. For the IBD cohort this included any IBD-related hospital admissions in the previous
19
20 188 year, Crohn's disease, ulcerative colitis, 5-ASA/sulfasalazine, budesonide, IBD-related procedures,
21
22
23 189 and endoscopy of the gastrointestinal tract (see Supplementary Table 3 for complete list of IMID
24
25 190 cohort specific covariates).

26
27 191
28
29
30 192 To balance the covariates in the exposed and unexposed groups, we fitted propensity score (PS)
31
32 193 models for each IMID cohort separately. Propensity scores were calculated using logistic regression
33
34 194 for the probability of exposure (treatment with immunosuppressives) conditional on the covariates
35
36 195 defined above [20]. We subsequently implemented the PS using standardized mortality ratio (SMR)
37
38
39 196 weights (with trimming of subjects with extreme weights beyond 1st and 99th centiles). We assessed
40
41 197 the distribution of covariates with standardized differences before and after PS weighting.

42
43 198
44
45
46 199 We used weighted Cox proportional-hazards regression models [21] to estimate risk of the COVID-
47
48 200 19 infection in IMID patients exposed to immunosuppressive therapy compared to unexposed patients
49
50 201 for each disease cohort separately. We used calendar time as the underlying time scale to account for
51
52
53 202 period effects on the risk of the outcomes which may relate to varying infection prevalence and patient
54
55 203 characteristics as patients vulnerable to severe outcomes were vaccinated earlier in the year.

56
57 204
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

205 We performed secondary analyses to further delineate the impact of immunosuppressives on vaccine effectiveness over time by stratifying time since vaccination into the following intervals: 0-3 months, 206 3-6 months, 6-11 months. This not only allowed us to capture the period effects of COVID-19 207 infection risk earlier and later in the pandemic period but also allowed us to assess the impact of 208 censoring at different time points in the follow-up period.

209
210
211 We then undertook Fixed Effects Model (FEM) meta-analysis to calculate the pooled HR of infection, 212 hospitalization, and death for IBD, arthropathy and psoriasis cohorts as overall risk in 213 immunosuppressive exposed IMID by COVID-19 outcome, and the HR of infection during 0-3, 3-6, 214 and 6-11 months of follow-up period, as overall risk in immunosuppressive exposed IMID by period.

215
216 Finally, we also undertook drug specific analysis for risk of COVID-19 infection by 217 immunosuppressive drug class. In this analysis, patients receiving multiple immunosuppressive 218 treatments were treated as independently exposed to each drug class. To account for the potential 219 impact of immunosuppressants commonly prescribed in a weaning dose, which would not be captured 220 using the definition of ≥ 7.5 mg dose equivalent per day, we undertook a sensitivity analysis to assess 221 whether having any prescription for systemic corticosteroids over the 120-day period before the index 222 date had an impact on the risk of infection, hospitalization, or death for those exposed to this class of 223 immunosuppressants.

224 225 **RESULTS**

226 A total of 184,346 patients diagnosed with IBD, arthropathy or psoriasis were identified. After 227 exclusion of patients not receiving two doses of SARS-CoV-2 mRNA vaccine, migration prior to 228 receipt of second vaccination, and trimming of those with extreme propensity scores a total 152,440

1
2
3
4 229 patients were included, contributing a total 19,341 person-years of follow-up. During the 120-day
5
6 exposure assessment period, 39,765 IMID patients received immunosuppressive treatment (10,480
7 230
8 IBD, 24,261 arthropathy, and 5,024 psoriasis), and 112,675 IMID patients (47,001 IBD, 44,669
9 231
10 arthropathy, and 21,005 psoriasis) patients did not. A total of 11 exposed and 51 unexposed IMID
11 232
12 patients are censored from overall analysis due to migration or inclusion on the date of study end
13 233
14 (therefore contributing no follow-up time). One arthropathy patient in the exposed group, and 5 IBD
15 234
16 or psoriasis patients in the unexposed group are excluded from the infection analysis due to positive
17 235
18 test on the date of study entry, these are subsequently included in the analysis for risk of
19 236
20 hospitalization or death following COVID-19 infection (Figure 1; Supplementary Table 4). Following
21 237
22 application of SMR weighting, the cohorts were balanced on the included covariates (see Table 1 for
23 238
24 covariate prevalence and standardised differences [SD]).
25 239
26
27
28
29
30 240

31
32 241 A total of 866 (2.2%) COVID-19 infections were recorded among immunosuppressive exposed IMID
33
34 242 patients during the follow-up period compared with 2,077 (1.8%) for unexposed IMID patients. This
35
36 gave an incidence rate of 55 (49-61) per 1,000 person-years in immunosuppressive exposed IBD
37 243
38 patients compared with 43 (40-45) in unexposed IBD patients, 40 (37-44) per 1,000 person-years for
39 244
40 immunosuppressive exposed arthropathy patients compared with 38 (35-41) in unexposed
41 245
42 arthropathy patients, and 45 (37-55) per 1,000 person-years for immunosuppressive exposed psoriasis
43 246
44 patients compared with 42 (38-46) per 1,000 person-years in unexposed psoriasis patients.
45 247
46
47

48 248 A significantly increased weighted hazard for infection among exposed patients was seen for both
49
50 249 IBD (HR: 1.6, 95% CI: 1.4, 1.9) and arthropathy (HR: 1.3, 95% CI: 1.1, 1.4) cohorts but not for the
51
52 psoriasis cohort (HR: 1.1, 95 % CI: 0.88, 1.4). Meta-analysis of the three IMID cohorts showed a
53 250
54 pooled HR for COVID-19 infection in exposed patients of 1.4 (95% CI: 1.2, 1.5; Figure 2). Fewer
55 251
56 than 52 exposed and 122 unexposed IMID patients were hospitalized with COVID-19 infection
57 252
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

during the follow-up period, which corresponded to a significantly increased risk of hospitalization overall for immunosuppressive exposed IMID patients (pooled HR: 1.4, 95% CI: 1.0, 2.0). This increased risk of overall hospitalization is largely due to the contribution of the risk of hospitalization in IBD patients 2.05 (95% CI: 1.03-4.07). Less than five immunosuppressive exposed IBD patients died in the 60 days following a COVID-19 diagnosis compared to six unexposed IBD patients. Six patients in the arthropathy cohort exposed to immunosuppressives compared with 13 unexposed arthropathy patients died in the 60 days following a COVID-19 diagnosis and fewer than five patients with a psoriasis diagnosis, either immunosuppressive exposed or unexposed died with a COVID-19 diagnosis. These did not correspond to a significantly increased risk of death among exposed patients in any of the three cohorts or overall (pooled HR: 0.92, 95% CI: 0.38, 2.2; Figure 2).

In the first 0-3 months following vaccination, both IBD and arthropathy immunosuppressive exposed patients had a significantly increased risk of COVID-19 infection (HR: 1.5, 95% CI: 1.1, 2.2 and HR: 1.3, 95% CI: 1.0, 1.7, respectively; see Supplementary Table 5). Most COVID-19 infections following second vaccination occurred in the 3–6-month period with a total of 470 infections in exposed IMID patients compared with 1,277 unexposed IMID patients. Only exposed arthropathy patients had a significantly increased risk of infection compared to their unexposed counterparts during this period however (HR: 1.2, 95% CI: 1.1, 1.4). The highest incidence rate of COVID-19 infection following second vaccination was seen in the 6–11-month period for both immunosuppressive exposed and unexposed IMID patients and risk of infection during this period was only increased among exposed IBD patients (HR: 1.4, 95% CI: 1.1, 1.9). There was however a high rate of censoring among both the immunosuppressive exposed (over 50%) and the unexposed (almost 49%) groups in the 6–11-month period due to receipt of the third SARS-CoV-2 vaccination so direct comparison of the risk of infection between time periods is challenging. Kaplan-Meier plots

1
2
3
4 277 and HR showing probability of infection over the calendar time of follow-up (January-November
5
6 278 2021) are presented in Supplementary Figure 1 and post-hoc analysis for HR for infection by calendar
7
8
9 279 period (January-November 2021) is shown in Supplementary Table 6.
10

11 280
12
13 281 Analysis for risk of infection among IMID cohorts by immunosuppressive drug class exposure
14
15
16 282 showed a significantly increased risk of infection among users of anti-TNF (HR: 1.8, 95% CI: 1.6,
17
18 283 2.0), systemic corticosteroid (HR: 1.2, 95% CI: 1.0,1.5), and rituximab and other immunosuppressant
19
20 284 (HR: 1.3, 95% CI: 1.1, 1.4; Figure 3). No other immunosuppressant was significantly associated with
21
22
23 285 COVID-19 infection following second vaccination. Anti-TNF and systemic corticosteroid exposure
24
25 286 were also associated with an increased risk of COVID-19 associated hospitalization (HR 1.8, 95% CI
26
27 287 1.0, 3.3 and HR 1.8, 95% CI 1.0,3.0, respectively; Figure 4). No immunosuppressive drug class was
28
29
30 288 associated with death among IMID patients following receipt of second vaccination (Supplementary
31
32 289 Table 7). Sensitivity analysis assessing outcomes following any systemic corticosteroid exposure in
33
34 290 the 120-day period prior to the index date showed no significant difference in risk of infection (crude
35
36 291 HR: 1.2, 95% CI: 1.0, 1.4; adjusted HR: 1.1, 95% CI: 0.95, 1.3) or death (crude HR: 3.1, 95% CI:
37
38
39 292 1.4, 7.0; adjusted HR: 1.9, 95% CI: 0.77, 4.7). However, risk of hospitalization following infection
40
41 293 was significantly increased in those ever exposed to systemic corticosteroids in the 120-day period
42
43 294 prior to receipt of second vaccination (crude HR: 2.8, 95% CI: 1.9, 4.1; adjusted HR: 2.1, 95% CI:
44
45
46 295 1.4, 3.2), showing similar results compared with analysis restricting to a ≥ 7.5 mg daily equivalent
47
48 296 dose.
49

50 297 51 52 298 **DISCUSSION**

53
54
55 299 In this large nation-wide cohort study of three IMID patient cohorts, we identified a total of 39,756
56
57 300 immunosuppressive exposed patients matched to 112,629 immunosuppressive unexposed IMID
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

301 patients to investigate the risk of COVID-19 infection, hospitalization, and death among IBD,
302 arthropathy and psoriasis patients following second SARS-CoV-2 vaccination. Meta-analysis of the
303 three cohorts showed an overall 35% increased risk of infection and, 42% increased risk of COVID-
304 19 associated hospitalization in immunosuppressive exposed compared to immunosuppressive
305 unexposed IMID patients.

307 Mortality was not significantly increased in immunosuppressive exposed patients as these events
308 were rare. Drug class analysis showed anti-TNF, systemic corticosteroid, and rituximab and other
309 immunosuppressant exposure was significantly associated with both increased risk of COVID-19
310 infection and hospitalization following second vaccination in immunosuppressive exposed compared
311 to unexposed IMID patients.

313 We attempted to ascertain the effectiveness of SARS-CoV-2 mRNA vaccination among IMID
314 patients exposed to immunosuppressive therapies, while controlling for the severity of the underlying
315 disease indicating immunosuppressive treatment with a propensity score model. We found that
316 immunosuppressants were associated with an increased risk of infection, likely due to the impact of
317 immunosuppressive medication on vaccination against COVID-19 infection. This is particularly seen
318 in IBD (HR: 1.6, 95% CI: 1.4-1.9) but is also present in arthropathy (HR: 1.3, 95% CI: 1.1, 1.4) patients
319 and, to a lesser extent, in psoriasis (HR: 1.1, 95% CI: 0.88, 1.4). Immunosuppressive exposed
320 psoriasis patients showed no increased infection risk compared to their unexposed counterparts.
321 Similarly, when assessing risk of hospitalization following vaccination by immunosuppressive
322 exposure, we find a significantly increased risk in IBD patients (HR: 2.1, 95% CI 1.0, 4.1), which is
323 not observed in arthropathy (HR: 1.3, 95% CI: 0.9, 2.0) or psoriasis (HR: 0.6, 95% CI: 0.1, 2.5). The
324 poorer outcomes observed in immunosuppressive exposed IBD patients is in keeping with wider

1
2
3
4 325 findings. In a meta-analysis of serological response to SARS-CoV-2 vaccination among IMID treated
5
6 326 patients, IBD patients were found to have a lower response to first mRNA vaccination dose than
7
8
9 327 rheumatoid patients (response rate: 0.49, 95% CI: 0.32, 0.66 and 0.78, 95% CI: 0.67, 0.86,
10
11 328 respectively) [22]. This may be due to the more extensive disease seen in typical IBD patients, which
12
13 329 often necessitates higher doses of immunosuppressive therapies, over longer periods to achieve
14
15
16 330 disease remission than that required for psoriasis or arthropathies [23–25]. However, the difference
17
18 331 in increased risk of infection and hospitalization in immunosuppressive exposed IBD compared with
19
20 332 unexposed IBD patients is like the other IMID cohorts in this study, with overall pooled IMID cohort
21
22
23 333 meta-analysis showing a significantly increased risk for both these outcomes. These findings indicate
24
25 334 a general trend towards poorer outcomes in immunosuppressive exposed patients regardless of IMID
26
27 335 cohort.

28
29 336
30
31
32 337 Reassuringly, immunosuppressant exposure was not associated with increased risk of death due to
33
34 338 COVID-19 in any of the IMID patient cohorts, suggesting immunosuppressants do not reduce the
35
36 339 effectiveness of vaccination in preventing this important outcome. However, caution should be
37
38
39 340 exercised in the interpretation of this finding as deaths were recorded in either immunosuppressive
40
41 341 exposed or unexposed patients and this may be due to the relatively short follow-up period of 11-
42
43 342 months in this study. Although Kaplan-Meier plots for risk of infection may appear in contradiction
44
45
46 343 to the overall findings of the primary analysis (with apparent increased rate of COVID infection in
47
48 344 the unexposed IMID population in the first 7 months of follow-up), the findings from post-hoc Cox
49
50 345 regression analysis by calendar period shows that the difference between the groups, reflected in the
51
52
53 346 overall HR, only becomes apparent in the final 3 months of follow-up as the majority of cases of
54
55 347 COVID are seen in this period.

56
57 348
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

349 Meta-analysis showed an overall increased risk of COVID-19 infection among exposed IMID
350 patients during the 0-3 and 3-6-month period only. Only exposed arthropathy patients showed a
351 significantly increased risk of infection in the 3–6-month period. Although this might be interpreted
352 as waning immunity, it is important to note that half of the baseline IMID cohort were censored,
353 largely due to receipt of third vaccination, therefore the remaining population likely differed
354 substantially from the initial cohort. Hence this interpretation of period specific risk estimates should
355 be made tentatively [26]. Although the three periods are not directly comparable, it is likely that our
356 observation of an increased risk of infection in exposed patients in the 0-3- and 3-6-month period
357 reflects a true risk, as is observed in the risk identified over the total follow-up period.

359 Treatment with TNF-alpha inhibitors, systemic corticosteroid, and rituximab other
360 immunosuppressants was associated with a significantly increased risk of infection, and TNF-alpha
361 inhibitors and systemic corticosteroids were associated with a significantly increased risk of
362 hospitalization following receipt of second vaccination. This is consistent with previous studies,
363 which suggests that treatment with cytokine inhibitors or B-cell depleting immunosuppressives is
364 related to particularly poor COVID-19 outcomes [27–29], however the association with TNF-alpha
365 inhibitors is novel. Our findings of increased risk of infection and hospitalization, but not death, in
366 sensitivity analysis among IMID patients exposed to systemic corticosteroids is also in keeping with
367 those other studies of unvaccinated IMID cohorts in Denmark [4] and internationally [6,30]. These
368 findings indicate that corticosteroid exposure weakens the protection conferred by vaccination. As
369 glucocorticoids are known to inhibit the breadth of the immune response, including aspects of both
370 the cellular and humoral immunity induced by mRNA vaccination, these findings appear to be
371 intuitive [31]. The interaction of IMID, the impact of treatments to control disease and response to
372 vaccination, particularly considering the effects of dose and duration of administration is however

1
2
3
4 373 complex [32,33]. Further studies directly exploring the effects of vaccination whilst controlling for
5
6 374 disease severity and exposure of immunosuppressive drugs by dose and duration would be required
7
8
9 375 to disentangle the association of the different immunosuppressive drug classes with COVID-19
10
11 376 outcomes following vaccination. Such studies would also better inform guidance relating to timelines
12
13 377 for SARS-CoV-2 vaccination in relation to the administration of immunosuppressive therapies in
14
15
16 378 IMID patients.

17
18 379
19
20 380 One of the key strengths of this study is that it is large and population-representative, exploring the
21
22
23 381 effectiveness of COVID-19 infection using real-world data from comprehensive, nationwide health
24
25 382 registries. Vaccination does not directly correlate with protection from infection and the findings from
26
27 383 this work provides important evidence on effectiveness of post-marketing mRNA vaccination in a
28
29
30 384 vulnerable patient group. To our knowledge, this is the first study to assess the effectiveness of SARS-
31
32 385 CoV-2 vaccination against COVID-19 infection, hospitalization, and mortality among IMID patients,
33
34 386 based on immunosuppressive exposure. Additionally, our use of PS weighted regression models
35
36 387 allows us to accurately control for the underlying treatment indicating disease, so we are better able
37
38
39 388 to extrapolate the effects of the drug exposure from the disease itself.

40
41 389
42
43 390 Limitations include not being able to extrapolate in the context of the omicron variant, or subsequent
44
45
46 391 subvariants as we restricted to a period of the pandemic where the delta variant was the dominant
47
48 392 circulating strain of COVID-19 to ensure consistency in the assessment of our outcomes. Although it
49
50 393 is difficult to define a reliable threshold for which we consider a patient unexposed to
51
52
53 394 immunosuppressive medication, it is reassuring that only approximately 12% of our unexposed group
54
55 395 had filled a prescription in the 365 days prior to the 120-day exposure window assessed, and that
56
57 396 removing the minimum threshold of 7.5 mg of systemic corticosteroids as an exposure requirement
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

397 did not change our findings. A lack of individual-level data relating to confounders such as smoking
behaviour, risk of occupational exposure to COVID-19, socio-economic status and dose of drug
therapies could potentially limit our findings. Due to lack of availability to such data, we could not
account of shielding behaviour in this analysis. There may also be a residual effect of confounding
due to unmeasured disease severity not completely accounted for in our PS model. However, these
are unlikely to systemically impact the direction of association or strength of significance identified
in the risk of infection due to immunosuppressive exposure observed here. We limited our study to
IBD, inflammatory arthropathy, and psoriasis although other IMIDs exist, because these are
commonly treated with immunosuppressives such as anti-TNF.

407 In conclusion, our findings suggest a reduced effectiveness of mRNA SARS-CoV-2 vaccination
against COVID-19 infection and hospitalization in IMID patients receiving immunosuppressive
therapies. This risk is particularly seen in IBD and arthropathy patients, and COVID-19 infection is
associated with anti-TNF, systemic corticosteroids, and rituximab and other immunosuppressant
exposure, while TNF-alpha inhibitors and systemic corticosteroids were associated with a
significantly increased risk of hospitalization.

Author Contributions: DW, RE, AP and TJ developed the study protocol. ME undertook primary
data analysis with support from GP. DW and RE were responsible for first draft of the manuscript.
All authors were responsible for interpretation of results and critical revisions to the final manuscript.

Funding Sources: This work was funded by grants from the Novo Nordisk Foundation
(NNF21OC0068631) and the Danish National Research Foundation (DNRF-148).

1
2
3
4 421 **Conflict of Interest Statement:** All authors have none to declare.
5
6
7 422

8
9 423 **Data Sharing Statement:** The study was based on data from the Danish National Health registers
10
11 424 (<https://sundhedsdatastyrelsen.dk>). The register data are protected by the Danish Act on Processing
12
13 425 of Personal Data and are accessed through application to and approval from the Danish Data
14
15
16 426 Protection Agency and the Danish Health Data Authority. The code is available promptly on request
17
18 427 made to the corresponding author
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- 1 European Medicines Agency. COVID-19 vaccines safety update: 3 August 2022 Rev. 1. Amsterdam: www.ema.europa.eu (accessed 11 Aug 2022).
- 2 El Sahly HM, Baden LR, Essink B, *et al.* Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *N Engl J Med* 2021;**385**:1774–85.
doi:10.1056/nejmoa2113017
- 3 Polack FP, Thomas SJ, Kitchin N, *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020;**383**:2603–15.
doi:10.1056/NEJMOA2034577/SUPPL_FILE/NEJMOA2034577_PROTOCOL.PDF
- 4 Ward D, Gørtz S, Ernst MT, *et al.* The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection. *Eur Respir J* 2022;**59**. doi:10.1183/13993003.00769-2021
- 5 Gianfrancesco M, Hyrich KL, Al-Adely S, *et al.* Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis* 2020;**79**:859–66.
doi:10.1136/ANNRHEUMDIS-2020-217871
- 6 Brenner EJ, Ungaro RC, Gearry RB, *et al.* Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. *Gastroenterology* 2020;**159**:481-491.e3.
doi:10.1053/J.GASTRO.2020.05.032
- 7 Salter A, Fox RJ, Newsome SD, *et al.* Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. *JAMA Neurol* 2021;**78**:699–708. doi:10.1001/JAMANEUROL.2021.0688
- 8 Strangfeld A, Schäfer M, Gianfrancesco MA, *et al.* Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global

- 1
2
3
4 Rheumatology Alliance physician-reported registry. *Ann Rheum Dis* 2021;**80**:930–42.
5
6 doi:10.1136/ANNRHEUMDIS-2020-219498
7
8
9 Lee ARY Bin, Wong SY, Chai LYA, *et al.* Efficacy of covid-19 vaccines in
10 immunocompromised patients: systematic review and meta-analysis. *BMJ*
11 2022;**376**:e068632. doi:10.1136/BMJ-2021-068632
12
13
14
15
16 10 Boekel L, Steenhuis M, Hooijberg F, *et al.* Antibody development after COVID-19
17 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from
18 two prospective cohort studies. *Lancet Rheumatol* 2021;**3**:e778–88. doi:10.1016/S2665-
19 9913(21)00222-8
20
21
22
23
24
25 11 Alexander JL, Kennedy NA, Ibraheim H, *et al.* COVID-19 vaccine-induced antibody
26 responses in immunosuppressed patients with inflammatory bowel disease (VIP): a
27 multicentre, prospective, case-control study. *lancet Gastroenterol Hepatol* 2022;**7**:342–52.
28 doi:10.1016/S2468-1253(22)00005-X
29
30
31
32
33
34 12 de Boer SE, Berger SP, van Leer–Buter CC, *et al.* Enhanced Humoral Immune Response
35 After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus
36 Mycophenolate Mofetil-containing Immunosuppressive Regimens. *Transplantation*
37 2022;**106**. doi:10.1097/TP.0000000000004177
38
39
40
41
42
43 13 Pottegård A, Kristensen KB, Reilev M, *et al.* Existing Data Sources in Clinical
44 Epidemiology: The Danish COVID-19 Cohort. *Clin Epidemiol* 2020;**12**:875–81.
45 doi:10.2147/CLEP.S257519
46
47
48
49
50 14 Voldstedlund M, Haarh M, Mølbak K. The Danish Microbiology Database (MiBa) 2010 to
51 2013. *Euro Surveill* 2014;**19**. doi:10.2807/1560-7917.ES2014.19.1.20667
52
53
54
55 15 Jensen JS, Jensen DH, Grønhøj C, *et al.* Incidence and survival of oropharyngeal cancer in
56 Denmark: a nation-wide, population-based study from 1980 to 2014. *Acta Oncol (Madr)*
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2018;**57**:269–75. doi:10.1080/0284186X.2017.1390251

- 16 Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, *et al.* Data Resource Profile: The Danish National Prescription Registry. *Int J Epidemiol* 2017;**46**:798. doi:10.1093/IJE/DYW213
- 17 Maaser C, Sturm A, Vavricka SR, *et al.* ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. *J Crohn's Colitis* 2019;**13**:144-164K. doi:10.1093/ECCO-JCC/JJY113
- 18 Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. *Rheumatology* 2012;**51**:vi5–9. doi:10.1093/RHEUMATOLOGY/KES279
- 19 Espenhain L, Funk T, Overvad M, *et al.* Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. *Euro Surveill* 2021;**26**. doi:10.2807/1560-7917.ES.2021.26.50.2101146
- 20 Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. *Biometrika* 1983;**70**:41–55. doi:10.1093/BIOMET/70.1.41
- 21 Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. *BMJ* 2019;**367**. doi:10.1136/BMJ.L5657
- 22 Sakuraba A, Luna A, Micic D. Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis. *Gastroenterology* 2022;**162**:88-108.e9. doi:10.1053/J.GASTRO.2021.09.055
- 23 Singh JA, Guyatt G, Ogdie A, *et al.* 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis: <https://doi.org/10.1177/2475530318812244> 2018;**4**:31–58. doi:10.1177/2475530318812244
- 24 Larsen L, Jensen MD, Larsen MD, *et al.* The Danish National Registry for Biological

- 1
2
3
4 Therapy in Inflammatory Bowel Disease. *Clin Epidemiol* 2016;**8**:607–12.
5
6 doi:10.2147/CLEP.S99478
7
8
9 25 Cottone M, Sapienza C, Macaluso FS, *et al.* Psoriasis and Inflammatory Bowel Disease. *Dig*
10
11 *Dis* 2019;**37**. doi:10.1159/000500116
12
13 26 Hernán MA. The hazards of hazard ratios. *Epidemiology* 2010;**21**:13–5.
14
15 doi:10.1097/EDE.0B013E3181C1EA43
16
17
18 27 Izadi Z, Brenner EJ, Mahil SK, *et al.* Association Between Tumor Necrosis Factor Inhibitors
19
20 and the Risk of Hospitalization or Death Among Patients With Immune-Mediated
21
22 Inflammatory Disease and COVID-19. *JAMA Netw open* 2021;**4**.
23
24 doi:10.1001/JAMANETWORKOPEN.2021.29639
25
26
27 28 Simon D, Tascilar K, Kleyer A, *et al.* Impact of Cytokine Inhibitor Therapy on the
28
29 Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against
30
31 SARS-CoV-2 in an Unvaccinated Cohort. *Arthritis Rheumatol (Hoboken, NJ)* 2022;**74**:783–
32
33 90. doi:10.1002/ART.42035
34
35
36 29 Simon D, Tascilar K, Fagni F, *et al.* SARS-CoV-2 vaccination responses in untreated,
37
38 conventionally treated and anticytokine-treated patients with immune-mediated inflammatory
39
40 diseases. *Ann Rheum Dis* 2021;**80**:1312–6. doi:10.1136/ANNRHEUMDIS-2021-220461
41
42
43 30 Favalli EG, Bugatti S, Klersy C, *et al.* Impact of corticosteroids and immunosuppressive
44
45 therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic
46
47 inflammatory arthritis. *Arthritis Res Ther* 2020;**22**. doi:10.1186/S13075-020-02395-6
48
49
50 31 McKay LI, Cidlowski JA. Physiologic and Pharmacologic Effects of Corticosteroids.
51
52 Published Online First: 2003. <https://www.ncbi.nlm.nih.gov/books/NBK13780/> (accessed 1
53
54 Sep 2022).
55
56
57 32 Rahier JF, Moutschen M, van Gompel A, *et al.* Vaccinations in patients with immune-
58
59
60

1
2
3
4 mediated inflammatory diseases. *Rheumatology (Oxford)* 2010;**49**:1815–27.

5
6
7 doi:10.1093/RHEUMATOLOGY/KEQ183

- 8
9 33 Croce E, Hatz C, Jonker EF, *et al.* Safety of live vaccinations on immunosuppressive therapy
10 in patients with immune-mediated inflammatory diseases, solid organ transplantation or after
11 bone-marrow transplantation - A systematic review of randomized trials, observational
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
studies and case reports. *Vaccine* 2017;**35**:1216–26. doi:10.1016/J.VACCINE.2017.01.048

For peer review only

TABLES & FIGURES

Table 1. Characteristics of immune-mediated inflammatory disease patients at baseline and after propensity score weighting, by exposure to immunosuppressive therapy.

	Baseline IMID Cohort*			Weighted IMID Cohort		
	Unexposed	Exposed	SD	Unexposed	Exposed	SD
Total, n (%)	112 675 (100)	39 765 (100)	NA	39 524 (100)	39 765 (100)	NA
Inflammatory bowel disease, n (%)	47 001 (41.7)	10 480 (26.4)	NA	10 284 (26.0)	10 480 (26.4)	NA
Arthropathy, n (%)	44 669 (39.6)	24 261 (61.0)	NA	24 227 (61.3)	24 261 (61.0)	NA
Psoriasis, n (%)	21 005 (18.6)	5 024 (12.6)	NA	5 014 (12.7)	5 024 (12.6)	NA
Age, median (IQR)	59 (46-71)	58 (45-71)	0.06	58 (44-71)	58 (45-71)	0.01
Male, n (%)	48 941 (43.4)	17 080 (43.0)	0.01	16 934 (42.8)	17 080 (43.0)	0.00
SARS-CoV-2 test in the previous month, median (IQR)	0 (0-1)	0 (0-1)	0.04	0 (0-1)	0 (0-1)	0.00
Calendar date of entry 2021, n (%)						
January to April	27,865 (24.7)	16,689 (42.0)	0.37	10,124 (25.6)	16,689 (42.0)	0.35
May to August	81,682 (72.5)	22,361 (56.2)	0.34	28,211 (71.4)	22,361 (56.2)	0.32
September to November	3,128 (2.8)	715 (1.8)	0.07	1,189 (3.0)	715 (1.8)	0.08
Comorbidities, n (%)						
Cardiovascular disease	41 056 (36.4)	14 010 (35.2)	0.03	14 050 (35.5)	14 010 (35.2)	0.01
Pulmonary disease	14 994 (13.3)	5 793 (14.6)	0.04	5796 (14.7)	5 793 (14.6)	0.00
Liver disease	3 630 (3.2)	1 528 (3.8)	0.03	1 525 (3.9)	1 528 (3.8)	0.00
Kidney disease	6 859 (6.1)	2 260 (5.7)	0.02	2 279 (5.8)	2 260 (5.7)	0.00
Other gastrointestinal diseases	21 505 (19.1)	7 086 (17.8)	0.03	6 984 (17.7)	7 086 (17.8)	0.00
Skin disease	9 889 (8.8)	3 748 (9.4)	0.02	3 703 (9.4)	3 748 (9.4)	0.00
Musculoskeletal disease	45 393 (40.3)	16 620 (41.8)	0.03	16 649 (42.1)	16 620 (41.8)	0.01
Medications, n (%)						
Cardiovascular drugs	80 529 (71.5)	28 179 (70.9)	0.01	28 054 (71.0)	28 179 (70.9)	0.00
Antibiotics	108 502 (96.3)	38 405 (96.6)	0.02	38 181 (96.6)	38 405 (96.6)	0.00
Oral anticoagulants	11 111 (9.9)	4 022 (10.1)	0.01	4 034 (10.2)	4 022 (10.1)	0.00
Drugs used in diabetes	12 935 (11.5)	4 034 (10.1)	0.04	4 030 (10.2)	4 034 (10.1)	0.00

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Drugs for obstructive airway diseases	36 970 (32.8)	13 118 (33.0)	0.00	13 (33.2)	116 (33.0)	13	118	0.00
IBD-specific treatments, n (%)								
Any IBD-related hospital admissions in the previous year	564 (1.2)	714 (6.8)	0.12	584 (5.7)		714 (6.8)		0.05
5-ASA/sulfasalazine	12 596 (26.8)	2 845 (27.1)	0.00	2 857 (27.8)	2 (27.1)	845 (27.1)		0.01
Budesonide	646 (1.4)	272 (2.6)	0.02	277 (2.7)		272 (2.6)		0.01
IBD related procedures	18 553 (39.5)	4 551 (43.4)	0.05	4 473 (43.5)	4 (43.4)	551 (43.4)		0.00
Endoscopy of the gastrointestinal tract	7 454 (15.9)	3 702 (35.3)	0.12	3 543 (34.5)	3 (35.3)	702 (35.3)		0.02
Arthropathy-specific treatments, n (%)								
Arthropathy-related procedures	13 932 (31.2)	8 415 (34.7)	0.09	8 399 (34.7)	8 (34.7)	415 (34.7)		0.00
Anti-inflammatory and anti-rheumatic drugs	5 678 (12.7)	3 462 (14.3)	0.07	3 480 (14.4)	3 (14.3)	462 (14.3)		0.00
Hydroxychloroquine	540 (1.2)	845 (3.5)	0.15	801 (3.3)		845 (3.5)		0.01
Psoriasis-specific treatments, n (%)								
5-ASA/sulfasalazine	2 149 (10.2)	807 (16.1)	0.03	805 (16.1)		807 (16.1)		0.00
Topical corticosteroids	73 (0.3)	42 (0.8)	0.00	39 (0.8)		42 (0.8)		0.01
Anti-psoriatic medication	7 441 (35.4)	1 894 (37.7)	0.01	1 900 (37.9)	1 (37.7)	894 (37.7)		0.00
Topical calcineurin inhibitors	3 731 (17.8)	1 106 (22.0)	0.00	1 110 (22.1)	1 (22.0)	106 (22.0)		0.00
Psoriasis related procedures	542 (2.6)	144 (2.9)	0.00	144 (2.9)		144 (2.9)		0.00
5-ASA/sulfasalazine	2 149 (10.2)	807 (16.1)	0.03	805 (16.1)		807 (16.1)		0.00

Abbreviations: IMID = immune-mediated inflammatory disease; SD = standardized differences; IQR = inter-quartile range; NA = not applicable. *Total cohort numbers prior to trimming.

FIGURE LEGENDS

Figure 1. Flow chart for inclusion into the exposed and unexposed IMID cohort.

Figure 2. Risk of infection, hospitalization and death associated with immunosuppressive exposure from Jan 2021-Nov 2021 in Inflammatory Bowel Disease, Arthropathy, Psoriasis and across all IMID cohorts.

Figure 3. Risk of infection associated with immunosuppressive drug class exposure (Selective Immunosuppressants, Tumour Necrosis Factor Inhibitors, Interleukin Inhibitors, Calcineurin Inhibitors, Systemic Corticosteroids, and Other Immunosuppressants including Rituximab) in IMID patients.

Figure 4. Risk of hospitalization associated with immunosuppressive drug class exposure (Selective Immunosuppressants, Tumour Necrosis Factor Inhibitors, Interleukin Inhibitors, Calcineurin Inhibitors, Systemic Corticosteroids, and Other Immunosuppressants including Rituximab) in IMID patients.




Figure 1. Flow chart for inclusion into the exposed and unexposed IMID cohort.

190x275mm (200 x 200 DPI)


Figure 2.

Figure 2. Risk of infection, hospitalization and death associated with immunosuppressive exposure from Jan 2021-Nov 2021 in Inflammatory Bowel Disease, Arthropathy, Psoriasis and across all IMID cohorts.

296x209mm (200 x 200 DPI)

Figure 3.




Figure 3. Risk of infection associated with immunosuppressive drug class exposure (Selective Immunosuppressants, Tumour Necrosis Factor Inhibitors, Interleukin Inhibitors, Calcineurin Inhibitors, Systemic Corticosteroids, and Other Immunosuppressants including Rituximab) in IMID patients.

296x209mm (200 x 200 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 4.




Figure 4. Risk of hospitalization associated with immunosuppressive drug class exposure (Selective Immunosuppressants, Tumour Necrosis Factor Inhibitors, Interleukin Inhibitors, Calcineurin Inhibitors, Systemic Corticosteroids, and Other Immunosuppressants including Rituximab) in IMID patients.

296x209mm (200 x 200 DPI)

The Impact of Immunosuppressive Therapy on SARS-CoV-2 mRNA Vaccine Effectiveness in Patients with Immune-mediated Inflammatory Diseases: A Danish Nationwide Cohort Study

Rahma Elmahdi^{*1,2} (0000-0002-7013-9548), Daniel Ward^{*1} (0000-0003-0405-7250), Martin Thomsen Ernst³ (0000-0001-9003-3823), Gry Juul Poulsen¹ (0000-0003-2744-2469), Jesper Hallas³ (0000-0002-8097-8708), Anton Pottegård³ (0000-0001-9314-5679), Tine Jess^{1,4} (0000-0002-4391-7332)

SUPPLEMENTARY TABLES

Supplementary Table 1. Exposures and corresponding ATC and procedure codes for immunosuppressives

Medication	ATC code	Procedure code
Selective immunosuppressants		
Muromonab-CD3	L04AA02	
Antilymphocyte immunoglobulin (horse)	L04AA03 L04AA04	BOHJ12
Antithymocyte immunoglobulin (rabbit)	L04AA06	BOHJ22
Mycophenolic acid	L04AA10	BOHJ23
Sirolimus	L04AA13	
Leflunomide	L04AA18	BOHJ24
Everolimus	L04AA23	BOHJ26
Natalizumab	L04AA24	BOHJ18C1
Abatacept	L04AA25	BWHB84
Eculizumab	L04AA26	BOHJ19H6
Belimumab	L04AA27	BOHJ27
Fingolimod	L04AA28	
Belatacept	L04AA29	BOHJ28D
Tofacitinib	L04AA31	BOHJ28A
Teriflunomide	L04AA32	
Aprelimast	L04AA33	BOHJ19H4
Vedolizumab	L04AA34	BOHJ16A
Alemtuzumab	L04AA36	
Ocrelizumab	L04AA37	
Baricitinib	L04AA38	
Ozanimod	L04AA39	
Emapalumab	L04AA40	BWHA178
Cladribine	L04AA41	
Imlifidase	L04AA42	BWHB87
Siponimod	L04AA43	
Ravulizumab	L04AA44	
Upadacitinib		

Tumour necrosis factor inhibitors		
Etanercept	L04AB01	BOHJ18A2
Infliximab	L04AB02	BOHJ18A1
Adalimumab	L04AB04	BOHJ18A3
Certolizumab pegol	L04AB05	BOHJ18A5
Golimumab	L04AB06	BOHJ18A4
Interleukin inhibitors		
Basiliximab	L04AC02	
Anakinra	L04AC03	BOHJ18B1
Ustekinumab	L04AC05	BOHJ18B3
Tocilizumab	L04AC07	BOHJ18B2
Canakinumab	L04AC08	BOHJ18B4
Secukinumab	L04AC10	BOHJ18B5
Siltuximab	L04AC11	
Brodalumab	L04AC12	BOHJ18B6
Ixekizumab	L04AC13	
Sarilumab	L04AC14	BOHJ18B9
Guselkumab	L04AC16	
Tildrakizumab	L04AC17	BOHJ18B7
Risankizumab	L04AC18	BOHJ19N1
Calcineurin inhibitors		
Ciclosporin	L04AD01	BOHJ20
Tacrolimus	L04AD02	BOHJ21
Other immunosuppressants		
Azathioprine	L04AX01	BWHB83
Thalidomide	L04AX02	BWHB81
Methotrexate	L04AX03	BWHA115
Lenalidomide	L04AX04	BWHB82
Pirfenidone	L04AX05	BWHB85
Pomalidomide	L04AX06	BWHB86
Dimethyl fumarate	L04AX07	BOHJ28B
Darvadstrocel	L04AX08	
Systemic corticosteroids	H02AB	
Rituximab	L01XC02	

Supplementary Table 2. Minimum daily dose of corticosteroid in exposed persons

Compound	Equivalent dose
Cortisone	38mg
Hydrocortisone	30mg
Prednisone	7.5mg
Prednisolone	7.5mg
Triamcinolone	6mg
Methylprednisolone	6mg
Betamethasone	0.9mg
Dexamethasone	1.2mg

Supplementary Table 3. Covariates by disease cohort

IBD COHORT		
Covariate	Categories/ ATC/ICD codes	Assessment window
Age	-	At cohort entry
Sex	-	At cohort entry
SARS-CoV-2 tests in the previous month	-	At cohort entry
Ever previous SARS-CoV-2 positive test	-	From February 2020
IBD specific covariates		
Any IBD-related hospital admissions in the previous year	K50/K51	1 year before cohort entry
Crohn's disease	K50	At cohort entry
Ulcerative colitis	K51	At cohort entry
5-ASA/sulfasalazine	MA07EC0	1 year before matching date
Budesonide	MA07EA06	3 months before matching date
IBD related procedures Operations of the small bowel and colon Operations of the rectum Operations of the anus and perianal tissue Operational of the abdominal wall, peritoneum, mesentery and omentum Lysis of adhesion in the abdominal cavity Closure of intestinovaginal fistula Closure of vesiculointestinal fistula	KJF KJG KJH KJA KJAP KLEE30 KKCH30	Any time before cohort entry
Endoscopy of the gastrointestinal tract	KUJ	1 year before the cohort entry
Comorbidities		
Cardiovascular disease	DI1-I7	Any time before cohort entry
Pulmonary disease Chronic disease of the lower airways Other interstitial lung disease Diseases with pus and necrosis in the lower airway Interstitial lung emphysema compensatory emphysema	DJ4 DJ84 DJ85 DJ982 DJ983	Any time before cohort entry
Liver disease	DK70-K77	Any time before cohort entry
Kidney disease Glomerular disease Tubulointerstitial kidney disease and kidney insufficiency	DN0 DN1	Any time before cohort entry
Other gastrointestinal diseases Gingivitis and periodontal disease Inflammation of the oral mucosa and related Stomach and duodenal ulcers Fissure and rifts in and around the anus Abscess in and around the anus Other diseases of the rectum and anus Other bowel disease	DK05 DK12 DK25-27 DK60 DK61 DK62 DK63	Any time before cohort entry

1 2 3 4 5 6 7 8 9 10 11 12 13	Skin disease Bullous skin disease Dermatitis and eczema Alopecia areata Vitiligo Granulomatous disease in the skin and subcutaneous tissue Lupus Other localised connective tissue disease Vasculitis limited to the skin	DL10-14 DL20-30 DL63 DL80 DL92 DL93 DL94 DL95	Any time before cohort entry
14 15 16 17 18	Musculoskeletal disease Generalised connective tissue diseases Diseases of the muscles Soft-tissue rheumatism	DM30- DM36 DM60-63 DM70-79	Any time before cohort entry
19	Medications		
20 21 22	Cardiovascular drugs	MC01-MC10	Any time before cohort entry
23 24	Antibiotics	MJ01	Any time before cohort entry
25 26	Oral anticoagulants	MB01AA MB01AF	Any time before cohort entry
27 28	Drugs used in diabetes	MA10	Any time before cohort entry
29 30	Drugs for obstructive airway diseases	MR03	Any time before cohort entry
31	INFLAMMATORY ARTHROPATHIES COHORT		
32	Age	-	At cohort entry
33	Sex	-	At cohort entry
34	SARS-CoV-2 tests in the previous month	-	At cohort entry
35	Arthropathy-specific covariates		
36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	Arthropathy-related procedures Shoulder and upper arm Primary insertion of joint prosthesis Secondary insertion of joint prosthesis Operations on the joint capsule and ligaments Operations of the synovia and joint surface Joint resections, arthroplasties, and arthrodesis Excision of bursa Elbow and lower arm Primary insertion of joint prosthesis Secondary insertion of joint prosthesis Operations on the joint capsule and ligaments Operations of the synovia and joint surface Joint resections, arthroplasties, and arthrodesis Excision of bursa Wrist and hand Primary insertion of joint prosthesis Secondary insertion of joint prosthesis Operations on the joint capsule and ligaments Operations of the synovia and joint surface Joint resections, arthroplasties, and arthrodesis Operations on the fascia, tendon sheaths, ganglia and bursae	KNBB KNBC KNBE KNBF KNBG KBM79 KNCB KNCC KNCE KNCF KNCG KNCM79 KNDB KNDC KNDE KNDF KNDG KNDM	Any time before cohort entry

<p>Hip and thigh</p> <p>Primary insertion of joint prosthesis</p> <p>Secondary insertion of joint prosthesis</p> <p>Operations on the joint capsule and ligaments</p> <p>Operations of the synovia and joint surface</p> <p>Joint resections, arthroplasties, and arthrodesis</p> <p>Excision of bursa in the</p> <p>Knee and lower leg</p> <p>Primary insertion of joint prosthesis</p> <p>Secondary insertion of joint prosthesis</p> <p>Operations on the joint capsule and ligaments</p> <p>Operations of the synovia and joint surface</p> <p>Joint resections, arthroplasties, and arthrodesis</p> <p>Excision of bursae</p> <p>Ankle and foot</p> <p>Primary insertion of joint prosthesis</p> <p>Secondary insertion of joint prosthesis</p> <p>Operations on the joint capsule and ligaments</p> <p>Operations of the synovia and joint surface</p> <p>Joint resections, arthroplasties, and arthrodesis</p> <p>Operations on the fascia, tendon sheaths, ganglia and bursae</p>	<p>KNFB</p> <p>KNFC</p> <p>KNFE</p> <p>KNFF</p> <p>KNFG</p> <p>KNFM79</p> <p>KNGB</p> <p>KNGC</p> <p>KNGE</p> <p>KNGF</p> <p>KNGG</p> <p>KNGM79</p> <p>KNHB</p> <p>KNHC</p> <p>KNHE</p> <p>KNHF</p> <p>KNHG</p> <p>KNHM</p>	
<p>Anti-inflammatory and anti-rheumatic drugs inc. specific anti-rheumatic therapies, non-steroidals, and combination medications</p> <p>Hydroxychloroquine</p>	<p>M01</p> <p>P01BA02</p>	<p>3 months before cohort entry</p>
Comorbidities		
Cardiovascular disease	DI1-I7	Any time before cohort entry
<p>Pulmonary disease</p> <p>Chronic disease of the lower airways</p> <p>Other interstitial lung disease</p> <p>Diseases with pus and necrosis in the lower airway</p> <p>Interstitial lung emphysema</p> <p>compensatory emphysema</p>	<p>DJ4</p> <p>DJ84</p> <p>DJ85</p> <p>DJ982</p> <p>DJ983</p>	Any time before cohort entry
Liver disease	DK70-K77	Any time before cohort entry
<p>Kidney disease</p> <p>Glomerular disease</p> <p>Tubulointerstitial kidney disease and kidney insufficiency</p>	<p>DN0</p> <p>DN1</p>	Any time before cohort entry
<p>Other gastrointestinal diseases</p> <p>Gingivitis and periodontal disease</p> <p>Inflammation of the oral mucosa and related</p> <p>Stomach and duodenal ulcers</p> <p>Fissure and rifts in and around the anus</p> <p>Abscess in and around the anus</p> <p>Other diseases of the rectum and anus</p> <p>Other bowel disease</p>	<p>DK05</p> <p>DK12</p> <p>DK25-27</p> <p>DK60</p> <p>DK61</p> <p>DK62</p> <p>DK63</p>	Any time before cohort entry
<p>Skin disease</p> <p>Bullous skin disease</p> <p>Dermatitis and eczema</p> <p>Alopecia areata</p>	<p>DL10-14</p> <p>DL20-30</p> <p>DL63</p>	Any time before cohort entry

Vitiligo Granulomatous disease in the skin and subcutaneous tissue Lupus Other localised connective tissue disease Vasculitis limited to the skin	DL80 DL92 DL93 DL94 DL95	
Musculoskeletal disease Generalised connective tissue diseases Diseases of the muscles Soft-tissue rheumatism	DM30- DM36 DM60-63 DM70-79	Any time before cohort entry
Medications		
Cardiovascular drugs	MC01-MC10	Any time before cohort entry
Antibiotics	MJ01	Any time before cohort entry
Oral anticoagulants	MB01AA MB01AF	Any time before cohort entry
Drugs used in diabetes	MA10	Any time before cohort entry
Drugs for obstructive airway diseases	MR03	Any time before cohort entry
PSORIASIS COHORT		
Age	-	At cohort entry
Sex	-	At cohort entry
SARS-CoV-2 tests in the previous month	-	At cohort entry
Psoriasis-specific covariates		
Procedures Ultraviolet therapy: UV-A with psoralen/broad-spectrum UVB / narrow-spectrum UVB	BNGA1/ BNGA2/ BNGA3	Any time before cohort entry
Therapeutic steroid injection in the joints and soft tissues	BLHN0	Any time before cohort entry
5-ASA/sulfasalazine	A07EC0	1 year before cohort entry
Topical corticosteroids	D07	1 year before cohort entry
Antipsoriatic medication	D05	1 year before cohort entry
Topical calcineurin inhibitors	D11AH01-02,	1 year before cohort entry
Comorbidities		
Cardiovascular disease	DI1-I7	Any time before cohort entry
Pulmonary disease Chronic disease of the lower airways Other interstitial lung disease Diseases with pus and necrosis in the lower airway Interstitial lung emphysema compensatory emphysema	DJ4 DJ84 DJ85 DJ982 DJ983	Any time before cohort entry

Liver disease	DK70-K77	Any time before cohort entry
Kidney disease Glomerular disease Tubulointerstitial kidney disease and kidney insufficiency	DN0 DN1	Any time before cohort entry
Other gastrointestinal diseases Gingivitis and periodontal disease Inflammation of the oral mucosa and related Stomach and duodenal ulcers Fissure and rifts in and around the anus Abscess in and around the anus Other diseases of the rectum and anus Other bowel disease	DK05 DK12 DK25-27 DK60 DK61 DK62 DK63	Any time before cohort entry
Skin disease Bullous skin disease Dermatitis and eczema Alopecia areata Vitiligo Granulomatous disease in the skin and subcutaneous tissue Lupus Other localised connective tissue disease Vasculitis limited to the skin	DL10-14 DL20-30 DL63 DL80 DL92 DL93 DL94 DL95	Any time before cohort entry
Musculoskeletal disease Generalised connective tissue diseases Diseases of the muscles Soft-tissue rheumatism	DM30- DM36 DM60-63 DM70-79	Any time before cohort entry
Medications		
Cardiovascular drugs	MC01-MC10	Any time before cohort entry
Antibiotics	MJ01	Any time before cohort entry
Oral anticoagulants	MB01AA MB01AF	Any time before cohort entry
Drugs used in diabetes	MA10	Any time before cohort entry
Drugs for obstructive airway diseases	MR03	Any time before cohort entry

Supplementary Table 4. Risk of infection, hospitalisation and death associated with immunosuppressive therapy in vaccinated patients with immune-mediated inflammatory diseases.

	Exposed				Unexposed				Crude HR (95% CI) ***	Weighted HR (95% CI) ***
	Total	Events	Incidence rate (95% CI) **	PY	Total	Events	Incidence rate (95% CI) **	PY		
COVID-19 Infection*										
IBD	10 477	287	54.7 (48.7-61.4)	5 246	46 974	885	42.5 (39.8-45.4)	20 809	1.7 (1.5-1.9)	1.6 (1.4-1.9)
Arthropathy	24 255	476	40.3 (36.8-44.1)	11 822	44 650	800	37.8 (35.3-40.6)	21 140	1.3 (1.1-1.4)	1.3 (1.1-1.4)
Psoriasis	5 023	103	45.3 (37.4-55.00)	2 273	20 995	392	41.5 (37.6-45.8)	9 441	1.1 (0.9-1.4)	1.1 (0.9-1.4)
Combined cohorts	39 755	866	-	19 341	112 619	2 077	-	51 390	1.4 (1.3-1.5)	1.4 (1.2-1.5)
COVID-19 Hospitalization*										
IBD	10 477	15	2.8 (1.7-4.7)	5 280	46 980	43	2.1 (1.5-2.8)	20 892	2.8 (1.5-5.1)	2.1 (1.0-4.1)
Arthropathy	24 256	37	3.1 (2.3-4.3)	11 873	44 650	59	2.8 (2.2-3.6)	21 215	1.3 (0.9-2.0)	1.3 (0.9-2.0)
Psoriasis	5 023	n<5	-	2 284	20 999	20	2.1 (1.4-3.3)	9 479	0.5 (0.1-2.3)	0.6 (0.1-2.5)
Combined cohorts	39 756	52	-	19 437	112 629	122	-	51 594	1.6	1.4

									(1.1-2.2)	(1.0-2.0)
Death*										
IBD	10 477	n<5	-	5 281	46 980	6	0.3 (0.1-0.6)	20 897	1.1 (0.1-9.7)	0.4 (0-5.6)
Arthropathy	24 256	6	0.51 (0.2-1.1)	11 875	44 650	13	0.6 (0.4-1.1)	21 222	1.0 (0.4-2.7)	1.0 (0.4-2.6)
Psoriasis	5 023	0	-	2 284	20 999	n<5	-	9 480	-	-
Combined cohorts	39 756	6	-	19 440	112 629	19	-	51 599	1.0 (0.4-2.5)	0.9 (0.4-2.2)
Abbreviations: CI = confidence interval; HR = hazard ratio; IBD= inflammatory bowel disease; PY = person-years.										
*COVID19- Infection = confirmed positive antigen or PCR test result for SARS-CoV2; COVID-19 Hospital Admission = Hospitalisation with SARS-CoV2 infection as primary diagnosis code; Death within 60 days of positive SARS-CoV2 test.										
**Events/1000 PY (95% CI)										
*** Sex and age adjusted crude and weighted hazard ratios										

Supplementary Table 5. Risk of COVID-19 infection associated with immunosuppressive therapy in vaccinated patients with immune-mediated inflammatory diseases at 0-3 months, 3-6 months, and 6-11 months post-vaccination.

	Exposed				Unexposed				Crude HR (95% CI) **	Weighted HR (95% CI) **
	Total	Events	Incidence rate (95% CI) *	PY	Total	Events	Incidence rate (95% CI) *	PY		
COVID-19 infection 0-3 months post-vaccination										
IBD	10 477	57	22.2 (17.1-28.8)	2 570	46 974	196	17.0 (14.8-19.5)	11 546	1.6 (1.2-2.2)	1.5 (1.1-2.2)
Arthropathy	24 255	96	16.1 (13.2-19.6)	5 978	44 650	166	15.1 (13.0-17.6)	10 990	1.3 (1.0-1.7)	1.3 (1.0-1.7)
Psoriasis	5 023	24	19.4 (13.0-29.0)	1 236	20 995	83	16.1 (13.0-19.9)	5 163	1.3 (0.3-2.1)	1.3 (0.8-2.1)
Combined cohorts	39 755	177	-	4 403	112 619	445	-	27 699	1.4 (1.2-1.7)	1.4 (1.1-1.6)
COVID-19 infection 3-6 months post-vaccination										
IBD	10 010	123	45.8 (38.4-54.7)	2 683	45 202	526	56.8 (52.1-61.8)	9 266	0.9 (0.8-1.2)	1.0 (0.8-1.2)
Arthropathy	23 503	284	48.6 (43.2-54.5)	5 849	43 186	482	47.5 (43.4-51.9)	10 149	1.2 (1.1-1.4)	1.2 (1.1-1.4)
Psoriasis	4 860	63	60.7 (47.4-77.7)	1 038	20 203	233	54.5 (47.9-61.9)	4 279	1.1 (0.8-1.4)	1.0 (0.8-1.4)
Combined cohorts	38 373	470	-	19 437	108 591	1 241	-	23 694	1.1 (1.0-1.2)	1.1 (1.0-1.3)

COVID-19 infection 6-11 months post-vaccination										
IBD	6 058	107	160.6 (132.9-194.1)	666	15 742	163	107.1 (91.9-124.9)	1 522	1.3 (0.9-1.7)	1.4 (1.1-1.9)
Arthropathy	12 223	96	82.7 (67.7-101.0)	1 160	19 839	152	80.8 (68.9-94.7)	1 881	1.1 (0.8-1.4)	1.1 (0.8-1.4)
Psoriasis	1 719	16	93.8 (57.5-153.1)	170	7 444	76	109.8 (87.7-137.5)	691	0.9 (0.5-1.5)	0.9 (0.5-1.5)
Combined cohorts	20 000	219	-	1 996	43 025	391	-	4 094	1.1 (0.9-1.3)	1.11 (0.9-1.3)
Abbreviations: CI = confidence interval; HR = hazard ratio; IBD= inflammatory bowel disease; PY = person-years.										
*Events/1000 PY										
**Sex and age adjusted crude and weighted hazard ratios										

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Supplementary Table 6. Risk of COVID infection associated with immunosuppressive therapy in vaccinated patients with immune-mediated inflammatory diseases by calendar period (1st January-31st November 2021)

	Exposed		Unexposed		Hazard Ratio (HR)	
	Total	Events	Total	Events	Crude HR (95% CI)	Weighted HR (95% CI) **
*COVID-19 infection from 1st January to 30th April						
IBD	5 745	n<5	10 306	7	0.67 (0.17-2.61)	0.39 (0.09-1.71)
Arthropathy	9 646	9	13 044	17	0.75 (0.33-1.69)	0.78 (0.35-1.71)
Psoriasis	1 298	n<5	4 512	6	2.00 (0.50-8.02)	1.98 (0.48-8.19)
Combined IMID	16 689	<19	27 862	30	0.87 (0.48-1.59)	0.83 (0.44-1.54)
COVID-19 infection 1st May to 31st August						
IBD	10 141	56	45 486	121	1.61 (1.17-2.22)	1.19 (0.82-1.73)
Arthropathy	23 885	74	43 457	116	1.08 (0.81-1.45)	1.07 (0.79-1.43)
Psoriasis	4 912	12	20 337	53	0.88 (0.47-1.65)	0.84 (0.44-1.58)
Combined IMID	38 938	142	109 280	290	1.24 (1.01-1.52)	1.08 (0.87-1.34)
COVID-19 infection 1st September to 30st November						
IBD	1 0349	228	46 590	757	1.69 (1.45-1.97)	1.74 (1.48-2.04)
Arthropathy	23 898	393	44 079	667	1.34 (1.18-1.51)	1.33 (1.17-1.51)
Psoriasis	4 974	88	20 803	333	1.17 (0.93-1.48)	1.13 (0.89-1.44)
Combined IMID	39 221	709	111 472	1757	1.42 (1.30-1.55)	1.42 (1.29-1.56)
Abbreviations: CI = confidence interval; HR = hazard ratio; IBD= inflammatory bowel disease.						
*COVID19- Infection = confirmed positive antigen or PCR test result for SARS-CoV2						
** Sex and age adjusted crude and weighted hazard ratios						

Supplementary Table 7. Risk of infection, hospitalisation and death associated with immunosuppressive therapy in vaccinated patients with immune-mediated inflammatory diseases by immunosuppressive drug class.

	Exposed				Unexposed				Crude HR (95% CI) ***	Weighted HR (95% CI) ***
	Total	Events	PY	Incidence rate (95% CI) **	Total	Events	PY	Incidence rate (95% CI) **		
COVID-19 Infection*										
Selective Immunosuppressants	3 384	68	1 846	39.4 (31.0-49.9)	151 936	2 079	51 334	40.5 (38.8-42.3)	1.3 (1.0-1.7)	1.3 (1.0-1.6)
Tumour Necrosis Factor Inhibitors	14 277	418	6 908	62.5 (56.7-68.7)	140 797	2 070	51 355	40.3 (38.6-42.1)	1.8 (1.6-2.0)	1.8 (1.6-2.0)
Interleukin Inhibitors	2 781	52	1 385	40.1 (30.6-52.7)	152 584	2 082	51 352	40.5 (38.8-42.3)	1.1 (0.8-1.4)	1.0 (0.8-1.4)
Calcineurin Inhibitors	154	n<5	129	-	155 309	2 073	51 298	40.4 (38.7-42.2)	1.3 (0.3-5.2)	0.5 (0.2-1.5)
Systemic Corticosteroids	5 504	97	2 991	34.6 (28.4-42.3)	149 667	2 079	51 503	40.4 (38.7-42.1)	1.3 (1.0-1.6)	1.2 (1.0-1.5)
Rituximab and Other Immunosuppressants	21 038	426	10 703	41.2 (37.5-45.3)	112 593	2 075	51 409	40.4 (38.7-42.1)	1.3 (1.2-1.4)	1.3 (1.1-1.4)
COVID-19 Hospitalization*										
Selective Immunosuppressants	3 384	7	1 735	4.0 (1.9-8.5)	112 479	122	51 531	2.4 (2.0-2.8)	3.0 (1.4-6.5)	2.2 (1.0-5.2)
Tumour Necrosis Factor Inhibitors	14 277	16	6 740	2.4 (1.5-3.9)	112 506	116	51 551	2.3 (1.9-2.1)	2.0 (1.2-3.3)	1.8 (1.0-3.3)

Interleukin Inhibitors	2 781	0	1 302	-	112 445	125	51 549	2.4 (2.0-2.9)	-	-
Calcineurin Inhibitors	154	0	83	-	112 404	122	51 493	2.4 (2.0-2.8)	-	-
Systemic Corticosteroids	5 504	18	2 811	6.4 (4.0-10.2)	112 587	122	51 699	2.4 (2.0-2.8)	2.4 (1.4-3.9)	1.8 (1.0-3.0)
Rituximab and Other Immunosuppressants	21 038	25	10 387	2.4 (1.6-3.6)	112 593	121	51 604	2.3 (2.0-2.8)	1.2 (0.5-1.0)	1.1 (0.7-1.8)
Death*										
Selective Immunosuppressants	3 384	0	1 736	-	112479	23	51 545	0.5 (0.3-0.7)	-	-
Tumour Necrosis Factor Inhibitors	14 277	0	6 741	-	112506	19	5 1564	0.4 (0.2-0.6)	-	-
Interleukin Inhibitors	2 781	0	1 302	-	112 445	24	51 564	0.5 (0.3-0.7)	-	-
Calcineurin Inhibitors	154	0	83	-	112 404	24	51 507	0.5 (0.3-0.7)	-	-
Systemic Corticosteroids	5 504	6	2 812	2.1 (2.0-4.8)	112 587	23	51 713	0.4 (0.3-0.7)	4.0 (1.6-9.9)	2.3 (0.9-6.2)
Rituximab and Other Immunosuppressants	21 038	n<5	10 388	-	112 593	22	51 619	0.4 (0.3-0.7)	0.5 (0.1-2.3)	0.5 (0.1-2.4)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Abbreviations: CI = confidence interval; HR = hazard ratio; IBD= inflammatory bowel disease; PY = person-years.

Immunosuppressive Drug Class: Selective Immunosuppressants, Tumour Necrosis Factor Inhibitors, Interleukin Inhibitors, Calcineurin Inhibitors, Systemic Corticosteroids, and Other Immunosuppressants including Rituximab (See Supplementary for complete ATC codes)



*COVID19- Infection = confirmed positive antigen or PCR test result for SARS-CoV2; COVID-19 Hospital Admission = Hospitalisation with SARS-CoV2 infection as primary diagnosis code; Death within 60 days of positive SARS-CoV2 test.

**Events/1000 PY

*** Sex and age adjusted crude and weighted hazard ratios


SUPPLEMENTARY FIGURES

Supplementary Figure 1. Kaplan-Meier plots for probability of infection with COVID-19 following second mRNA vaccination in immunosuppressive exposed compared to propensity score matched immunosuppressive unexposed a. IBD patients b. Arthropathy patients c. Psoriasis patients over the calendar year from January 1st to 31st November 2021. SMR weighted = standardized mortality ratio weighted.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

c. Psoriasis



review only

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

The Impact of Immunosuppressive Therapy on SARS-CoV-2 mRNA Vaccine Effectiveness in Patients with Immune-mediated Inflammatory Diseases: A Nationwide Danish Cohort Study

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5, 6
Methods			
Study design	4	Present key elements of study design early in the paper	6-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6, 7 & Fig.1
6-10Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	6-8 & Fig.1
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7,8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7,8
Bias	9	Describe any efforts to address potential sources of bias	6-9
Study size	10	Explain how the study size was arrived at	Fig. 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	7-9
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	9,10 & Table 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9,10

1		(b) Indicate number of participants with missing data for each variable of interest	
2		(c) Summarise follow-up time (eg, average and total amount)	
3			
4			
5	Outcome data	15* Report numbers of outcome events or summary measures over time	9 Fig.2-4
6			
7	Main results	16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9,10 & Fig. 2-4
8		(b) Report category boundaries when continuous variables were categorized	
9		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful period	
10			
11			
12			
13			
14			
15	Other analyses	17 Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses	10 Fig.4
16			
17			
18	Discussion		
19	Key results	18 Summarise key results with reference to study objectives	10
20			
21	Limitations	19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
22			
23	Interpretation	20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13
24			
25	Generalisability	21 Discuss the generalisability (external validity) of the study results	11,12
26			
27	Other information		
28	Funding	22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Abstract & 14
29			
30			

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

The Impact of Immunosuppressive Therapy on SARS-CoV-2 mRNA Vaccine Effectiveness in Patients with Immune-mediated Inflammatory Diseases: A Danish Nationwide Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-077408.R2
Article Type:	Original research
Date Submitted by the Author:	05-Feb-2024
Complete List of Authors:	Elmahdi, Rahma; Aalborg Universitet, Department of Clinical Medicine ; Aalborg University Hospital, Department of Gastroenterology and Hepatology Ward, Daniel; Aalborg Universitet, Department of Clinical Medicine Ernst, Martin; University of Southern Denmark, Clinical Pharmacology and Pharmacy, Department of Public Health Poulsen, Gry; Aalborg University, Department of Clinical Medicine Hallas, Jesper; University of Southern Denmark, Clinical pharmacology and pharmacy Pottgard, Anton; University of Southern Denmark, Clinical Pharmacology and Pharmacy, Department of Public Health Jess, Tine; Aalborg Universitet, Department of Clinical Medicine; Aalborg University Hospital, Department of Gastroenterology and Hepatology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Gastroenterology and hepatology, Infectious diseases
Keywords:	COVID-19, EPIDEMIOLOGY, Inflammatory bowel disease < GASTROENTEROLOGY, RHEUMATOLOGY, Psoriasis < DERMATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 **The Impact of Immunosuppressive Therapy on SARS-CoV-2 mRNA Vaccine Effectiveness in**
5
6 2 **Patients with Immune-mediated Inflammatory Diseases: A Danish Nationwide Cohort Study**

7
8
9 3 **Short Title: COVID-19 Vaccination in Immunosuppressed IMID Patients**

10
11 4
12
13 5 Rahma Elmahdi^{*1,2} (0000-0002-7013-9548), Daniel Ward^{*1} (0000-0003-0405-7250), Martin
14
15 6 Thomsen Ernst³ (0000-0001-9003-3823), Gry Juul Poulsen¹ (0000-0003-2744-2469), Jesper Hallas³
16
17 7 (0000-0002-8097-8708), Anton Pottegård³ (0000-0001-9314-5679), Tine Jess^{1,2} (0000-0002-4391-
18
19 8 7332)

20
21
22 9 * Co-first author

23
24
25 10
26
27 11 Rahma Elmahdi, Associate Professor, Center for the Molecular Prediction of Inflammatory Bowel
28
29 12 Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Denmark (1)

30
31 13 Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark
32
33 14 (2)

34
35
36 15 Daniel Ward, Associate Research Fellow, Center for the Molecular Prediction of Inflammatory
37
38 16 Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Denmark (1)

39
40
41 17 Martin Ernst Thomsen, Data Manager, Department of Public Health, Clinical Pharmacology,
42
43 18 Pharmacy and Environmental Medicine, University of Southern Denmark, J.B. Winsløvs Vej 19,
44
45 19 5000 Odense, Denmark (3)

46
47
48 20 Gry Juul Poulsen, Chief Statistician, Center for the Molecular Prediction of Inflammatory Bowel
49
50 21 Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Denmark (1)

51
52 22 Jesper Hallas, Professor, Research Unit of Clinical Pharmacology, University of Southern Denmark,
53
54 23 J.B. Winsløvs Vej 9, 5000 Odense, Denmark (3)

55
56
57 24 Anton Pottegård, Professor, Department of Clinical Pharmacology and Pharmacy, University of
58
59 25 Southern Denmark, J.B. Winsløvs Vej 9, 5000 Odense, Denmark (3)

1
2
3
4 26 Tine Jess, Professor, Center for the Molecular Prediction of Inflammatory Bowel Disease
5
6 27 (PREDICT), Department of Clinical Medicine, Aalborg University, Denmark (1)
7
8
9 28 Professor, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg,
10
11 29 Denmark (2)
12

13
14 30

15
16 31 **Correspondence:** Dr Rahma Elmahdi, National Center of Excellence for Molecular Prediction of
17
18 32 Inflammatory Bowel Disease, PREDICT, Aalborg University, A. C. Meyers Vænge 15, DK-2450
19
20 33 Copenhagen, Denmark. E-mail: rahmae@dcm.aau.dk
21
22

23 34

24
25 35 **Key words:** Immune-mediated inflammatory disease; Cohort study; SARS-CoV-2; Vaccination;
26
27 36 Immunosuppressives
28

29
30 37

31
32 38 **Word count:** Abstract (excluding Strengths and limitations of this study), 288; manuscript body
33
34 39 (excluding tables, figure legends and references), 3840
35

1
2
3
4 41 **ABSTRACT**
5
6

7 42 **Objective:** Patients receiving immunosuppressives have been excluded from trials for SARS-CoV-2
8
9 43 vaccine efficacy. Investigation of immunosuppressants' impact on effectiveness of vaccines,
10
11 44 particularly in patients with immune-mediated inflammatory diseases (IMID), are therefore required.
12
13
14 45

16 46 **Design:** We performed a nationwide cohort study to assess the risk of COVID-19 infection in
17
18 47 vaccinated IMID patients exposed to immunosuppressives compared to IMID unexposed to
19
20 48 immunosuppressives. Exposure to immunosuppressives in the 120 days before receiving the second
21
22 49 SARS-CoV-2 mRNA vaccination was assessed. Patients were followed from date of second
23
24 50 vaccination and weighted Cox models were used to estimate the risk of infection associated with
25
26 51 immunosuppressives. Secondary outcomes included hospitalization and death associated with a
27
28 52 positive SARS-CoV-2 test. Risk of infection by immunosuppressant drug class was also analysed.
29
30
31
32
33 53

35 54 **Setting:** This study used population-representative data from Danish national health registries in the
36
37 55 period from 1st January to 30th November 2021.
38
39
40 56

42 57 **Results:** Overall, 152,440 patients were followed over 19,341 person-years. Immunosuppressants
43
44 58 were associated with a significantly increased risk of infection across IMID (HR: 1.4, 95% CI: 1.2,
45
46 59 1.5), in inflammatory bowel disease (IBD) (HR: 1.6, 95% CI: 1.4, 1.9) and arthropathy (HR: 1.3, 95%
47
48 60 CI: 1.1, 1.4) but not psoriasis (HR: 1.1, 95% CI: 0.88, 1.4). Immunosuppressants were also associated
49
50 61 with an increased risk of hospitalization across IMID (HR: 1.4, 95% CI: 1.0, 2.0), particularly in IBD
51
52 62 (HR: 2.1, 95% CI: 1.0, 4.1). No significantly increased risk of death in immunosuppressant exposed
53
54 63 patients was identified. Analyses by immunosuppressant drug class showed increased COVID-19
55
56
57
58
59
60

1
2
3
4 64 infection and hospitalization with anti-TNF, systemic corticosteroid, and rituximab and other
5
6 65 immunosuppressants in vaccinated IMID patients.
7
8

9 66

10
11 67 **Conclusion:** Immunosuppressive therapies reduced effectiveness of mRNA SARS-CoV-2
12
13 68 vaccination against infection and hospitalization in IMID patients. Anti-TNF, systemic
14
15 69 corticosteroids, and rituximab and other immunosuppressants were particularly associated with these
16
17
18 70 risks.
19

20 71

21 72 **Strengths and limitations of this study**

- 22
23 73 • Use of a non-selected, population representative cohort to source inflammatory and immune
24
25 74 mediated disease (IMID) patients.
- 26
27 75 • Inclusion of a total of 184,346 immunosuppressive exposed IMID patients and 152,440
28
29 76 propensity score matched, unexposed controls.
- 30
31 77 • Complete vaccination, and immunosuppressive treatment exposure data along with complete
32
33 78 infection, hospitalization, and death outcome data with no loss to follow-up.
- 34
35 79 • Lack of individual level data on level of exposure to infection, such as shielding behaviour.
36
37
38
39
40
41

42 80

43 81

44 82

45 83

46 84

47 85

48 86

49 87

50 88

88 INTRODUCTION

89 SARS-CoV-2 mRNA vaccines Comirnaty® (Pfizer-BioNTech) and Spikevax® (Moderna) were
90 found to be efficacious in clinical trials prior to authorisation, and by December 2022 over 758 million
91 doses of Pfizer-BioNTech and 164 million doses of Moderna were administered in the European
92 Union [1]. Pre-marketing trials excluded individuals considered at risk of immunocompromise,
93 including those receiving immunosuppressive therapies [2,3], therefore there remains a paucity of
94 data on the real-world effectiveness of SARS-CoV-2 vaccines in patients treated with
95 immunosuppressive drugs.

96
97 Research published early in the SARS-CoV-2 epidemic suggested that, in the absence of vaccination,
98 some types of immunosuppressives including rituximab, sulfasalazine, and corticosteroids are
99 associated with an increased risk of severe outcomes in COVID-19 infection [4–8]. Immune-mediated
100 inflammatory diseases (IMID), including inflammatory bowel disease, inflammatory arthropathy, and
101 psoriasis have themselves independently been associated with lower serological responses to SARS-
102 CoV-2 vaccination than in healthy controls [9]. Immunosuppressants are key therapies in IMID, so
103 patients with IMID may be at increased risk of infection and severe outcomes of COVID-19 infection
104 both due to the natural history of the diseases and the therapies used to treat them. Even in the context
105 of second vaccination against SARS-CoV-2, exposure to immunosuppressives has been associated
106 with a significantly poorer humoral response; lower than that which is required to confer immunity
107 against infection and severe outcomes of COVID-19 infection in patients treated with
108 immunosuppressive therapies [10–12].

109

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

110 It is therefore important to investigate the impact of immunosuppressants on SARS-CoV-2 vaccine effectiveness, while controlling for the underlying disease-indicating treatment, and other confounders that may impact vaccine effectiveness.

113
114 The real-world effectiveness of SARS-CoV-2 mRNA vaccinations against COVID-19 infection and associated outcomes such as hospitalization or death, in the context of immunosuppressive therapy exposure among IMID patients has not yet been investigated. The aim of this study was to use Danish nationwide population-based data to assess the impact of immunosuppressive exposure on the risk of COVID-19 infection in three cohorts of vaccinated IMID patients.

120 MATERIALS AND METHODS

121 Data sources

122 We conducted a nationwide cohort study using the Danish COVID-19 cohort [13], based on data from the Danish Microbiology Registry [14], which includes individual-level information on vaccine type, dose, and date of administration; SARS-CoV-2 test type and date administered. This data was linked at the individual level to both the Danish National Patient Registry [15] and the Danish National Prescription Registry [16] using a unique Danish Civil Registration number (assigned to all individuals residing in Denmark). The Danish National Patient Registry, a register of hospital activities, includes medical diagnoses coded using International Classification of Disease (ICD-10), and medical procedures and prescriptions including treatment with intravenous medications. The Danish National Prescription Registry contains information on prescriptions dispensed at all community retail pharmacies, including date of dispensing, tablet strength, and pack sizes. Ethics board review is not required for epidemiological research using nationwide registers in Denmark as data is pseudonymised and does not involve patients.

134 **Population, follow-up, and outcomes**

135 The IMID cohort comprised of three disease specific cohorts of all patients diagnosed with
136 inflammatory bowel disease, including Crohn's disease and ulcerative colitis (IBD; ICD-10: K50,
137 K51), inflammatory arthropathy, including ankylosing spondylitis, other inflammatory
138 spondylopathies, seropositive rheumatoid arthritis, other rheumatoid arthritis, and psoriatic and
139 enteropathic arthropathy (ICD-10: M45, M46, M05, M06, M07) or psoriasis (ICD-10: L40) in
140 Denmark, who had received two doses of SARS-CoV-2 mRNA (Pfizer-BioNTech or Moderna)
141 vaccine. Exclusion criteria were not receiving two doses of SARS-CoV-2 mRNA vaccine and
142 migration prior to receipt of second vaccination. Patients with more than one of these IMID
143 diagnoses were included in only one cohort, with IBD taking precedence, then inflammatory
144 arthropathy, finally psoriasis. Therefore, only patients with psoriasis and neither an IBD nor an
145 inflammatory arthropathy diagnosis were included in the psoriasis cohort. This order was preferred
146 as extent of organ-specific disease likely determines the dose for immunosuppressive therapy.
147 Registration of IMID is based on clinical diagnoses, in line with national and international
148 guidelines, such as ECCO-ESGAR guidelines for IBD diagnosis [17,18].

149

150 Patients were followed from the date of administration of second mRNA vaccine (the index date)
151 after 1 January 2021. The primary outcome was a positive SARS-CoV-2 PCR test in the observation
152 period. Secondary outcomes were hospitalization between 7 days prior to and up to 28 days after a
153 positive test or death within 60 days of a positive test (both recorded in Danish National Patient
154 Register). Follow-up was censored at administration of a third vaccination, emigration, death (in the
155 absence of a positive SARS-CoV-2 test) or the end of the study period, 30th November 2021 (Figure
156 1), as prevalence of the omicron variant became substantial after 28th November 2021 [19]. As the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

registers are complete for the presence of patients up to emigration or death, therefore all patients are retained until the event and there is no missing data.

Patient and Public Involvement

None.

Exposures

The exposures for this study include dispensed prescriptions or hospital administration of an immunosuppressive in the 120 days preceding the index date (date of administration of second vaccination). Immunosuppressants included selective immunosuppressants, anti-TNFs, interleukin inhibitors, calcineurin inhibitors, corticosteroids, rituximab and other immunosuppressants (see Supplementary Table 1 for complete list and ACT codes for immunosuppressants). The 120-day exposure window is chosen to cover the largest pack sizes of prescriptions which can contain medications for up to 120 days. A minimum daily dose of corticosteroids equivalent to 7.5 mg prednisolone per day was estimated as the entire dispensed quantity of corticosteroids during a sequence of prescriptions (within the 120-day exposure period) divided by the number of days from the first prescription to the index date (Supplementary Table 2). Unexposed IMID patients were defined as those with a diagnosis of one of the three IMID, who had not received an immunosuppressive in the 120 days preceding the index date, and those receiving <7.5 mg prednisolone-equivalent average per day.

Statistical models

Covariates included age (handled as a continuous covariate), sex, comorbidities (cardiovascular disease, pulmonary disease, liver disease, kidney disease, other gastrointestinal diseases, skin disease,

1
2
3
4 181 and musculoskeletal disease), medications (cardiovascular drugs, antibiotics, oral anticoagulants,
5
6 182 diabetes, and chronic airway disease medications). Testing frequency varied during the period studied
7
8
9 183 due to changes in national and international guidelines and travel restrictions, along with the
10
11 184 background prevalence of SARS-CoV-2, which could introduce bias in case detection. We therefore
12
13 185 adjusted for individual testing frequency by including number of tests in the month preceding index
14
15 186 date as a continuous covariate. Further, covariates specific to each IMID were included separately for
16
17
18 187 each cohort. For the IBD cohort this included any IBD-related hospital admissions in the previous
19
20 188 year, Crohn's disease, ulcerative colitis, 5-ASA/sulfasalazine, budesonide, IBD-related procedures,
21
22
23 189 and endoscopy of the gastrointestinal tract (see Supplementary Table 3 for complete list of IMID
24
25 190 cohort specific covariates).

26
27 191
28
29
30 192 To balance the covariates in the exposed and unexposed groups, we fitted propensity score (PS)
31
32 193 models for each IMID cohort separately. Propensity scores were calculated using logistic regression
33
34 194 for the probability of exposure (treatment with immunosuppressives) conditional on the covariates
35
36 195 defined above [20]. We subsequently implemented the PS using standardized mortality ratio (SMR)
37
38
39 196 weights (with trimming of subjects with extreme weights beyond 1st and 99th centiles). We assessed
40
41 197 the distribution of covariates with standardized differences before and after PS weighting.

42
43 198
44
45
46 199 We used weighted Cox proportional-hazards regression models [21] to estimate risk of the COVID-
47
48 200 19 infection in IMID patients exposed to immunosuppressive therapy compared to unexposed patients
49
50 201 for each disease cohort separately. We used calendar time as the underlying time scale to account for
51
52
53 202 period effects on the risk of the outcomes which may relate to varying infection prevalence and patient
54
55 203 characteristics as patients vulnerable to severe outcomes were vaccinated earlier in the year.

56
57 204
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

205 We performed secondary analyses to further delineate the impact of immunosuppressives on vaccine
206 effectiveness over time by stratifying time since vaccination into the following intervals: 0-3 months,
207 3-6 months, 6-11 months. This not only allowed us to capture the period effects of COVID-19
208 infection risk earlier and later in the pandemic period but also allowed us to assess the impact of
209 censoring at different time points in the follow-up period.

211 We then undertook Fixed Effects Model meta-analysis to calculate the pooled HR of infection,
212 hospitalization, and death for IBD, arthropathy and psoriasis cohorts as overall risk in
213 immunosuppressive exposed IMID by COVID-19 outcome, and the HR of infection during 0-3, 3-6,
214 and 6-11 months of follow-up period, as overall risk in immunosuppressive exposed IMID by period.

215
216 Finally, we also undertook drug specific analysis for risk of COVID-19 infection by
217 immunosuppressive drug class. In this analysis, patients receiving multiple immunosuppressive
218 treatments were treated as independently exposed to each drug class. To account for the potential
219 impact of immunosuppressants commonly prescribed in a weaning dose, which would not be captured
220 using the definition of ≥ 7.5 mg dose equivalent per day, we undertook a sensitivity analysis to assess
221 whether having any prescription for systemic corticosteroids over the 120-day period before the index
222 date had an impact on the risk of infection, hospitalization, or death for those exposed to this class of
223 immunosuppressants.

225 RESULTS

226 A total of 184,346 patients diagnosed with IBD, arthropathy or psoriasis were identified. After
227 exclusion of patients not receiving two doses of SARS-CoV-2 mRNA vaccine, migration prior to
228 receipt of second vaccination, and trimming of those with extreme propensity scores a total 152,440

1
2
3
4 229 patients were included, contributing a total 19,341 person-years of follow-up. During the 120-day
5
6 230 exposure assessment period, 39,765 IMID patients received immunosuppressive treatment (10,480
7
8
9 231 IBD, 24,261 arthropathy, and 5,023 psoriasis), and 112,629 IMID patients (46,980 IBD, 44,650
10
11 232 arthropathy, and 201,999 psoriasis) patients did not. A total of 11 exposed and 55 unexposed IMID
12
13 233 patients are censored from overall analysis due to migration or inclusion on the date of study end
14
15
16 234 (therefore contributing no follow-up time). One arthropathy patient in the exposed group, and 10 IBD
17
18 235 or psoriasis patients in the unexposed group are excluded from the infection analysis due to positive
19
20 236 test on the date of study entry, these are subsequently included in the analysis for risk of
21
22
23 237 hospitalization or death following COVID-19 infection (Figure 1; Supplementary Table 4). Following
24
25 238 application of SMR weighting, the cohorts were balanced on the included covariates (see Table 1 for
26
27 239 covariate prevalence and standardised differences).

28
29
30 240
31
32 241 A total of 866 (2.2%) COVID-19 infections were recorded among immunosuppressive exposed IMID
33
34 242 patients during the follow-up period compared with 2,077 (1.8%) for unexposed IMID patients. This
35
36 243 gave an incidence rate of 55 (49-61) per 1,000 person-years in immunosuppressive exposed IBD
37
38
39 244 patients compared with 43 (40-45) in unexposed IBD patients, 40 (37-44) per 1,000 person-years for
40
41 245 immunosuppressive exposed arthropathy patients compared with 38 (35-41) in unexposed
42
43 246 arthropathy patients, and 45 (37-55) per 1,000 person-years for immunosuppressive exposed psoriasis
44
45
46 247 patients compared with 42 (38-46) per 1,000 person-years in unexposed psoriasis patients.

47
48 248
49
50 249 A significantly increased weighted hazard for infection among exposed patients was seen for both
51
52
53 250 IBD (HR: 1.6, 95% CI: 1.4, 1.9) and arthropathy (HR: 1.3, 95% CI: 1.1, 1.4) cohorts but not for the
54
55 251 psoriasis cohort (HR: 1.1, 95 % CI: 0.88, 1.4). Meta-analysis of the three IMID cohorts showed a
56
57 252 pooled HR for COVID-19 infection in exposed patients of 1.4 (95% CI: 1.2, 1.5; Figure 2). Fewer
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

253 than 57 exposed and 122 unexposed IMID patients were hospitalized with COVID-19 infection
254 during the follow-up period, which corresponded to a significantly increased risk of hospitalization
255 overall for immunosuppressive exposed IMID patients (pooled HR: 1.4, 95% CI: 1.0, 2.0). This
256 increased risk of overall hospitalization is largely due to the contribution of the risk of hospitalization
257 in IBD patients 2.05 (95% CI: 1.03-4.07). Less than five immunosuppressive exposed IBD patients
258 died in the 60 days following a COVID-19 diagnosis compared to six unexposed IBD patients. Six
259 patients in the arthropathy cohort exposed to immunosuppressives compared with 13 unexposed
260 arthropathy patients died in the 60 days following a COVID-19 diagnosis and fewer than five patients
261 with a psoriasis diagnosis, either immunosuppressive exposed or unexposed died with a COVID-19
262 diagnosis. These did not correspond to a significantly increased risk of death among exposed patients
263 in any of the three cohorts or overall (pooled HR: 0.92, 95% CI: 0.38, 2.2; Figure 2).

265 In the first 0-3 months following vaccination, both IBD and arthropathy immunosuppressive exposed
266 patients had a significantly increased risk of COVID-19 infection (HR: 1.5, 95% CI: 1.1, 2.2 and HR:
267 1.3, 95% CI: 1.0, 1.7, respectively; see Supplementary Table 5). Most COVID-19 infections
268 following second vaccination occurred in the 3–6-month period with a total of 470 infections in
269 exposed IMID patients compared with 1,241 unexposed IMID patients. Only exposed arthropathy
270 patients had a significantly increased risk of infection compared to their unexposed counterparts
271 during this period however (HR: 1.2, 95% CI: 1.1, 1.4). The highest incidence rate of COVID-19
272 infection following second vaccination was seen in the 6–11-month period for both
273 immunosuppressive exposed and unexposed IMID patients and risk of infection during this period
274 was only increased among exposed IBD patients (HR: 1.4, 95% CI: 1.1, 1.9). There was however a
275 high rate of censoring among both the immunosuppressive exposed (over 50%) and the unexposed
276 (almost 49%) groups in the 6–11-month period due to receipt of the third SARS-CoV-2 vaccination

1
2
3
4 277 so direct comparison of the risk of infection between time periods is challenging. Kaplan-Meier plots
5
6 278 and HR showing probability of infection over the calendar time of follow-up (January-November
7
8
9 279 2021) are presented in Supplementary Figure 1 and post-hoc analysis for HR for infection by calendar
10
11 280 period (January-November 2021) is shown in Supplementary Table 6.
12

13 281
14
15
16 282 Analysis for risk of infection among IMID cohorts by immunosuppressive drug class exposure
17
18 283 showed a significantly increased risk of infection among users of anti-TNF (HR: 1.8, 95% CI: 1.6,
19
20 284 2.0), systemic corticosteroid (HR: 1.2, 95% CI: 1.0,1.5), and rituximab and other immunosuppressant
21
22 (HR: 1.3, 95% CI: 1.1, 1.4; Figure 3). No other immunosuppressant was significantly associated with
23 285 COVID-19 infection following second vaccination. Anti-TNF and systemic corticosteroid exposure
24
25 286 were also associated with an increased risk of COVID-19 associated hospitalization (HR 1.8, 95% CI
26
27 287 1.0, 3.3 and HR 1.8, 95% CI 1.0,3.0, respectively; Figure 4). No immunosuppressive drug class was
28
29 288 associated with death among IMID patients following receipt of second vaccination (Supplementary
30
31 Table 7). Sensitivity analysis assessing outcomes following any systemic corticosteroid exposure in
32 289 the 120-day period prior to the index date showed no significant difference in risk of infection (crude
33
34 290 HR: 1.2, 95% CI: 1.0, 1.4; adjusted HR: 1.1, 95% CI: 0.95, 1.3) or death (crude HR: 3.1, 95% CI:
35
36 291 1.4, 7.0; adjusted HR: 1.9, 95% CI: 0.77, 4.7). However, risk of hospitalization following infection
37
38 292 was significantly increased in those ever exposed to systemic corticosteroids in the 120-day period
39
40 293 prior to receipt of second vaccination (crude HR: 2.8, 95% CI: 1.9, 4.1; adjusted HR: 2.1, 95% CI:
41
42 294 1.4, 3.2), showing similar results compared with analysis restricting to a ≥ 7.5 mg daily equivalent
43
44 295 dose.
45
46 296
47
48 297
49
50 298
51
52
53
54

55 299 **DISCUSSION**

56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

300 In this large nationwide cohort study of three IMID patient cohorts, we identified a total of 39,756
301 immunosuppressive exposed patients matched to 112,629 immunosuppressive unexposed IMID
302 patients to investigate the risk of COVID-19 infection, hospitalization, and death among IBD,
303 arthropathy and psoriasis patients following second SARS-CoV-2 vaccination. Meta-analysis of the
304 three cohorts showed an overall 35% increased risk of infection and, 42% increased risk of COVID-
305 19 associated hospitalization in immunosuppressive exposed compared to immunosuppressive
306 unexposed IMID patients.

307
308 Mortality was not significantly increased in immunosuppressive exposed patients and these events
309 were rare in both groups. Drug class analysis showed anti-TNF, systemic corticosteroid, and
310 rituximab and other immunosuppressant exposure was significantly associated with both increased
311 risk of COVID-19 infection and hospitalization following second vaccination in immunosuppressive
312 exposed compared to unexposed IMID patients.

313
314 We attempted to ascertain the effectiveness of SARS-CoV-2 mRNA vaccination among IMID
315 patients exposed to immunosuppressive therapies, while controlling for the severity of the underlying
316 disease indicating immunosuppressive treatment with a propensity score model. We found that
317 immunosuppressants were associated with an increased risk of infection, likely due to the impact of
318 immunosuppressive medication on vaccination against COVID-19 infection. This is particularly seen
319 in IBD (HR: 1.6, 95% CI: 1.4-1.9) but is also present in arthropathy (HR: 1.3, 95% CI: 1.1, 1.4) patients
320 and, to a lesser extent, in psoriasis (HR: 1.1, 95% CI: 0.88, 1.4). Immunosuppressive exposed
321 psoriasis patients showed no increased infection risk compared to their unexposed counterparts.
322 Similarly, when assessing risk of hospitalization following vaccination by immunosuppressive
323 exposure, we find a significantly increased risk in IBD patients (HR: 2.1, 95% CI 1.0,4,1), which is

1
2
3
4 324 not observed in arthropathy (HR: 1.3, 95% CI: 0.9, 2.0) or psoriasis (HR: 0.6, 95% CI: 0.1, 2.5). The
5
6
7 325 poorer outcomes observed in immunosuppressive exposed IBD patients is in keeping with wider
8
9 326 findings. In a meta-analysis of serological response to SARS-CoV-2 vaccination among IMID treated
10
11 327 patients, IBD patients were found to have a significantly lower response to first mRNA vaccination
12
13 328 dose than rheumatoid patients (response rate: 0.49, 95% CI: 0.32-0.66 and 0.78, 95% CI: 0.67-0.86,
14
15
16 329 respectively) [22]. This may be due to the more extensive disease seen in typical IBD patients, which
17
18 330 often necessitates higher doses of immunosuppressive therapies, over longer periods to achieve
19
20 331 disease remission than that required for psoriasis or arthropathy [23–25]. However, the difference in
21
22
23 332 increased risk of infection and hospitalization in immunosuppressive exposed IBD compared with
24
25 333 unexposed IBD patients is similar to the other IMID cohorts in this study, with overall pooled IMID
26
27 334 cohort meta-analysis showing a significantly increased risk for both these outcomes. These findings
28
29
30 335 indicate a general trend towards poorer outcomes in immunosuppressive exposed patients regardless
31
32 336 of IMID cohort.

33
34 337
35
36 338 Reassuringly, immunosuppressant exposure was not associated with increased risk of death due to
37
38
39 339 COVID-19 in any of the IMID patient cohorts, suggesting immunosuppressants do not reduce the
40
41 340 effectiveness of vaccination in preventing this important outcome. However, caution should be
42
43 341 exercised in the interpretation of this finding as deaths were recorded in either immunosuppressive
44
45
46 342 exposed or unexposed patients and this may be due to the relatively short follow-up period of 11-
47
48 343 months in this study. Although Kaplan-Meier plots for risk of infection may appear in contradiction
49
50 344 to the overall findings of the primary analysis (with apparent increased rate of COVID infection in
51
52
53 345 the unexposed IMID population in the first 7 months of follow-up), the findings from post-hoc Cox
54
55 346 regression analysis by calendar period shows that the difference between the groups, reflected in the
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

347 overall HR, only becomes apparent in the final 3 months of follow-up as the majority of cases of
348 COVID are seen in this period.

349
350 Meta-analysis showed an overall increased risk of COVID-19 infection among exposed IMID
351 patients during the 0-3 and 3-6-month period only. Only exposed arthropathy patients showed a
352 significantly increased risk of infection in the 3–6-month period. Although this might be interpreted
353 as waning immunity, it is important to note that half of the baseline IMID cohort were censored,
354 largely due to receipt of third vaccination, therefore the remaining population likely differed
355 substantially from the initial cohort. Hence this interpretation of period specific risk estimates should
356 be made tentatively [26]. Although the three periods are not directly comparable, it is likely that our
357 observation of an increased risk of infection in exposed patients in the 0-3- and 3-6-month period
358 reflects a true risk, as is observed in the risk identified over the total follow-up period.

359
360 Treatment with TNF-alpha inhibitors, systemic corticosteroid, and rituximab other
361 immunosuppressants was associated with a significantly increased risk of infection, and TNF-alpha
362 inhibitors and systemic corticosteroids were associated with a significantly increased risk of
363 hospitalization following receipt of second vaccination. This is consistent with previous studies,
364 which suggests that treatment with cytokine inhibitors or B-cell depleting immunosuppressives is
365 related to particularly poor COVID-19 outcomes [27–29], however the association with TNF-alpha
366 inhibitors is novel. Our findings of increased risk of infection and hospitalization, but not death, in
367 sensitivity analysis among IMID patients exposed to systemic corticosteroids is also in keeping with
368 those other studies of unvaccinated IMID cohorts in Denmark [4] and internationally [6,30]. These
369 findings indicate that corticosteroid exposure weakens the protection conferred by vaccination. As
370 glucocorticoids are known to inhibit the breadth of the immune response, including aspects of both

1
2
3
4 371 the cellular and humoral immunity induced by mRNA vaccination, these findings appear to be
5
6 372 intuitive [31]. The interaction of IMID, the impact of treatments to control disease and response to
7
8
9 373 vaccination, particularly considering the effects of dose and duration of administration is however
10
11 374 complex [32,33]. Further studies directly exploring the effects of vaccination whilst controlling for
12
13 375 disease severity and exposure of immunosuppressive drugs by dose and duration would be required
14
15
16 376 to disentangle the association of the different immunosuppressive drug classes with COVID-19
17
18 377 outcomes following vaccination. Such studies would also better inform guidance relating to timelines
19
20 378 for SARS-CoV-2 vaccination in relation to the administration of immunosuppressive therapies in
21
22
23 379 IMID patients.
24

25 380
26
27 381 One of the key strengths of this study is that it is large and population-representative, exploring the
28
29 382 effectiveness of COVID-19 infection using real-world data from comprehensive, nationwide health
30
31 383 registries. Vaccination does not directly correlate with protection from infection and the findings from
32
33 384 this work provides important evidence on effectiveness of post-marketing mRNA vaccination in a
34
35 385 vulnerable patient group. To our knowledge, this is the first study to assess the effectiveness of SARS-
36
37 386 CoV-2 vaccination against COVID-19 infection, hospitalization, and mortality among IMID patients,
38
39 387 based on immunosuppressive exposure. Additionally, our use of PS weighted regression models
40
41 388 allows us to accurately control for the underlying treatment indicating disease, so we are better able
42
43 389 to extrapolate the effects of the drug exposure from the disease itself.
44
45
46 390
47

48 391 Limitations include not being able to extrapolate in the context of the omicron variant, or subsequent
49
50 392 subvariants as we restricted to a period of the pandemic where the delta variant was the dominant
51
52 393 circulating strain of COVID-19 to ensure consistency in the assessment of our outcomes. Although it
53
54 394 is difficult to define a reliable threshold for which we consider a patient unexposed to
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

395 immunosuppressive medication, it is reassuring that only approximately 12% of our unexposed group
396 had filled a prescription in the 365 days prior to the 120-day exposure window assessed, and that
397 removing the minimum threshold of 7.5 mg of systemic corticosteroids as an exposure requirement
398 did not change our findings. A lack of individual-level data relating to confounders such as smoking
399 behaviour, risk of occupational exposure to COVID-19, socio-economic status and dose of drug
400 therapies could potentially limit our findings. Due to lack of availability of such data, we could not
401 account for shielding behaviour in this analysis. There may also be a residual effect of confounding
402 due to unmeasured disease severity not completely accounted for in our PS model. However, these
403 are unlikely to systemically impact the direction of association or strength of significance identified
404 in the risk of infection due to immunosuppressive exposure observed here. We limited our study to
405 IBD, inflammatory arthropathy, and psoriasis although other IMID exist, because these are commonly
406 treated with immunosuppressives such as anti-TNF.

408 In conclusion, our findings suggest a reduced effectiveness of mRNA SARS-CoV-2 vaccination
409 against COVID-19 infection and hospitalization in IMID patients receiving immunosuppressive
410 therapies. This risk is particularly seen in IBD and arthropathy patients, and COVID-19 infection is
411 associated with anti-TNF, systemic corticosteroids, and rituximab and other immunosuppressant
412 exposure, while TNF-alpha inhibitors and systemic corticosteroids were associated with a
413 significantly increased risk of hospitalization.

Author Contributions: DW, RE, AP and TJ developed the study protocol. ME undertook primary
416 data analysis with support from GP. DW and RE were responsible for first draft of the manuscript.
417 All authors were responsible for interpretation of results and critical revisions to the final manuscript.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

419 **Funding Sources:** This work was funded by grants from the Novo Nordisk Foundation
420 (NNF21OC0068631) and the Danish National Research Foundation (DNRF-148).

421
422 **Conflict of Interest Statement:** All authors have none to declare.

423
424 **Data Sharing Statement:** The study was based on data from the Danish National Health registers
425 (<https://sundhedsdatastyrelsen.dk>). The register data are protected by the Danish Act on Processing
426 of Personal Data and are accessed through application to and approval from the Danish Data
427 Protection Agency and the Danish Health Data Authority. The code is available promptly on request
428 made to the corresponding author

REFERENCES

- 1 European Medicines Agency. COVID-19 vaccines safety update: 3 August 2022 Rev. 1. Amsterdam: www.ema.europa.eu (accessed 11 Aug 2022).
- 2 El Sahly HM, Baden LR, Essink B, *et al.* Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *N Engl J Med* 2021;**385**:1774–85.
doi:10.1056/nejmoa2113017
- 3 Polack FP, Thomas SJ, Kitchin N, *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020;**383**:2603–15.
doi:10.1056/NEJMOA2034577/SUPPL_FILE/NEJMOA2034577_PROTOCOL.PDF
- 4 Ward D, Gørtz S, Ernst MT, *et al.* The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection. *Eur Respir J* 2022;**59**. doi:10.1183/13993003.00769-2021
- 5 Gianfrancesco M, Hyrich KL, Al-Adely S, *et al.* Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis* 2020;**79**:859–66.
doi:10.1136/ANNRHEUMDIS-2020-217871
- 6 Brenner EJ, Ungaro RC, Gearry RB, *et al.* Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. *Gastroenterology* 2020;**159**:481-491.e3.
doi:10.1053/J.GASTRO.2020.05.032
- 7 Salter A, Fox RJ, Newsome SD, *et al.* Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. *JAMA Neurol* 2021;**78**:699–708. doi:10.1001/JAMANEUROL.2021.0688
- 8 Strangfeld A, Schäfer M, Gianfrancesco MA, *et al.* Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global

- 1
2
3
4 Rheumatology Alliance physician-reported registry. *Ann Rheum Dis* 2021;**80**:930–42.
5
6 doi:10.1136/ANNRHEUMDIS-2020-219498
7
8
9 Lee ARY Bin, Wong SY, Chai LYA, *et al.* Efficacy of covid-19 vaccines in
10 immunocompromised patients: systematic review and meta-analysis. *BMJ*
11 2022;**376**:e068632. doi:10.1136/BMJ-2021-068632
12
13
14
15
16 10 Boekel L, Steenhuis M, Hooijberg F, *et al.* Antibody development after COVID-19
17 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from
18 two prospective cohort studies. *Lancet Rheumatol* 2021;**3**:e778–88. doi:10.1016/S2665-
19 9913(21)00222-8
20
21
22
23
24
25 11 Alexander JL, Kennedy NA, Ibraheim H, *et al.* COVID-19 vaccine-induced antibody
26 responses in immunosuppressed patients with inflammatory bowel disease (VIP): a
27 multicentre, prospective, case-control study. *lancet Gastroenterol Hepatol* 2022;**7**:342–52.
28 doi:10.1016/S2468-1253(22)00005-X
29
30
31
32
33
34 12 de Boer SE, Berger SP, van Leer–Buter CC, *et al.* Enhanced Humoral Immune Response
35 After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus
36 Mycophenolate Mofetil-containing Immunosuppressive Regimens. *Transplantation*
37 2022;**106**. doi:10.1097/TP.0000000000004177
38
39
40
41
42
43 13 Pottegård A, Kristensen KB, Reilev M, *et al.* Existing Data Sources in Clinical
44 Epidemiology: The Danish COVID-19 Cohort. *Clin Epidemiol* 2020;**12**:875–81.
45 doi:10.2147/CLEP.S257519
46
47
48
49
50 14 Voldstedlund M, Haarh M, Mølbak K. The Danish Microbiology Database (MiBa) 2010 to
51 2013. *Euro Surveill* 2014;**19**. doi:10.2807/1560-7917.ES2014.19.1.20667
52
53
54
55 15 Jensen JS, Jensen DH, Grønhøj C, *et al.* Incidence and survival of oropharyngeal cancer in
56 Denmark: a nation-wide, population-based study from 1980 to 2014. *Acta Oncol (Madr)*
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2018;**57**:269–75. doi:10.1080/0284186X.2017.1390251

- 16 Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, *et al.* Data Resource Profile: The Danish National Prescription Registry. *Int J Epidemiol* 2017;**46**:798. doi:10.1093/IJE/DYW213
- 17 Maaser C, Sturm A, Vavricka SR, *et al.* ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. *J Crohn's Colitis* 2019;**13**:144-164K. doi:10.1093/ECCO-JCC/JJY113
- 18 Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. *Rheumatology* 2012;**51**:vi5–9. doi:10.1093/RHEUMATOLOGY/KES279
- 19 Espenhain L, Funk T, Overvad M, *et al.* Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. *Euro Surveill* 2021;**26**. doi:10.2807/1560-7917.ES.2021.26.50.2101146
- 20 Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. *Biometrika* 1983;**70**:41–55. doi:10.1093/BIOMET/70.1.41
- 21 Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. *BMJ* 2019;**367**. doi:10.1136/BMJ.L5657
- 22 Sakuraba A, Luna A, Micic D. Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis. *Gastroenterology* 2022;**162**:88-108.e9. doi:10.1053/J.GASTRO.2021.09.055
- 23 Singh JA, Guyatt G, Ogdie A, *et al.* 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis: <https://doi.org/10.1177/2475530318812244> 2018;**4**:31–58. doi:10.1177/2475530318812244
- 24 Larsen L, Jensen MD, Larsen MD, *et al.* The Danish National Registry for Biological

- 1
2
3
4 Therapy in Inflammatory Bowel Disease. *Clin Epidemiol* 2016;**8**:607–12.
5
6 doi:10.2147/CLEP.S99478
7
8
9 25 Cottone M, Sapienza C, Macaluso FS, *et al.* Psoriasis and Inflammatory Bowel Disease. *Dig*
10
11 *Dis* 2019;**37**. doi:10.1159/000500116
12
13 26 Hernán MA. The hazards of hazard ratios. *Epidemiology* 2010;**21**:13–5.
14
15 doi:10.1097/EDE.0B013E3181C1EA43
16
17
18 27 Izadi Z, Brenner EJ, Mahil SK, *et al.* Association Between Tumor Necrosis Factor Inhibitors
19
20 and the Risk of Hospitalization or Death Among Patients With Immune-Mediated
21
22 Inflammatory Disease and COVID-19. *JAMA Netw open* 2021;**4**.
23
24 doi:10.1001/JAMANETWORKOPEN.2021.29639
25
26
27 28 Simon D, Tascilar K, Kleyer A, *et al.* Impact of Cytokine Inhibitor Therapy on the
28
29 Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against
30
31 SARS-CoV-2 in an Unvaccinated Cohort. *Arthritis Rheumatol (Hoboken, NJ)* 2022;**74**:783–
32
33 90. doi:10.1002/ART.42035
34
35
36 29 Simon D, Tascilar K, Fagni F, *et al.* SARS-CoV-2 vaccination responses in untreated,
37
38 conventionally treated and anticytokine-treated patients with immune-mediated inflammatory
39
40 diseases. *Ann Rheum Dis* 2021;**80**:1312–6. doi:10.1136/ANNRHEUMDIS-2021-220461
41
42
43 30 Favalli EG, Bugatti S, Klersy C, *et al.* Impact of corticosteroids and immunosuppressive
44
45 therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic
46
47 inflammatory arthritis. *Arthritis Res Ther* 2020;**22**. doi:10.1186/S13075-020-02395-6
48
49
50 31 McKay LI, Cidlowski JA. Physiologic and Pharmacologic Effects of Corticosteroids.
51
52 Published Online First: 2003. <https://www.ncbi.nlm.nih.gov/books/NBK13780/> (accessed 1
53
54 Sep 2022).
55
56
57 32 Rahier JF, Moutschen M, van Gompel A, *et al.* Vaccinations in patients with immune-
58
59
60

1
2
3
4 mediated inflammatory diseases. *Rheumatology (Oxford)* 2010;**49**:1815–27.

5
6
7 doi:10.1093/RHEUMATOLOGY/KEQ183

- 8
9 33 Croce E, Hatz C, Jonker EF, *et al.* Safety of live vaccinations on immunosuppressive therapy
10 in patients with immune-mediated inflammatory diseases, solid organ transplantation or after
11 bone-marrow transplantation - A systematic review of randomized trials, observational
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
studies and case reports. *Vaccine* 2017;**35**:1216–26. doi:10.1016/J.VACCINE.2017.01.048

For peer review only

TABLES & FIGURES

Table 1. Characteristics of immune-mediated inflammatory disease patients at baseline and after propensity score weighting, by exposure to immunosuppressive therapy.

	Baseline IMID Cohort*			Weighted IMID Cohort		
	Unexposed	Exposed	SD	Unexposed	Exposed	SD
Total, n (%)	112 675 (100)	39 765 (100)	NA	39 524 (100)	39 765 (100)	NA
Inflammatory bowel disease, n (%)	47 001 (41.7)	10 480 (26.4)	NA	10 284 (26.0)	10 480 (26.4)	NA
Arthropathy, n (%)	44 669 (39.6)	24 261 (61.0)	NA	24 227 (61.3)	24 261 (61.0)	NA
Psoriasis, n (%)	21 005 (18.6)	5 024 (12.6)	NA	5 014 (12.7)	5 024 (12.6)	NA
Age, median (IQR)	59 (46-71)	58 (45-71)	0.06	58 (44-71)	58 (45-71)	0.01
Male, n (%)	48 941 (43.4)	17 080 (43.0)	0.01	16 934 (42.8)	17 080 (43.0)	0.00
SARS-CoV-2 test in the previous month, median (IQR)	0 (0-1)	0 (0-1)	0.04	0 (0-1)	0 (0-1)	0.00
Calendar date of entry 2021, n (%)						
January to April	27,865 (24.7)	16,689 (42.0)	0.37	10,124 (25.6)	16,689 (42.0)	0.35
May to August	81,682 (72.5)	22,361 (56.2)	0.34	28,211 (71.4)	22,361 (56.2)	0.32
September to November	3,128 (2.8)	715 (1.8)	0.07	1,189 (3.0)	715 (1.8)	0.08
Comorbidities, n (%)						
Cardiovascular disease	41 056 (36.4)	14 010 (35.2)	0.03	14 050 (35.5)	14 010 (35.2)	0.01
Pulmonary disease	14 994 (13.3)	5 793 (14.6)	0.04	5796 (14.7)	5 793 (14.6)	0.00
Liver disease	3 630 (3.2)	1 528 (3.8)	0.03	1 525 (3.9)	1 528 (3.8)	0.00
Kidney disease	6 859 (6.1)	2 260 (5.7)	0.02	2 279 (5.8)	2 260 (5.7)	0.00
Other gastrointestinal diseases	21 505 (19.1)	7 086 (17.8)	0.03	6 984 (17.7)	7 086 (17.8)	0.00
Skin disease	9 889 (8.8)	3 748 (9.4)	0.02	3 703 (9.4)	3 748 (9.4)	0.00
Musculoskeletal disease	45 393 (40.3)	16 620 (41.8)	0.03	16 649 (42.1)	16 620 (41.8)	0.01
Medications, n (%)						
Cardiovascular drugs	80 529 (71.5)	28 179 (70.9)	0.01	28 054 (71.0)	28 179 (70.9)	0.00
Antibiotics	108 502 (96.3)	38 405 (96.6)	0.02	38 181 (96.6)	38 405 (96.6)	0.00
Oral anticoagulants	11 111 (9.9)	4 022 (10.1)	0.01	4 034 (10.2)	4 022 (10.1)	0.00
Drugs used in diabetes	12 935 (11.5)	4 034 (10.1)	0.04	4 030 (10.2)	4 034 (10.1)	0.00

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Drugs for obstructive airway diseases	36 970 (32.8)	13 118 (33.0)	0.00	13 (33.2)	116 (33.0)	13	118	0.00
IBD-specific treatments, n (%)								
Any IBD-related hospital admissions in the previous year	564 (1.2)	714 (6.8)	0.12	584 (5.7)	714 (6.8)			0.05
5-ASA/sulfasalazine	12 596 (26.8)	2 845 (27.1)	0.00	2 857 (27.8)	2 845 (27.1)			0.01
Budesonide	646 (1.4)	272 (2.6)	0.02	277 (2.7)	272 (2.6)			0.01
IBD related procedures	18 553 (39.5)	4 551 (43.4)	0.05	4 473 (43.5)	4 551 (43.4)			0.00
Endoscopy of the gastrointestinal tract	7 454 (15.9)	3 702 (35.3)	0.12	3 543 (34.5)	3 702 (35.3)			0.02
Arthropathy-specific treatments, n (%)								
Arthropathy-related procedures	13 932 (31.2)	8 415 (34.7)	0.09	8 399 (34.7)	8 415 (34.7)			0.00
Anti-inflammatory and anti-rheumatic drugs	5 678 (12.7)	3 462 (14.3)	0.07	3 480 (14.4)	3 462 (14.3)			0.00
Hydroxychloroquine	540 (1.2)	845 (3.5)	0.15	801 (3.3)	845 (3.5)			0.01
Psoriasis-specific treatments, n (%)								
5-ASA/sulfasalazine	2 149 (10.2)	807 (16.1)	0.03	805 (16.1)	807 (16.1)			0.00
Topical corticosteroids	73 (0.3)	42 (0.8)	0.00	39 (0.8)	42 (0.8)			0.01
Anti-psoriatic medication	7 441 (35.4)	1 894 (37.7)	0.01	1 900 (37.9)	1 894 (37.7)			0.00
Topical calcineurin inhibitors	3 731 (17.8)	1 106 (22.0)	0.00	1 110 (22.1)	1 106 (22.0)			0.00
Psoriasis related procedures	542 (2.6)	144 (2.9)	0.00	144 (2.9)	144 (2.9)			0.00
5-ASA/sulfasalazine	2 149 (10.2)	807 (16.1)	0.03	805 (16.1)	807 (16.1)			0.00

Abbreviations: IMID = immune-mediated inflammatory disease; SD = standardized differences; IQR = inter-quartile range; NA = not applicable. *Total cohort numbers prior to trimming.

FIGURE LEGENDS

Figure 1. Flow chart for inclusion into the exposed and unexposed IMID cohort.

Figure 2. Risk of infection, hospitalization and death associated with immunosuppressive exposure from Jan 2021-Nov 2021 in Inflammatory Bowel Disease, Arthropathy, Psoriasis and across all IMID cohorts.

Figure 3. Risk of infection associated with immunosuppressive drug class exposure (Selective Immunosuppressants, Tumour Necrosis Factor Inhibitors, Interleukin Inhibitors, Calcineurin Inhibitors, Systemic Corticosteroids, and Other Immunosuppressants including Rituximab) in IMID patients.

Figure 4. Risk of hospitalization associated with immunosuppressive drug class exposure (Selective Immunosuppressants, Tumour Necrosis Factor Inhibitors, Interleukin Inhibitors, Calcineurin Inhibitors, Systemic Corticosteroids, and Other Immunosuppressants including Rituximab) in IMID patients.




Figure 1. Flow chart for inclusion into the exposed and unexposed IMID cohort.

190x275mm (200 x 200 DPI)


Figure 2.

Figure 2. Risk of infection, hospitalization and death associated with immunosuppressive exposure from Jan 2021–Nov 2021 in Inflammatory Bowel Disease, Arthropathy, Psoriasis and across all IMID cohorts.

296x209mm (200 x 200 DPI)

Figure 3.




Figure 3. Risk of infection associated with immunosuppressive drug class exposure (Selective Immunosuppressants, Tumour Necrosis Factor Inhibitors, Interleukin Inhibitors, Calcineurin Inhibitors, Systemic Corticosteroids, and Other Immunosuppressants including Rituximab) in IMID patients.

296x209mm (200 x 200 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 4.




Figure 4. Risk of hospitalization associated with immunosuppressive drug class exposure (Selective Immunosuppressants, Tumour Necrosis Factor Inhibitors, Interleukin Inhibitors, Calcineurin Inhibitors, Systemic Corticosteroids, and Other Immunosuppressants including Rituximab) in IMID patients.

296x209mm (200 x 200 DPI)

The Impact of Immunosuppressive Therapy on SARS-CoV-2 mRNA Vaccine Effectiveness in Patients with Immune-mediated Inflammatory Diseases: A Danish Nationwide Cohort Study

Rahma Elmahdi^{*1,2} (0000-0002-7013-9548), Daniel Ward^{*1} (0000-0003-0405-7250), Martin Thomsen Ernst³ (0000-0001-9003-3823), Gry Juul Poulsen¹ (0000-0003-2744-2469), Jesper Hallas³ (0000-0002-8097-8708), Anton Pottegård³ (0000-0001-9314-5679), Tine Jess^{1,4} (0000-0002-4391-7332)

SUPPLEMENTARY TABLES

Supplementary Table 1. Exposures and corresponding ATC and procedure codes for immunosuppressives

Medication	ATC code	Procedure code
Selective immunosuppressants		
Muromonab-CD3	L04AA02	
Antilymphocyte immunoglobulin (horse)	L04AA03 L04AA04	BOHJ12
Antithymocyte immunoglobulin (rabbit)	L04AA06	BOHJ22
Mycophenolic acid	L04AA10	BOHJ23
Sirolimus	L04AA13	
Leflunomide	L04AA18	BOHJ24
Everolimus	L04AA23	BOHJ26
Natalizumab	L04AA24	BOHJ18C1
Abatacept	L04AA25	BWHB84
Eculizumab	L04AA26	BOHJ19H6
Belimumab	L04AA27	BOHJ27
Fingolimod	L04AA28	
Belatacept	L04AA29	BOHJ28D
Tofacitinib	L04AA31	BOHJ28A
Teriflunomide	L04AA32	
Aprelimast	L04AA33	BOHJ19H4
Vedolizumab	L04AA34	BOHJ16A
Alemtuzumab	L04AA36	
Ocrelizumab	L04AA37	
Baricitinib	L04AA38	
Ozanimod	L04AA39	
Emapalumab	L04AA40	BWHA178
Cladribine	L04AA41	
Imlifidase	L04AA42	BWHB87
Siponimod	L04AA43	
Ravulizumab	L04AA44	
Upadacitinib		

Tumour necrosis factor inhibitors		
Etanercept	L04AB01	BOHJ18A2
Infliximab	L04AB02	BOHJ18A1
Adalimumab	L04AB04	BOHJ18A3
Certolizumab pegol	L04AB05	BOHJ18A5
Golimumab	L04AB06	BOHJ18A4
Interleukin inhibitors		
Basiliximab	L04AC02	
Anakinra	L04AC03	BOHJ18B1
Ustekinumab	L04AC05	BOHJ18B3
Tocilizumab	L04AC07	BOHJ18B2
Canakinumab	L04AC08	BOHJ18B4
Secukinumab	L04AC10	BOHJ18B5
Siltuximab	L04AC11	
Brodalumab	L04AC12	BOHJ18B6
Ixekizumab	L04AC13	
Sarilumab	L04AC14	BOHJ18B9
Guselkumab	L04AC16	
Tildrakizumab	L04AC17	BOHJ18B7
Risankizumab	L04AC18	BOHJ19N1
Calcineurin inhibitors		
Ciclosporin	L04AD01	BOHJ20
Tacrolimus	L04AD02	BOHJ21
Other immunosuppressants		
Azathioprine	L04AX01	BWHB83
Thalidomide	L04AX02	BWHB81
Methotrexate	L04AX03	BWHA115
Lenalidomide	L04AX04	BWHB82
Pirfenidone	L04AX05	BWHB85
Pomalidomide	L04AX06	BWHB86
Dimethyl fumarate	L04AX07	BOHJ28B
Darvadstrocel	L04AX08	
Systemic corticosteroids	H02AB	
Rituximab	L01XC02	

Supplementary Table 2. Minimum daily dose of corticosteroid in exposed persons

Compound	Equivalent dose
Cortisone	38mg
Hydrocortisone	30mg
Prednisone	7.5mg
Prednisolone	7.5mg
Triamcinolone	6mg
Methylprednisolone	6mg
Betamethasone	0.9mg
Dexamethasone	1.2mg

Supplementary Table 3. Covariates by disease cohort

IBD COHORT		
Covariate	Categories/ ATC/ICD codes	Assessment window
Age	-	At cohort entry
Sex	-	At cohort entry
SARS-CoV-2 tests in the previous month	-	At cohort entry
Ever previous SARS-CoV-2 positive test	-	From February 2020
IBD specific covariates		
Any IBD-related hospital admissions in the previous year	K50/K51	1 year before cohort entry
Crohn's disease	K50	At cohort entry
Ulcerative colitis	K51	At cohort entry
5-ASA/sulfasalazine	MA07EC0	1 year before matching date
Budesonide	MA07EA06	3 months before matching date
IBD related procedures Operations of the small bowel and colon Operations of the rectum Operations of the anus and perianal tissue Operational of the abdominal wall, peritoneum, mesentery and omentum Lysis of adhesion in the abdominal cavity Closure of intestinovaginal fistula Closure of vesiculointestinal fistula	KJF KJG KJH KJA KJAP KLEE30 KKCH30	Any time before cohort entry
Endoscopy of the gastrointestinal tract	KUJ	1 year before the cohort entry
Comorbidities		
Cardiovascular disease	DI1-I7	Any time before cohort entry
Pulmonary disease Chronic disease of the lower airways Other interstitial lung disease Diseases with pus and necrosis in the lower airway Interstitial lung emphysema compensatory emphysema	DJ4 DJ84 DJ85 DJ982 DJ983	Any time before cohort entry
Liver disease	DK70-K77	Any time before cohort entry
Kidney disease Glomerular disease Tubulointerstitial kidney disease and kidney insufficiency	DN0 DN1	Any time before cohort entry
Other gastrointestinal diseases Gingivitis and periodontal disease Inflammation of the oral mucosa and related Stomach and duodenal ulcers Fissure and rifts in and around the anus Abscess in and around the anus Other diseases of the rectum and anus Other bowel disease	DK05 DK12 DK25-27 DK60 DK61 DK62 DK63	Any time before cohort entry

1 2 3 4 5 6 7 8 9 10 11 12 13	Skin disease Bullous skin disease Dermatitis and eczema Alopecia areata Vitiligo Granulomatous disease in the skin and subcutaneous tissue Lupus Other localised connective tissue disease Vasculitis limited to the skin	DL10-14 DL20-30 DL63 DL80 DL92 DL93 DL94 DL95	Any time before cohort entry
14 15 16 17 18	Musculoskeletal disease Generalised connective tissue diseases Diseases of the muscles Soft-tissue rheumatism	DM30- DM36 DM60-63 DM70-79	Any time before cohort entry
19	Medications		
20 21 22	Cardiovascular drugs	MC01-MC10	Any time before cohort entry
23 24	Antibiotics	MJ01	Any time before cohort entry
25 26	Oral anticoagulants	MB01AA MB01AF	Any time before cohort entry
27 28	Drugs used in diabetes	MA10	Any time before cohort entry
29 30	Drugs for obstructive airway diseases	MR03	Any time before cohort entry
31	INFLAMMATORY ARTHROPATHIES COHORT		
32	Age	-	At cohort entry
33	Sex	-	At cohort entry
34	SARS-CoV-2 tests in the previous month	-	At cohort entry
35	Arthropathy-specific covariates		
36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	Arthropathy-related procedures Shoulder and upper arm Primary insertion of joint prosthesis Secondary insertion of joint prosthesis Operations on the joint capsule and ligaments Operations of the synovia and joint surface Joint resections, arthroplasties, and arthrodesis Excision of bursa Elbow and lower arm Primary insertion of joint prosthesis Secondary insertion of joint prosthesis Operations on the joint capsule and ligaments Operations of the synovia and joint surface Joint resections, arthroplasties, and arthrodesis Excision of bursa Wrist and hand Primary insertion of joint prosthesis Secondary insertion of joint prosthesis Operations on the joint capsule and ligaments Operations of the synovia and joint surface Joint resections, arthroplasties, and arthrodesis Operations on the fascia, tendon sheaths, ganglia and bursae	KNBB KNBC KNBE KNBF KNBG KBM79 KNCB KNCC KNCE KNCF KNCG KNCM79 KNDB KNDC KNDE KNDF KNDG KNDM	Any time before cohort entry

<p>Hip and thigh</p> <p>Primary insertion of joint prosthesis</p> <p>Secondary insertion of joint prosthesis</p> <p>Operations on the joint capsule and ligaments</p> <p>Operations of the synovia and joint surface</p> <p>Joint resections, arthroplasties, and arthrodesis</p> <p>Excision of bursa in the</p> <p>Knee and lower leg</p> <p>Primary insertion of joint prosthesis</p> <p>Secondary insertion of joint prosthesis</p> <p>Operations on the joint capsule and ligaments</p> <p>Operations of the synovia and joint surface</p> <p>Joint resections, arthroplasties, and arthrodesis</p> <p>Excision of bursae</p> <p>Ankle and foot</p> <p>Primary insertion of joint prosthesis</p> <p>Secondary insertion of joint prosthesis</p> <p>Operations on the joint capsule and ligaments</p> <p>Operations of the synovia and joint surface</p> <p>Joint resections, arthroplasties, and arthrodesis</p> <p>Operations on the fascia, tendon sheaths, ganglia and bursae</p>	<p>KNFB</p> <p>KNFC</p> <p>KNFE</p> <p>KNFF</p> <p>KNFG</p> <p>KNFM79</p> <p>KNGB</p> <p>KNGC</p> <p>KNGE</p> <p>KNGF</p> <p>KNGG</p> <p>KNGM79</p> <p>KNHB</p> <p>KNHC</p> <p>KNHE</p> <p>KNHF</p> <p>KNHG</p> <p>KNHM</p>	
<p>Anti-inflammatory and anti-rheumatic drugs inc. specific anti-rheumatic therapies, non-steroidals, and combination medications</p> <p>Hydroxychloroquine</p>	<p>M01</p> <p>P01BA02</p>	<p>3 months before cohort entry</p>
Comorbidities		
Cardiovascular disease	DI1-I7	Any time before cohort entry
<p>Pulmonary disease</p> <p>Chronic disease of the lower airways</p> <p>Other interstitial lung disease</p> <p>Diseases with pus and necrosis in the lower airway</p> <p>Interstitial lung emphysema</p> <p>compensatory emphysema</p>	<p>DJ4</p> <p>DJ84</p> <p>DJ85</p> <p>DJ982</p> <p>DJ983</p>	Any time before cohort entry
Liver disease	DK70-K77	Any time before cohort entry
<p>Kidney disease</p> <p>Glomerular disease</p> <p>Tubulointerstitial kidney disease and kidney insufficiency</p>	<p>DN0</p> <p>DN1</p>	Any time before cohort entry
<p>Other gastrointestinal diseases</p> <p>Gingivitis and periodontal disease</p> <p>Inflammation of the oral mucosa and related</p> <p>Stomach and duodenal ulcers</p> <p>Fissure and rifts in and around the anus</p> <p>Abscess in and around the anus</p> <p>Other diseases of the rectum and anus</p> <p>Other bowel disease</p>	<p>DK05</p> <p>DK12</p> <p>DK25-27</p> <p>DK60</p> <p>DK61</p> <p>DK62</p> <p>DK63</p>	Any time before cohort entry
<p>Skin disease</p> <p>Bullous skin disease</p> <p>Dermatitis and eczema</p> <p>Alopecia areata</p>	<p>DL10-14</p> <p>DL20-30</p> <p>DL63</p>	Any time before cohort entry

Vitiligo Granulomatous disease in the skin and subcutaneous tissue Lupus Other localised connective tissue disease Vasculitis limited to the skin	DL80 DL92 DL93 DL94 DL95	
Musculoskeletal disease Generalised connective tissue diseases Diseases of the muscles Soft-tissue rheumatism	DM30- DM36 DM60-63 DM70-79	Any time before cohort entry
Medications		
Cardiovascular drugs	MC01-MC10	Any time before cohort entry
Antibiotics	MJ01	Any time before cohort entry
Oral anticoagulants	MB01AA MB01AF	Any time before cohort entry
Drugs used in diabetes	MA10	Any time before cohort entry
Drugs for obstructive airway diseases	MR03	Any time before cohort entry
PSORIASIS COHORT		
Age	-	At cohort entry
Sex	-	At cohort entry
SARS-CoV-2 tests in the previous month	-	At cohort entry
Psoriasis-specific covariates		
Procedures Ultraviolet therapy: UV-A with psoralen/broad-spectrum UVB / narrow-spectrum UVB	BNGA1/ BNGA2/ BNGA3	Any time before cohort entry
Therapeutic steroid injection in the joints and soft tissues	BLHN0	Any time before cohort entry
5-ASA/sulfasalazine	A07EC0	1 year before cohort entry
Topical corticosteroids	D07	1 year before cohort entry
Antipsoriatic medication	D05	1 year before cohort entry
Topical calcineurin inhibitors	D11AH01-02,	1 year before cohort entry
Comorbidities		
Cardiovascular disease	DI1-I7	Any time before cohort entry
Pulmonary disease Chronic disease of the lower airways Other interstitial lung disease Diseases with pus and necrosis in the lower airway Interstitial lung emphysema compensatory emphysema	DJ4 DJ84 DJ85 DJ982 DJ983	Any time before cohort entry

Liver disease	DK70-K77	Any time before cohort entry
Kidney disease Glomerular disease Tubulointerstitial kidney disease and kidney insufficiency	DN0 DN1	Any time before cohort entry
Other gastrointestinal diseases Gingivitis and periodontal disease Inflammation of the oral mucosa and related Stomach and duodenal ulcers Fissure and rifts in and around the anus Abscess in and around the anus Other diseases of the rectum and anus Other bowel disease	DK05 DK12 DK25-27 DK60 DK61 DK62 DK63	Any time before cohort entry
Skin disease Bullous skin disease Dermatitis and eczema Alopecia areata Vitiligo Granulomatous disease in the skin and subcutaneous tissue Lupus Other localised connective tissue disease Vasculitis limited to the skin	DL10-14 DL20-30 DL63 DL80 DL92 DL93 DL94 DL95	Any time before cohort entry
Musculoskeletal disease Generalised connective tissue diseases Diseases of the muscles Soft-tissue rheumatism	DM30- DM36 DM60-63 DM70-79	Any time before cohort entry
Medications		
Cardiovascular drugs	MC01-MC10	Any time before cohort entry
Antibiotics	MJ01	Any time before cohort entry
Oral anticoagulants	MB01AA MB01AF	Any time before cohort entry
Drugs used in diabetes	MA10	Any time before cohort entry
Drugs for obstructive airway diseases	MR03	Any time before cohort entry

Supplementary Table 4. Risk of infection, hospitalisation and death associated with immunosuppressive therapy in vaccinated patients with immune-mediated inflammatory diseases.

	Exposed				Unexposed				Crude HR (95% CI) ***	Weighted HR (95% CI) ***
	Total	Events	Incidence rate (95% CI) **	PY	Total	Events	Incidence rate (95% CI) **	PY		
COVID-19 Infection*										
IBD	10 477	287	54.7 (48.7-61.4)	5 246	46 974	885	42.5 (39.8-45.4)	20 809	1.7 (1.5-1.9)	1.6 (1.4-1.9)
Arthropathy	24 255	476	40.3 (36.8-44.1)	11 822	44 650	800	37.8 (35.3-40.6)	21 140	1.3 (1.1-1.4)	1.3 (1.1-1.4)
Psoriasis	5 023	103	45.3 (37.4-55.00)	2 273	20 995	392	41.5 (37.6-45.8)	9 441	1.1 (0.9-1.4)	1.1 (0.9-1.4)
Combined cohorts	39 755	866	-	19 341	112 619	2 077	-	51 390	1.4 (1.3-1.5)	1.4 (1.2-1.5)
COVID-19 Hospitalization*										
IBD	10 477	15	2.8 (1.7-4.7)	5 280	46 980	43	2.1 (1.5-2.8)	20 892	2.8 (1.5-5.1)	2.1 (1.0-4.1)
Arthropathy	24 256	37	3.1 (2.3-4.3)	11 873	44 650	59	2.8 (2.2-3.6)	21 215	1.3 (0.9-2.0)	1.3 (0.9-2.0)
Psoriasis	5 023	<5	-	2 284	20 999	20	2.1 (1.4-3.3)	9 479	0.5 (0.1-2.3)	0.6 (0.1-2.5)
Combined cohorts	39 756	<57	-	19 437	112 629	122	-	51 594	1.6	1.4

									(1.1-2.2)	(1.0-2.0)
Death*										
IBD	10 477	<5	-	5 281	46 980	6	0.3 (0.1-0.6)	20 897	1.1 (0.1-9.7)	0.4 (0-5.6)
Arthropathy	24 256	6	0.51 (0.2-1.1)	11 875	44 650	13	0.6 (0.4-1.1)	21 222	1.0 (0.4-2.7)	1.0 (0.4-2.6)
Psoriasis	5 023	0	-	2 284	20 999	<5	-	9 480	-	-
Combined cohorts	39 756	<11	-	19 440	112 629	<24	-	51 599	1.0 (0.4-2.5)	0.9 (0.4-2.2)
Abbreviations: CI = confidence interval; HR = hazard ratio; IBD= inflammatory bowel disease; PY = person-years.										
*COVID19- Infection = confirmed positive antigen or PCR test result for SARS-CoV2; COVID-19 Hospital Admission = Hospitalisation with SARS-CoV2 infection as primary diagnosis code; Death within 60 days of positive SARS-CoV2 test.										
**Events/1000 PY (95% CI)										
*** Sex and age adjusted crude and weighted hazard ratios										

Supplementary Table 5. Risk of COVID-19 infection associated with immunosuppressive therapy in vaccinated patients with immune-mediated inflammatory diseases at 0-3 months, 3-6 months, and 6-11 months post-vaccination.

	Exposed				Unexposed				Crude HR (95% CI) **	Weighted HR (95% CI) **
	Total	Events	Incidence rate (95% CI) *	PY	Total	Events	Incidence rate (95% CI) *	PY		
COVID-19 infection 0-3 months post-vaccination										
IBD	10 477	57	22.2 (17.1-28.8)	2 570	46 974	196	17.0 (14.8-19.5)	11 546	1.6 (1.2-2.2)	1.5 (1.1-2.2)
Arthropathy	24 255	96	16.1 (13.2-19.6)	5 978	44 650	166	15.1 (13.0-17.6)	10 990	1.3 (1.0-1.7)	1.3 (1.0-1.7)
Psoriasis	5 023	24	19.4 (13.0-29.0)	1 236	20 995	83	16.1 (13.0-19.9)	5 163	1.3 (0.3-2.1)	1.3 (0.8-2.1)
Combined cohorts	39 755	177	-	4 403	112 619	445	-	27 699	1.4 (1.2-1.7)	1.4 (1.1-1.6)
COVID-19 infection 3-6 months post-vaccination										
IBD	10 010	123	45.8 (38.4-54.7)	2 683	45 202	526	56.8 (52.1-61.8)	9 266	0.9 (0.8-1.2)	1.0 (0.8-1.2)
Arthropathy	23 503	284	48.6 (43.2-54.5)	5 849	43 186	482	47.5 (43.4-51.9)	10 149	1.2 (1.1-1.4)	1.2 (1.1-1.4)
Psoriasis	4 860	63	60.7 (47.4-77.7)	1 038	20 203	233	54.5 (47.9-61.9)	4 279	1.1 (0.8-1.4)	1.0 (0.8-1.4)
Combined cohorts	38 373	470	-	19 437	108 591	1 241	-	23 694	1.1 (1.0-1.2)	1.1 (1.0-1.3)

COVID-19 infection 6-11 months post-vaccination										
IBD	6 058	107	160.6 (132.9-194.1)	666	15 742	163	107.1 (91.9-124.9)	1 522	1.3 (0.9-1.7)	1.4 (1.1-1.9)
Arthropathy	12 223	96	82.7 (67.7-101.0)	1 160	19 839	152	80.8 (68.9-94.7)	1 881	1.1 (0.8-1.4)	1.1 (0.8-1.4)
Psoriasis	1 719	16	93.8 (57.5-153.1)	170	7 444	76	109.8 (87.7-137.5)	691	0.9 (0.5-1.5)	0.9 (0.5-1.5)
Combined cohorts	20 000	219	-	1 996	43 025	391	-	4 094	1.1 (0.9-1.3)	1.11 (0.9-1.3)
Abbreviations: CI = confidence interval; HR = hazard ratio; IBD= inflammatory bowel disease; PY = person-years.										
*Events/1000 PY										
**Sex and age adjusted crude and weighted hazard ratios										

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Supplementary Table 6. Risk of COVID infection associated with immunosuppressive therapy in vaccinated patients with immune-mediated inflammatory diseases by calendar period (1st January-31st November 2021)

	Exposed		Unexposed		Hazard Ratio (HR)	
	Total	Events	Total	Events	Crude HR (95% CI)	Weighted HR (95% CI) **
*COVID-19 infection from 1st January to 30th April						
IBD	5 745	n<5	10 306	7	0.67 (0.17-2.61)	0.39 (0.09-1.71)
Arthropathy	9 646	9	13 044	17	0.75 (0.33-1.69)	0.78 (0.35-1.71)
Psoriasis	1 298	n<5	4 512	6	2.00 (0.50-8.02)	1.98 (0.48-8.19)
Combined IMID	16 689	<19	27 862	30	0.87 (0.48-1.59)	0.83 (0.44-1.54)
COVID-19 infection 1st May to 31st August						
IBD	10 141	56	45 486	121	1.61 (1.17-2.22)	1.19 (0.82-1.73)
Arthropathy	23 885	74	43 457	116	1.08 (0.81-1.45)	1.07 (0.79-1.43)
Psoriasis	4 912	12	20 337	53	0.88 (0.47-1.65)	0.84 (0.44-1.58)
Combined IMID	38 938	142	109 280	290	1.24 (1.01-1.52)	1.08 (0.87-1.34)
COVID-19 infection 1st September to 30st November						
IBD	1 0349	228	46 590	757	1.69 (1.45-1.97)	1.74 (1.48-2.04)
Arthropathy	23 898	393	44 079	667	1.34 (1.18-1.51)	1.33 (1.17-1.51)
Psoriasis	4 974	88	20 803	333	1.17 (0.93-1.48)	1.13 (0.89-1.44)
Combined IMID	39 221	709	111 472	1757	1.42 (1.30-1.55)	1.42 (1.29-1.56)
Abbreviations: CI = confidence interval; HR = hazard ratio; IBD= inflammatory bowel disease.						
*COVID19- Infection = confirmed positive antigen or PCR test result for SARS-CoV2						
** Sex and age adjusted crude and weighted hazard ratios						

Supplementary Table 7. Risk of infection, hospitalisation and death associated with immunosuppressive therapy in vaccinated patients with immune-mediated inflammatory diseases by immunosuppressive drug class.

	Exposed				Unexposed				Crude HR (95% CI) ***	Weighted HR (95% CI) ***
	Total	Events	PY	Incidence rate (95% CI) **	Total	Events	PY	Incidence rate (95% CI) **		
COVID-19 Infection*										
Selective Immunosuppressants	3 384	68	1 846	39.4 (31.0-49.9)	151 936	2 079	51 334	40.5 (38.8-42.3)	1.3 (1.0-1.7)	1.3 (1.0-1.6)
Tumour Necrosis Factor Inhibitors	14 277	418	6 908	62.5 (56.7-68.7)	140 797	2 070	51 355	40.3 (38.6-42.1)	1.8 (1.6-2.0)	1.8 (1.6-2.0)
Interleukin Inhibitors	2 781	52	1 385	40.1 (30.6-52.7)	152 584	2 082	51 352	40.5 (38.8-42.3)	1.1 (0.8-1.4)	1.0 (0.8-1.4)
Calcineurin Inhibitors	154	n<5	129	-	155 309	2 073	51 298	40.4 (38.7-42.2)	1.3 (0.3-5.2)	0.5 (0.2-1.5)
Systemic Corticosteroids	5 504	97	2 991	34.6 (28.4-42.3)	149 667	2 079	51 503	40.4 (38.7-42.1)	1.3 (1.0-1.6)	1.2 (1.0-1.5)
Rituximab and Other Immunosuppressants	21 038	426	10 703	41.2 (37.5-45.3)	112 593	2 075	51 409	40.4 (38.7-42.1)	1.3 (1.2-1.4)	1.3 (1.1-1.4)
COVID-19 Hospitalization*										
Selective Immunosuppressants	3 384	7	1 735	4.0 (1.9-8.5)	112 479	122	51 531	2.4 (2.0-2.8)	3.0 (1.4-6.5)	2.2 (1.0-5.2)
Tumour Necrosis Factor Inhibitors	14 277	16	6 740	2.4 (1.5-3.9)	112 506	116	51 551	2.3 (1.9-2.1)	2.0 (1.2-3.3)	1.8 (1.0-3.3)

Interleukin Inhibitors	2 781	0	1 302	-	112 445	125	51 549	2.4 (2.0-2.9)	-	-
Calcineurin Inhibitors	154	0	83	-	112 404	122	51 493	2.4 (2.0-2.8)	-	-
Systemic Corticosteroids	5 504	18	2 811	6.4 (4.0-10.2)	112 587	122	51 699	2.4 (2.0-2.8)	2.4 (1.4-3.9)	1.8 (1.0-3.0)
Rituximab and Other Immunosuppressants	21 038	25	10 387	2.4 (1.6-3.6)	112 593	121	51 604	2.3 (2.0-2.8)	1.2 (0.5-1.0)	1.1 (0.7-1.8)
Death*										
Selective Immunosuppressants	3 384	0	1 736	-	112479	23	51 545	0.5 (0.3-0.7)	-	-
Tumour Necrosis Factor Inhibitors	14 277	0	6 741	-	112506	19	5 1564	0.4 (0.2-0.6)	-	-
Interleukin Inhibitors	2 781	0	1 302	-	112 445	24	51 564	0.5 (0.3-0.7)	-	-
Calcineurin Inhibitors	154	0	83	-	112 404	24	51 507	0.5 (0.3-0.7)	-	-
Systemic Corticosteroids	5 504	6	2 812	2.1 (2.0-4.8)	112 587	23	51 713	0.4 (0.3-0.7)	4.0 (1.6-9.9)	2.3 (0.9-6.2)
Rituximab and Other Immunosuppressants	21 038	n<5	10 388	-	112 593	22	51 619	0.4 (0.3-0.7)	0.5 (0.1-2.3)	0.5 (0.1-2.4)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Abbreviations: CI = confidence interval; HR = hazard ratio; IBD= inflammatory bowel disease; PY = person-years.

Immunosuppressive Drug Class: Selective Immunosuppressants, Tumour Necrosis Factor Inhibitors, Interleukin Inhibitors, Calcineurin Inhibitors, Systemic Corticosteroids, and Other Immunosuppressants including Rituximab (See Supplementary for complete ATC codes)



*COVID19- Infection = confirmed positive antigen or PCR test result for SARS-CoV2; COVID-19 Hospital Admission = Hospitalisation with SARS-CoV2 infection as primary diagnosis code; Death within 60 days of positive SARS-CoV2 test.

**Events/1000 PY

*** Sex and age adjusted crude and weighted hazard ratios


SUPPLEMENTARY FIGURES

Supplementary Figure 1. Kaplan-Meier plots for probability of infection with COVID-19 following second mRNA vaccination in immunosuppressive exposed compared to propensity score matched immunosuppressive unexposed a. IBD patients b. Arthropathy patients c. Psoriasis patients over the calendar year from January 1st to 31st November 2021. SMR weighted = standardized mortality ratio weighted.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

c. Psoriasis



review only

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

The Impact of Immunosuppressive Therapy on SARS-CoV-2 mRNA Vaccine Effectiveness in Patients with Immune-mediated Inflammatory Diseases: A Nationwide Danish Cohort Study

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5, 6
Methods			
Study design	4	Present key elements of study design early in the paper	6-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6, 7 & Fig.1
6-10Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	6-8 & Fig.1
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7,8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7,8
Bias	9	Describe any efforts to address potential sources of bias	6-9
Study size	10	Explain how the study size was arrived at	Fig. 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	7-9
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	9,10 & Table 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9,10

1		(b) Indicate number of participants with missing data for each variable of interest	
2		(c) Summarise follow-up time (eg, average and total amount)	
3			
4			
5	Outcome data	15* Report numbers of outcome events or summary measures over time	9 Fig.2-4
6			
7	Main results	16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9,10 & Fig. 2-4
8		(b) Report category boundaries when continuous variables were categorized	
9		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful period	
10			
11			
12			
13			
14			
15	Other analyses	17 Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses	10 Fig.4
16			
17			
18	Discussion		
19	Key results	18 Summarise key results with reference to study objectives	10
20			
21	Limitations	19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
22			
23	Interpretation	20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13
24			
25	Generalisability	21 Discuss the generalisability (external validity) of the study results	11,12
26			
27	Other information		
28	Funding	22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Abstract & 14
29			
30			

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.